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ABSTRACT 
 
Mitochondrial dysfunction plays a pivotal role in the development of aging phenotypes and 
aging-associated neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and Amyotrophic lateral sclerosis (ALS). Strategies that restore mitochondrial 
dysfunction may rescue the deficits of central metabolism in these disorders and improve cell 
survival. For example, we found that modulating the mTOR signaling pathway in a tissue culture 
model of aging-induced mitochondrial DNA mutation enhanced mitochondrial function as 
evidenced by increased oxygen consumption.  Our previous melatonin studies also led us to 
hypothesize that caloric restriction and the hormone melatonin would reverse brain 
mitochondrial dysfunction in animal models of AD.  Although caloric restriction did not improve 
mitochondrial function in a transgenic P301L tau model of AD, novel insight into the regulation 
of F0-F1 ATP synthase activity under CR was gained that may help explain the protective effects 
of CR in other disease models. In addition, we determined the effects of melatonin treatment on 
brain mitochondrial cytochrome c oxidase (COX) activity using the transgenic APPSWE mouse 
model of AD bred to double melatonin receptor (MT1 and MT2) knockout mice.  COX activity 
declined with aging in control mice, but increased with aging in AD mice, most likely as a 
response to mitochondrial reactive oxygen species (ROS) induced by amyloid-beta generated 
through APP proteolysis.  Both effects were blunted by melatonin treatment.  The effects of 
melatonin were partially dependent on the G-protein coupled melatonin receptorsWe also used 
PD models to identify therapies that restore mitochondrial dysfunction. We showed that 
xii 
 
overexpression of wild-type alpha synuclein (α-syn) in human neuroblastoma M17 cells resulted 
in mitochondrial oxygen consumption deficits; similar to the levels observed when PD mutant 
forms (A30P α-syn, E46K α-syn, and, A53T α-syn) were overexpressed. Mitochondria from 
cells overexpressing α-syn were more sensitive to a high iron environment, mimicking the 
physiological conditions in which dopaminergic neurons are found.  Diethyl oxaloacetate, 
succinate, and several amino acids were protective, suggesting the possibility for effective 
dietary interventions for PD. Lastly, we delineated the level of mitochondrial complex IV 
activity between gray and white matter in human cervical and lumbar spinal cord, as well as 
mitochondrial aggregation in the entire neurovascular units (NVU) as a consequence of ALS.  At 
the conclusion of these projects a better understanding of the molecular mechanisms leading to 
mitochondrial dysfunction in AD, PD, ALS, and aging was gained and promising strategies to 
delay or reverse these dysfunctions were developed.  
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CHAPTER ONE: INTRODUCTION 
Mitochondria are maternally inherited organelles with a bacterial origin. Mammals 
contain their own circular ~ 16,500 bp mitochondrial DNA genome, which replicates 
independently. Mitochondria undergo dynamic processes of fusion and fission. The vast majority 
of genes necessary for mitochondrial function have been purged from the mitochondrial genome. 
These genes were either transferred to the nuclear genome or were lost as the endo-symbiotic 
relationship between proto eukaryotic and proto mitochondrial cells developed. Mitochondria are 
found in almost all eukaryotes, from single celled eukaryotic organisms, to plants and animals, 
where they serve as the primary source of cellular energy production. The primary function of 
mitochondria is the production of intracellular adenosine triphosphate (ATP), the energy 
currency of the cell. Although some ATP is produced via glycolysis and substrate level 
phosphorylation, the bulk of ATP is produced through oxidative phosphorylation (OXPHOS). 
Other important functions performed by mitochondria include iron-sulfur cluster biogenesis, 
activation of stress responses, regulation of cell death, and intracellular signaling. In this chapter 
we provide an overview of mitochondrial function. We also provide a review of the role of 
mitochondrial dysfunction in the progress of aging, amyotrophic lateral sclerosis, Alzheimer’s 
disease, and Parkinson’s disease. 
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Mitochondrial electron transport chain and oxidative phosphorylation 
Following the breakdown of glucose in glycolysis, the resulting 2 molecules of pyruvate 
are decarboxylated, oxidized, and bound to coenzyme A. This is accomplished by the pyruvate 
dehydrogenase enzyme and results in the formation of acetyl-CoA. Similarly, during beta- 
oxidation of fatty acids, acetyl groups are bound to a coenzyme A yielding acetyl-CoA.  A 
condensation reaction catalyzed by citrate synthase breaks the high energy thioester bond 
between the acetyl group and coenzyme A, and condenses the acetyl group with a molecule of 
oxaloacetate to form citrate. This is the first step in the tricarboxylic acid cycle (TCA) (Krebs 
and Johnson 1980). The subsequent series of oxidations of the intermediates by nicotinamide 
adenine dinucleotide (NAD
+
) and flavin adenine dinucleotide (FAD), and decarboxylations, 
yield metabolic intermediates and high energy carrier molecules NADH and FADH2. The 
metabolic intermediates feed into important anabolic reactions such as nucleotide, fatty acid, and 
amino acid biosynthesis. NADH shuttles high energy electrons and hydrogens to the electron 
transport chain (ETC). The TCA cycle reactions are summarized in Figure 1.  
The ETC is made up of enzymatic complexes I, II, III, and IV (Hederstedt and Rutberg 
1981; Weiss, Friedrich et al. 1991; Benit, Lebon et al. 2009; Srinivasan and Avadhani 2012), that 
are involved in redox reactions. NADH molecules are oxidized by complex I 
(NADH:ubiquinone oxidoreductase), shuttling hydrogen ions (H
+
) out of the mitochondrial 
matrix and into the intermembrane space. In addition to proton translocation from the matrix to 
the intermembrane space, electrons are also passed onto the ubiquinone molecule.   Of the 37 
mitochondrial genes only 13 code for peptides of ETC complex I, III, IV, and V, the rest code for 
tRNA or rRNA molecules used for mitochondrial translation.  
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To date 45 proteins have been identified that make up the ETC complex I (Carroll, 
Fearnley et al. 2006). Of the 45 proteins, 14 are conserved catalytic subunits, essential for 
oxidation/reduction reactions (Hirst 2013). The 14 conserved subunits form a hydrophobic 
domain in the inner mitochondrial membrane and a hydrophilic domain. The hydrophilic domain 
extends into the mitochondrial matrix and contains subunits that interact with NADH, while the 
7 hydrophobic subunits are essential for ubiquinone binding and transfer of electrons from 
NADH (Nakamaru-Ogiso, Han et al. 2010). The soluble conserved subunits are encoded in the 
nuclear DNA while the hydrophobic subunits are encoded in the mitochondrial DNA (Yagi and 
Matsuno-Yagi 2003; Brandt 2006). The other 31supernumerary  proteins are also encoded in the 
nuclear DNA (Hirst 2013). These supernumerary proteins vary by species, and likely play an 
essential role in the stability of complex I, since mutations in their genes can cause diseases 
(Valsecchi, Koopman et al. 2010). The most common complex I disorders are however caused 
by mutations in the conserved regions. These disorders include Leber’s hereditary optic 
neuropathy (LHON), Leigh syndrome (LS), and mitochondrial encephalomyopathy with stroke-
like episodes (MELAS) (La Morgia, Caporali et al. 2014). At 45 subunits and 1,000 kDa in size, 
complex I is the single largest ETC complex (Hirst 2013). Further study is ongoing and 
warranted to determine the involvement of complex I in mitochondrial dysfunction of hereditary 
and non-hereditary neurodegenerative disorders.  
Complex II (succinate dehydrogenase) oxidizes succinate into fumarate, in a flavin 
adenine dinucleotide (FAD)-dependent manner. Unlike complex I, no protons are translocated 
across the inner membrane by complex II. Protons harvested at complex II are used to reduce 
ubiquinone. Complex II is composed of 4 nuclear-encoded subunits, which work in concert to 
oxidize succinate using FAD and shuttle protons and electrons via iron-sulfur clusters to 
4 
 
ubiquinone. Mutations in complex II subunits contribute to LS, mitochondrial 
encephalomyopathy, optic neuropathy, and tumor formation. Complex II has been described as a 
tumor suppressor (Selak, Armour et al. 2005)  
 The electrons are transferred to lipid soluble ubiquinone molecules, which carry the 
electrons (e-) to complex III (cytochrome bc1 complex) where they are transferred to cytochrome 
c. Complex III is a multi-subunit protein complex with both mitochondrial DNA and nuclear 
DNA encoded proteins. Complex III is composed of 11 subunits, of which cytochrome b is the 
only subunit encoded by mitochondrial DNA (Iwata, Lee et al. 1998). Complex III oxidizes 
ubiquinol back to ubiquinone, and in the process translocates 4 protons from the matrix to the 
intermembrane space. In the process complex III reduces cytochrome c. 
Mutations in the genes coding for Complex III subunits can result in a deficits ranging from 
exercise intolerance to encephalomyopathy.  
 Cytochrome c, a small soluble heme-containing protein in the intermembrane space, 
shuttles electrons from complex III to complex IV, where they are transferred onto a molecule of 
O2. By addition of e- to molecular oxygen, two more hydrogens are consumed from the matrix, 
and two molecules of water are generated. Complex IV (cytochrome c oxidase) is the last 
complex in the mitochondrial ETC. It is composed of 14 subunits, 11 of which are encoded in 
the nuclear DNA and 3 of which are encoded by the mitochondrial DNA (Balsa, Marco et al. 
2012). Complex IV oxidizes cytochrome c by sequentially transferring electrons onto oxygen, 
reducing it to water, consuming hydrogens in the process. It also translocates 4 additional 
hydrogens from the matrix into the intermembrane space. Mutations associated with nuclear 
encoded subunits may cause LS and cardiomyopathy. Genetic studies in yeast show that most 
complex IV deficits are due to mutations in nuclear-encoded genes (Zee and Glerum 2006).   
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Movement of H
+
 out of the matrix creates both an electrical and a chemical gradient 
across the inner mitochondrial membrane. The electrical and chemical contribution to energy 
available for work is summarized with the proton motive force (Nernst) equation ΔG = -2.303 
RT ΔpH + nFΔψm. Where ΔG is Gibbs free energy, Δψm is the electrical membrane potential, F 
is the Faraday constant, R is the gas constant, and T is the temperature. ΔpH indicates the 
difference in the concentration of protons inside the mitochondrial matrix compared to the 
intermembrane space.  This energy is utilized to convert adenosine diphosphate (ADP) into ATP 
by the F0-F1-ATP synthase or complex V.  
Complex V is a large 16 subunit complex responsible for the bulk of ATP synthesis in 
eukaryotic cells. At 600 kDa it is second only to complex I in size and complexity (Walker, 
Lutter et al. 1991). It is an F type ATPase, with two main components, the matrix facing F1 
catalytic component and the proton pump Fo component. Fo consists of a rotating cylinder made 
up of multiple c protein subunits, which bind hydrogen. Two other subunits of Fo are the a and b 
subunits, which help secure the Fo to the catalytic F1.   As the Fo turns due to hydrogen binding 
and proton motive force, it turns the gamma stock, projecting from its center (which itself is part 
of F1). This conformational change then induces one beta subunit at a time to bind ADP and 
inorganic phosphate and synthesize ATP. The F1 multi-subunit complex is a trimer of alpha-beta 
dimers whose beta subunits cycle through open and closed conformation and catalyze ATP 
synthesis. In order to generate one molecule of ATP, approximately four hydrogens need to be 
translocated into the matrix through the ATP synthase (Turina, Samoray et al. 2003). The ratio of 
H
+
/ATP likely varies under different cellular requirements.  Except for 2 mitochondrial DNA 
encoded subunits (A6 and A8), the rest of the complex V subunits are encoded by the nuclear 
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DNA (Schon, DiMauro et al. 2012) Mutations in either the mitochondrial genes or nuclear genes 
coding for complex V can cause neonatal death and encephalopathy.   
 
For a graphical summary of the ETC please see Figure 2. The nascent ATP molecule is 
either consumed in the matrix or is transported out of the mitochondria for use in the cytosol via 
the adenine nucleotide transporter, which transports 1 molecule of ATP across the inner 
mitochondrial membrane to the inner membrane space for every 1 molecule of ADP it brings in 
to the matrix (Liu and Chen 2013). Damage to TCA cycle enzymes or ETC complexes can result 
in profound energy and anabolic intermediate deficits. This makes highly dynamic and energy 
demanding cells like neurons more sensitive to mitochondrial damage.  
 
Mitochondrial fusion and fission  
Mitochondria replicate by fission and combine to exchange membrane, metabolites, and 
proteins by fusion.  Fission is mediated by a conserved cytosolic GTPase Drp1. This protein is 
conserved in flies, worms and mammals. Drp1 attaches to the outer membrane of the 
mitochondria and constricts the mitochondria, severing both the inner and outer membrane. 
Mitochondrial fusion is facilitated by 3 enzymes: Mitofusin-1 (Mfn1), Mitofusin-2 (Mfn2), and 
Opa1.  Mfn1 and Mfn2 facilitate fusion of the outer membrane between two mitochondria, while 
Opa1 governs the fusion of inner membranes. The processes are regulated by post-translational 
modifications and proteolysis (Hoppins, Lackner et al. 2007). Mitochondrial fission and fusion 
are necessary for dividing and non-dividing cells, i.e. neurons. Defects in mitochondrial fusion 
result in neurological problems like dominant optic atrophy and Charcot Marie Tooth disease 
type 2A (Youle and van der Bliek 2012). Single mitochondria contain multiple copies of their 
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genome, and at any time a mitochondrion can contain both normal copies and copies that have 
damage or mutations. This presence of both types of mitochondrial DNA in one cell  is called 
heteroplasmy. In order to compensate for DNA damage, mitochondria fuse and exchange 
proteins, membrane, and RNA, but not DNA, a process called transcomplementation (Schon and 
Gilkerson 2010). Failure of proper mitochondrial fusion and fission can lead to aggregation of 
mitochondria, formation of mega-mitochondria, and eventual cytochrome c release and cell 
death signaling. The formation of mega-mitochondria is a structural change that is different from 
simple mitochondrial swelling. It is a last attempt of mitochondria to decrease ROS production at 
the organelle level before the cell undergoes apoptosis. The mega-mitochondria produce 
significantly less ATP and consume less oxygen in an attempt to lower ROS production 
(Wakabayashi 2002). 
 
Cell signaling, activation of a stress response, and iron metabolism  
Mitochondrial function extends beyond its roles as the powerhouse of the cell. It is 
essential in intracellular signaling, activation of a stress responses, and heme metabolism. 
  
Mitochondrial cell signaling 
Proper signaling from the nucleus to the mitochondria (anterograde signaling) and from 
the mitochondria to the nucleus (retrograde signaling) is essential for proper mitochondrial and 
overall cellular function. Proteins involved in the TCA cycle, fatty acid beta oxidation, 
mitochondrial protein trafficking, mitochondrial transcription, and DNA replications are encoded 
in the nucleus (Dimmer, Fritz et al. 2002; Bolender, Sickmann et al. 2008). Transcription of 
mitochondrial genes coded in the nucleus is under tight control. Specifically, by the nuclear 
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respiratory factors 1 and 2 (NRF-1, NRF-2) that are involved in the regulation of mitochondrial 
biogenesis, and quality control (Kelly and Scarpulla 2004). NRF-1 also controls the transcription 
of mitochondrial transcription factor A, TFAM, which is essential for both mitochondrial DNA 
replication and transcription (Kelly and Scarpulla 2004) . This suggests that nuclear  NRF-1 has 
a high degree of control over mitochondrial DNA replication and transcription.  
 NRF-1 and NRF-2 are activated by a transcriptional co-activator that is responsive to 
nutrient availability and exercise.  This transcriptional co-activator is the peroxisome 
proliferator-activated receptor gamma (PPAR-γ) coactivator-1 alpha (PGC-1) (Puigserver, Wu 
et al. 1998; Wu, Puigserver et al. 1999). The gene coding for PGC-1 alpha, has a cyclic AMP 
response element, CRE, in its promoter region, which is under the transcriptional control of CRE 
binding protein, CREB. Transcription is also controlled by a coactivator CREB binding protein 
CBP.  Cyclic AMP is generated by the adenylyl cyclase enzyme from ATP, after adenylyl 
cyclase is activated by a G protein coupled receptor following receptor stimulation by nutrients, 
hormones, or neurotransmitters. 
It is important to distinguish between NRF-1, NRF-2, and nuclear factor related factor 2 
(Nrf2). Nrf2 is often incorrectly spelled as NRF2, while NRF-1 and NRF-2 are frequently 
incorrectly spelled without the dash further adding to the confusion. While NRF-1 and NRF-2 
are transcription factors increasing the transcription of complexes of the ETC in mitochondria 
(Scarpulla 1997), Nrf2 is a transcriptional activator of nuclear encoded genes containing the 
antioxidant response element (ARE), and code for proteins involved in ROS stress response and 
xenobiotic metabolism (Nguyen, Nioi et al. 2009). This distinction is essential, considering that 
both activation of NRF-1, NRF-2, and Nrf2 can occur under the same conditions (Lerner, Bitto et 
al. 2013).  For example, Lemer et al. showed that inhibition of the molecular target of rapamycin 
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(mTOR) resulted in increased expression of mitochondrial ETC complexes as well as increased 
expression of antioxidant response element containing proteins. Rapamycin was discovered in 
the 1970s in a soil sample from Easter Island, also called Rapa Nui, from which rapamycin was 
named. Rapamycin is produced by Streptomyces hygroscopicus and has been found to have 
antifungal properties (Vezina, Kudelski et al. 1975). Subsequent studies have shown that 
rapamycin resistance is conferred by mutation in any of the conserved regions of the TOR1 and 
TOR2 genes in yeast, which are necessary for the drug to effectively bind (Heitman, Movva et 
al. 1991). Inhibition of mTOR results in G1 cell cycle arrest in yeast and in mammalian T-
lymphocytes (Magnuson, Ekim et al. 2012). The reason for cell cycle arrest are due to the 
pleotropic downstream effects resulting from the inhibition of the master metabolic sensor 
mTOR, including stimulating autophagy and inducing a lack of ribosomal activation by 
phosphorylation of the ribosomal S6K subunit.      
 Retrograde signaling from mitochondria to the nucleus governs stress response, 
differentiation, and maintenance of stem cell populations (Xu, Duan et al. 2013). Mitochondrial 
DNA damage can lead to profound energy and metabolic intermediate deficits.  It is essential 
that genes necessary for a stress response, mitochondrial biogenesis, and repair are activated by 
proper retrograde and anterograde communication between the nucleus and the mitochondria. 
 
Mitochondrial stress response 
If mitochondrial damage is great enough, mitochondria can induce apoptosis by the 
release of cytochrome c into the cytosol. Cytochrome c (cytC) is released into the cytosol 
following ROS-mediated oxidation of cardiolipin, an inner mitochondrial membrane 
phospholipid (Orrenius and Zhivotovsky 2005). Cardiolipin normally anchors cytC to the outer 
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leaflet of the mitochondrial inner membrane.   Cytoplasmic cytC interacts with endoplasmic 
reticulum inositol trisphosphate receptors, which in turn leads to Ca
2+
 release. Excessive Ca
2+
 
levels lead to even higher levels of cytC release from mitochondria. In the cytoplasm cytC 
stimulates caspase-mediated apoptosis.  
To prevent ROS-induced apoptosis, Nrf2 is translocated from the cytoplasm into the 
nucleus where it initiates transcription of ROS responsive genes. Under normal conditions, Nrf2 
is bound to Kelch-like ECH-associated protein 1 (Keap1) and sequestered in the cytoplasm (Itoh, 
Wakabayashi et al. 1999). Possible mechanisms initiating this translocation are the interaction of 
ROS with cysteine sulfhydryl groups in Keap1 and subsequent Nrf2 phosphorylation by MAPK 
or PI3K (Kim, Cha et al. 2010). Once in the nucleus Nrf2 forms a heterodimer with a small Maf 
protein (sMaf) and binds to antioxidant response elements (ARE) 5’-GTGACNNNGCN-3’ in the 
promoter region of genes coding for proteins essential for ROS detoxification (Itoh, 
Wakabayashi et al. 1999; Kensler, Wakabayashi et al. 2007). Some of the proteins include 
catalase, glutathione-S-transfereases, peroxiredoxin I, and superoxide dismutase (Lee and 
Johnson 2004; Zhu, Itoh et al. 2005).       
ROS-mediated damage to ETC complexes can lead to alterations in ATP synthesis 
resulting in decreased ATP production. Ahigh ADP/ATP ratio can activate AMP-activated 
protein kinase (AMPK), which can in the short term stimulate catabolic pathways and in the long 
term activate mitochondrial biogenesis through PGC1-α or stimulate autophagy by inhibition of 
mTOR (Garcia-Roves, Osler et al. 2008; Egan, Shackelford et al. 2011). Like mTOR, AMPK is 
another sensor of cellular metabolic needs. In addition to AMP, AMPK can be activated by 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICAR). AICAR is an intermediate in de novo 
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nucleotide biosynthesis.    These examples of retrograde signaling are essential for maintaining 
proper mitochondrial function and cellular bioenergetics.   
NAD
+
 can directly activate poly (ADP-ribose) polymerase 1 (PARP1), which stimulates 
nuclear DNA repair and induces transcription of NRF-1 (Hossain, Ji et al. 2009; Thomas and 
Tulin 2013). Other retrograde signaling pathways (such as those activated by calcium influx, 
calcineurin, and hypoxia induced factor-1 alpha (HIF-1α)) exist, but were not explored in the 
following studies.  
As mentioned above succinate dehydrogenase has been previously described as a tumor 
suppressor (Selak, Armour et al. 2005). Under normal conditions, succinate is oxidized to 
fumarate. However, if damage or mutation to succinate dehydrogenase occurs, excess succinate 
is released into the cytoplasm, where it can inhibit hypoxia-inducible factor-1α (HIF-1α) prolyl 
hydroxylase, which results in HIF-1α stabilization and oncogenic signaling. HIF-1α responds to 
hypoxic environments and activation can result in angiogenesis. Abnormal signaling due to 
inefficient succinate dehydrogenase activity, therefore, can result in tumor formation.  
 
Iron metabolism  
Iron is essential for proper enzymatic activity in the cytoplasm and nearly every organelle 
of the cell including mitochondria (Sheftel, Stehling et al. 2010). Iron’s ability to readily undergo 
a change in oxidative state is why it is so essential in many redox enzymes. It is also the reason 
why inappropriately transported and sequestered iron can contribute to many neurodegenerative 
diseases, including Parkinson’s disease, by participating in Fenton chemistry. During the Fenton 
reaction hydrogen peroxide is converted to the hydroxyl radical, by interacting with Fe
2+
. To 
avoid generation of ROS, iron is sequestered by proteins or protein cofactors, as iron-sulfur 
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clusters or heme functional groups. Proper iron sequestration is essential, since heme synthesis 
and iron sequestration take place in the mitochondria. Mitochondria are also the largest producer 
of intracellular hydrogen peroxide from monoamine oxygenase activity and superoxide dismutase 
activity.  
Iron is brought into the cell via transferrin receptor 1 (TfR1)-mediated endocytosis and is 
directed to mitochondria for further processing (MacKenzie, Iwasaki et al. 2008). The endosome 
is acidified reducing the pH to 6, which releases iron from Tf, allowing it to bind to divalent 
metal transporter (DMT1) after the Fe
3+
,
 
now free from Tf, is reduced by endosomal membrane 
bound ferric reductase (Steap3) (Ohgami, Campagna et al. 2005). The endosome fuses with 
mitochondria in a “kiss-and-run” model delivering iron to the intermembrane space for further 
processing (Sheftel, Zhang et al. 2007). Fe
2+
 is transported into the matrix via mitoferrins, iron 
transporters (Shaw, Cope et al. 2006). Once in the matrix, Fe
2+ 
can either be sequestered (into 
mitochondrial ferritin oligomers), incorporated into heme groups, or into iron-sulfur clusters (Fe-
S clusters). For detailed reading on Fe-S clusters and heme biosynthesis in mammals we direct 
readers to the following reviews (Ajioka, Phillips et al. 2006; Lill and Muhlenhoff 2008). 
Dysfunctional endosomal transport of iron to mitochondria can predispose the cell to excessive 
ROS, as is suggested from much Parkinson’s disease research.  
 
Roles of mitochondria in aging and neurodegenerative diseases 
Mitochondrial dysfunction is a major contributor to the progress of neurodegenerative 
diseases, for which no cures or effectives treatments exist. Mitochondrial dysfunction is also a 
well-established contributor to the normal progress of biological aging. The mechanisms by 
which mitochondrial dysfunction contributes to the progress of these diseases, and methods by 
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which this dysfunction can be ameliorated remain incompletely understood. This lack of 
knowledge is underscored by the ongoing research into mitochondrial dysfunction in diseases 
such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). Here we propose 
mechanisms by which mitochondrial dysfunction occurs in Alzheimer’s disease models, 
Parkinson’s disease models, and in a novel in vitro model of mitochondrial mutation and age-
related mitochondrial dysfunction. We also explored metabolic and nutritional approaches that 
could potentially improve mitochondrial dysfunction and improve outcomes of these diseases. 
Additionally, we speculate on causes of mitochondrial dysfunction in the spinal cord of ALS 
patients. In this chapter we will discuss the role mitochondria play in each of these diseases 
followed by chapters detailing the research performed, the results, and a short discussion of the 
relevance of the research. Lastly, translational approaches and clinical applications will be 
discussed.  
 
Aging and mitochondria  
Mitochondrial dysfunction has been shown to contribute to human phenotypes of aging, 
which include alopecia, neuronal degeneration, kyphosis, and sarcopenia (Marzetti, Calvani et al. 
2013), and to age related neurodegenerative diseases (Osiewacz 2010).  Recently, these 
phenotypes were recapitulated in a premature aging mouse model (Kujoth, Hiona et al. 2005; 
Loeb, Wallace et al. 2005).  In this model, the exonuclease activity of the mitochondrial DNA 
polymerase γ (POLG) was knocked out (POLGD257A/D257A), resulting in a premature adult onset 
presentation of aging phenotypes.  We have used immortalized mouse embryonic fibroblasts 
(MEFs) from these mice as a model to study the efficacy of mTOR inhibition or AMPK 
activation, on delaying mitochondrial dysfunction in these cells to get a better understanding of 
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what effect these agents might have on the aging phenotypes of the mice.  AICAR and 
rapamycin are known modulators of AMPK and mTOR respectively. As previously discussed, 
inhibition of mTOR or activation of AMPK in some cell types can improve mitochondrial 
function. Inhibition of mTOR has also been shown to extend life in a heterogeneous population 
of mice (Harrison, Strong et al. 2009). We also determined how these modulators differentially 
affected mitochondrial function when glucose and pyruvate levels in the culture media were 
varied.   
 
Alzheimer’s and mitochondria 
Hyperphosphorylated tau protein and improperly processed amyloid precursor protein are 
well established contributors to the progress of Alzheimer’s disease and mitochondrial 
dysfunction (Villemagne, Ataka et al. 2009; Cohen, Guo et al. 2011; Huang and Mucke 2012; 
Garcia-Escudero, Martin-Maestro et al. 2013).  Amyloid-beta is a product of sequential 
processing of amyloid precursor protein (APP) by beta and gamma secretases. Several mutations 
in either the gene coding for APP, presenilin-1 (PSEN1) or presenilin-2 (PSEN2) result in 
increased amyloid-beta formation due to improper processing of APP. Presenilin proteins 
comprise a subunit of the gamma secretase complex. These findings and others have led to the 
dominant hypothesis that in the field of Alzheimer’s research coined the “amyloid cascade” 
hypothesis by Hardy and Higgins (Hardy and Higgins 1992). The exact role of APP is unknown, 
but its detection early in embryogenesis suggests it is important in early neuronal development 
(Ott and Bullock 2001). APP knockout mice are viable but show mild neurological deficits, 
suggesting that APP is important in maintaining normal neuronal function (Dawson, Seabrook et 
al. 1999). 
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The tau protein functions to stabilize microtubule networks within the cells. It has several 
serine/threonine and tyrosine sites at which it can be phosphorylated.  Hyperphosphorylation 
creates neurofibrilary tangles that impede intracellular trafficking, including that of 
mitochondria. Several mutations in APP have been found that result in improper amyloid 
processing but no mutations in tau exist that cause Alzheimer’s disease. Hyperphosphorylated 
tau is none the less a hallmark of AD pathology. Since the discovery of the APP mutants, and 
their contribution to early onset AD, much drug discovery research has been focused on 
amyloid-beta clearance. Familial forms of frontotemporal dementia and Parkinsonism, such as 
the form caused by a tau P301L missense mutation result in tau hyperphosphorylation, and AD-
like pathology (Mirra, Murrell et al. 1999). Mouse models of this FTD have been created and can 
be used to advance neurofibrillary tangle therapeutic research.  
Calorie restriction has been shown to be the only robust method to extend the lifespan 
and health span in multiple species including rodents and non-human primates (Weindruch, 
Walford et al. 1986; Colman, Beasley et al. 2014). This includes delaying the age of onset for 
many neurodegenerative diseases. Whether CR accomplishes this by improving global 
mitochondrial function in the brain by improving mitochondrial function in a specific 
subpopulation of cells, or by improving cognitive function in a mitochondria- independent 
manner remains incompletely understood (Lee, Seroogy et al. 2002; Levenson and Rich 2007) .  
Therefore, it is of interest to determine if CR can delay hyperphosphorylation of tau or improve 
mitochondrial dysfunction induced by hyperphosphorylated tau.   
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Parkinson’s disease and mitochondria 
Parkinson’s disease (PD) is a movement disorder brought on by degeneration and death 
of dopaminergic neurons in the substantia nigra pars compacta region of the brain. The alpha-
synuclein (α-syn) protein aggregates with other proteins to form Lewy bodies, which have been 
found in post mortem tissue of PD patients and have been hypothesized to be a major contributor 
to the progression of PD. Several mutations in the SNCA (α-syn) gene have been shown to result 
in familial form of PD.  These include the A30P, A53T, and E46K α-syn mutations and they 
continue to be studied (Mbefo, Fares et al. 2015).  Mutations in other genes can also contribute to 
the development of PD. These include mutations in leucine-rich repeat kinase 2 (LRRK2), 
PARK2 (Parkin), PTEN-induced putative kinase 1 (PINK1), DJ-1, and ATP13A2 (Kitada, 
Asakawa et al. 1998; Davie 2008). PINK1 and LRRK2 are associated with mitochondrial 
function and mitochondrial quality control. Pesticides, rotenone, paraquat, and exposure to heavy 
metals have been implicated in the development of sporadic PD (sPD) (de Lau and Breteler 
2006; Nistico, Mehdawy et al. 2011; Tanner, Kamel et al. 2011; Moretto and Colosio 2013). 
These environmental factors could contribute to the onset of PD, without the presence of a single 
causative mutation, which is the case in the late onset sporadic form of PD. The substantia nigra 
region of the brain is a rather harsh cellular environment, due to the presence of high levels of 
iron and frequent calcium transients. Exposure to pesticides and herbicides, which are powerful 
oxidants, can expose dopaminergic neurons to excessive ROS levels, resulting in their death.  
Although no mutations in α-syn have been shown to cause sporadic PD, Lewy bodies are 
present nonetheless. Recently, a dinucleotide polymorphism found in the promoter region of the 
α-syn gene (SNCA) has been linked to a sporadic form of PD (Chiba-Falek and Nussbaum 2001; 
Maraganore, de Andrade et al. 2006). This polymorphism results in higher expression of α-syn 
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and predisposition to PD. Overexpressed α-syn oligomerizes and may create amyloid pores, 
which can interfere with endosomal iron transport and mitochondrial iron metabolism as 
discussed above (Volles and Lansbury 2002; Maries, Dass et al. 2003) and also may alter cellular 
Ca
2+
 homeostasis. This disruption of cation homeostasis would result in increased ROS 
production, accelerated by Fenton chemistry. Excessive ROS can damage mitochondrial ETC 
complexes and enzymes involved in the tricarboxylic acid (TCA) cycle. It would be interesting 
to determine if mitochondrial susceptibility in the substantia nigra in PD is caused by cellular 
mitochondrial superoxide dismutase (SOD2) mislocalization and degradation. This has been 
reported in prion disease, which in many ways parallels the pathophysiology of PD (Sinclair, 
Lewis et al. 2013). SOD2 mislocalization could contribute both to the decrease of energy 
production and to the inability of mitochondria to provide metabolic intermediates necessary for 
anabolic reactions. Essential amino acid supplementation and strategies aimed at restoring these 
catabolic and anabolic deficits remain unexplored as potential therapeutic approaches for PD. 
Their use as potential therapeutics is particularly attractive since they are generally regarded as 
safe (GRAS) by the food and drug administration (FDA). Ester forms of amino acids and TCA 
cycle intermediates might be even more effective, since they would not require active transport 
to cross the blood brain barrier. Since amino acids are frequently co-transported with other 
amino acids, treatments with multiple amino acids could prove to be synergistic. Furthermore, 
transporters of essential amino acids serve as sensors and increase transcription of other amino 
acid transporters, which might further increase the effectiveness of this therapeutic approach. 
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ALS and mitochondria 
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease resulting 
in motor neuron degeneration and eventual death. Mitochondrial dysfunction is a well-
established contributor to the progress of ALS (Shi, Gal et al. 2010). Much of the focus of ALS 
research has been neurocentric, since mitochondrial dysfunction is indeed apparent in the upper 
and lower motor neurons. In particular, two competing hypothesis have emerged, the die back 
and die forward hypotheses(Baker 2014).  The die back hypothesis, which states that in ALS 
pathogenesis, death is caused first by events at the neuromuscular junction, and the die forward 
hypothesis, states that neuronal degeneration originates in the neuronal cell body, located in the 
spinal cord or motor cortex. Both of these hypotheses can be reconciled with respect to 
mitochondrial function. In either case mitochondrial dysfunction can occur, contributing to 
energy deficits and neuronal cell death.  However, this narrow view does not consider the 
interaction of neurons, glia, and blood vessels as a whole. Mitochondrial dysfunction could also 
contribute to collapse of the entire neurovascular unit. Furthermore, degeneration of the phrenic 
nerve, which originates in the cervical spine (C3-C6), results in the earliest ALS deaths. Loss of 
diaphragm innervation is the main cause of ALS related-death. We hypothesized that 
mitochondrial dysfunction could be more severe in the cervical spinal cord than the lumbar 
region. Therefore we initiated studies to delineate any differences between mitochondrial 
dysfunction in the cervical vs. lumbar spine, and focused on the role of mitochondrial 
dysfunction in the entire neurovascular unit.  
In the following studies we determined 1) the effects of calorie restriction (CR) on P301L 
tau Alzheimer’s mice mitochondria, 2) the effects of melatonin on mitochondrial complex IV 
activity in young, aged, and in an amyloid-beta producing Alzheimer’s mouse model. We  3) 
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determined the effects of altered glucose and pyruvate levels on mitochondrial electron transport 
chain (ETC) function following AICAR or rapamycin treatment of transformed murine 
embryonic fibroblasts (MEFs) from wild-type and homozygous mitochondrial DNA mutator 
(POLG
D257A/D257A
) mice. We also 4) characterized an syn overexpressing human 
neuroblastoma cell line for mitochondrial dysfunction and used it to screen dozens of metabolic 
intermediates for mitochondrial protection. And most recently, we 5) determined mitochondrial 
ETC alterations in postmortem spinal cord tissue from ALS patients.  From studying 
mitochondrial function in these diverse disease models, we have gained a better understanding of 
electron transport chain dysfunction and the most appropriate ways to ameliorate mitochondrial 
dysfunction to delay the onset and progression of disease.    
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Figure 1 Tricarboxylic acid cycle diagram 
Diagram of the tricarboxylic acid (TCA) cycle above. Gray boxes indicate metabolite produced 
by enzymes in bold. Arrows indicate oxidation of metabolic intermediates and formation of the 
reduced high energy carriers. The triangles indicates the normal direction of the cycle.  
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Figure 2 Electron transport chain diagram 
The diagram above shows the four multi-protein complexes that make up the electron transport 
chain, and complex V FoF1-ATPase. Complexes I-IV use the flux of high energy electrons 
obtained from the TCA cycle to drive the vectoral translocation of H
+
 from the mitochondrial 
matrix to the mitochondrial intermembrane space. This process generates the electro-chemical 
gradient that is then used by complex V to generate ATP.   
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Descriptive statistical analysis  
For the following studies descriptive statistics such as mean, standard deviation, standard error of 
the mean along with 95% confidence intervals were determined. Means were compared using a 
two sample student’s t-test. A normality test (Shapiro-Wilk) was performed. Equal variance tests 
were also performed. Analysis of variance using one-way or two-way ANOVA was performed 
where appropriate. When normality assumptions failed, conservative Bonferroni corrections 
were performed. All the statistical analyses were performed using Sigmaplot software.   
 
Outcomes of the following studies 
In these studies, strategies to prevent or reverse age or neurodegenerative disease-induced 
mitochondrial dysfunction were explored. These strategies included: calorie restriction, 
melatonin treatment, supplementation with metabolic intermediates, and modulation of carbon 
sources along with activation of AMPK or inhibition of mTOR.  
In two mouse models of Alzheimer's disease (APP/PS1 and P301L tau) calorie restriction 
and melatonin treatment were studied. In a cell culture model of sporadic Parkinson's disease, 
supplementation with metabolic intermediates was studied. In a cell culture model of age-related 
mitochondrial dysfunction we explored how modulating carbon sources will affect mitochondrial 
function following pharmacological activation of AMPK or deactivation mTOR. Of these 
strategies, melatonin treatment and supplementation with metabolic intermediates were found to 
be the most effective against Alzheimer's disease and Parkinson's disease respectively.   
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CHAPTER TWO: CALORIE RESTRICTION DOES NOT RESTORE BRAIN 
MITOCHONDRIAL FUNCTION IN P301L TAU MICE, BUT IT DOES DECREASE 
MITOCHONDRIAL FOF1-ATPASE ACTIVITY  
 
Note to Reader: This chapter was published in Molecular and Cellular Neuroscience. 2015 Jun 
3;67:46-54. This chapter has been reproduced with permission from the publisher. The lead 
author was responsible for designing, executing, and supervising all the mitochondrial assays in 
this study. The lead author was also responsible for generating figures, statistical analysis, and 
writing up the manuscript.  
Abstract 
Calorie restriction (CR) has been shown to increase lifespan and delay aging phenotypes 
in many diverse eukaryotic species.  In mouse models of Alzheimer’s disease (AD), CR has been 
shown to decrease amyloid-beta and hyperphosphorylated tau levels and preserve cognitive 
function. Overexpression of human mutant tau protein has been shown to induce deficits in 
mitochondrial electron transport chain complex I activity. Therefore, experiments were 
performed to determine the effects of 4-month CR on brain mitochondrial function in Tg4510 
mice, which express human P301L tau. Expression of mutant tau led to decreased ADP-
stimulated respiratory rates, but not uncoupler-stimulated respiratory rates.  The membrane 
potential was also slightly higher in mitochondria from the P301L tau mice.  As shown 
previously, tau expression decreased mitochondrial complex I activity.  The decreased complex I 
activity, decreased ADP-stimulated respiratory rate, and increased mitochondrial membrane 
potential occurring in mitochondria from Tg4510 mice were not restored by CR.  However, the 
CR diet did result in a genotype independent decrease in mitochondrial F0F1-ATPase activity. 
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This decrease in F0F1-ATPase activity was not due to lowered levels of the alpha or beta subunits 
of F0F1-ATPase. The possible mechanisms through which CR reduces the F0F1-ATPase activity 
in brain mitochondria are discussed.  
 
Introduction  
Alzheimer’s disease (AD) is characterized clinically by memory and functional deficits 
culminating in progressive cognitive decline. At the tissue level, AD is characterized by 
increased levels of intracellular and extracellular amyloid beta (Aβ) (LaFerla, Green et al. 2007) 
and by the presence of intracellular neurofibrillary tangles (NFTs) resulting from the 
hyperphosphorylation of tau protein (Grundke-Iqbal, Iqbal et al. 1986).  Mutations in the human 
tau gene lead to the progressive formation of NFTs, resulting in early onset frontotemporal 
dementia with Parkinsonism (Mirra, Murrell et al. 1999) and other tauopathies. When expressed 
in mice, mutant tau also results in the progressive formation of NFTs (Lewis, McGowan et al. 
2000). 
Association of mitochondrial dysfunction with AD is well established (Perry, Perry et al. 
1980; Sorbi, Bird et al. 1983; Parker 1991). Furthermore, mitochondrial dysfunction occurs with 
advanced age (Chomyn and Attardi 2003; Romano, Greco et al. 2014) and is hypothesized to 
play a role in the development of AD as outlined in the mitochondrial cascade hypothesis of AD 
(Swerdlow, Burns et al. 2014).  This hypothesis suggests that a patient’s basal mitochondrial 
function and rate of loss of mitochondrial function with age are determined genetically and 
contribute to AD susceptibility. Compensatory mechanisms occurring as a consequence of the 
accrued mitochondrial dysfunction then lead to the AD phenotypes observed (Swerdlow, Burns 
et al. 2014).  Past experiments using transgenic P301L tau mice have shown deficits in 
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mitochondrial electron transport chain complex I and uncoupled respiration (David, Hauptmann 
et al. 2005).  Proteomic analysis of mitochondria further identified a decline in the level of ATP 
synthase subunit D in the P301L mice, which was also identified in postmortem brain from 
human subjects with the P301L tau mutation (David, Hauptmann et al. 2005).  Mitochondrial 
cytochrome c oxidase (complex IV) activity was not altered in the tau transgenic mice (David, 
Hauptmann et al. 2005), but is commonly found in mouse models of AD overexpressing mutant 
forms of amyloid precursor protein (APP) (Du, Guo et al. 2010). 
CR is the only well-established regimen that extends lifespan and healthspan in a 
multitude of organisms including mice and non-human primates (Weindruch, Walford et al. 
1986; Colman, Anderson et al. 2009).  CR, a dietary regimen providing 30-40% less calories 
than normal ad libitum-fed animals, has been shown to be the most robust method of slowing 
down many of the detrimental effects of aging (Sohal and Weindruch 1996), such as increased 
oxygen free radical generation by ETC complex I (Sanz, Caro et al. 2005) and the reduced rate 
of oxygen consumption due in part to declines in ETC complex I and IV activities (Hepple, 
Baker et al. 2006; Singh, Lakhanpal et al. 2012).  However, the degree to which CR increases 
mitochondrial biogenesis remains contested (Nisoli, Tonello et al. 2005; Hancock, Han et al. 
2011; Cerqueira, Cunha et al. 2012).  In some tissues, CR has been shown to prevent the aging-
related decline of mitochondrial function without inducing mitochondrial biogenesis, while in 
other tissues, such as adipose tissue (Lambert, Wang et al. 2004), mitochondrial biogenesis is 
induced by CR. CR and intermittent fasting (IF) have previously been found to be protective for 
the performance of behavioral tasks, which measure cognitive function in triple transgenic 
(3xTgAD) mice that show increased levels of amyloid beta peptide and express P301L tau 
(Oddo, Caccamo et al. 2003; Halagappa, Guo et al. 2007).  This protection is likely mediated by 
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decreased levels of amyloid-beta and phospho-tau in the brains of the CR animals, but the 
protection occurred without significant changes in the levels of these proteins in the IF mice.  In 
another study using the 3xTgAD mice, dietary protein restriction cycles were found to decrease 
phospho-tau levels but not A levels in the brain (Parrella, Maxim et al. 2013).  However CR has 
been shown to be successful in reducing A levels in another report (Mouton, Chachich et al. 
2009), so the specific mouse model, dietary protocol used, or the duration of time on the 
restricted diet appears to be important.  Our current study sought to determine the effects of 4-
month CR on brain mitochondrial function in P301L tau-expressing Tg4510 mice. 
 
Material and methods 
 
Mice and experimental design 
Tg4510 mice and parental mutant tau and tetracycline-controlled transactivator protein 
lines were generated and maintained as described previously (Santacruz, Lewis et al. 2005). The 
major tau pathology in Tg4510 mice is in the forebrain neurons due to tet activator-driven 
expression by the CAM kinase II promoter. These animals develop discernible tau deposition by 
3 months of age, which progresses into neuronal atrophy and loss by 6 months of age.  All 
animals were 3 months old at the start of the study and nontransgenic (Ntg) littermates were used 
as positive control groups (FVB/129S background) (n=10 per group).  Tg4510 mice are 
hyperphagic, but hyperactive and leaner than controls (Brownlow, Joly-Amado et al. 2014). 
Mice were maintained in a specific pathogen-free environment (NIH Guidelines for the care and 
use of laboratory animals) and kept on a twelve-hour light/dark cycle. Water was provided ad 
libitum (AL) throughout the experiment. 
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All animals were individually caged for accurate assessments of food intake and body 
weight as described in (Brownlow, Joly-Amado et al. 2014).  Measurements of daily food 
consumption started when the animals were 3 months old and were carried out for 4 weeks 
before the start of the CR procedure. The CR group received a diet identical in chemical 
constituency to the ad libitum diet except that it was supplemented with micronutrients to 
maintain normal vitamin and mineral intake (diet devised by Dr. Robert Engelman) and 
manufactured at Harlan Teklad (Madison, WI). Thus, the CR diet provided all necessary 
nutrients in a smaller quantity of food.  The non-CR mice were fed ad libitum.  Due to possible 
Tg4510 deaths from acute weight loss due to abrupt initiation of the CR diet, the CR groups were 
slowly transitioned onto the fortified CR diet as described in (Brownlow, Joly-Amado et al. 
2014).  For example, in the first week of the diet the CR mice were given 10% food reduction 
with further reduction in food added on each week for 6 weeks.  The goal of the CR was to 
achieve a 35% reduction in body weight, which was achieved following 6 weeks of the diet and 
then maintained thereafter.  Body weight was assessed 3 times a week for careful observation of 
body weight loss so adjustments could be made to the food offered.  A detailed list of 
macronutrient components of each diet used in this experiment is presented in Table 1. 
At seven months of age the mice were submitted to a battery of behavioral testing as 
recently reported (Brownlow, Joly-Amado et al. 2014).  At 8 months of age, after four months on 
their respective diets, mice were weighed, euthanized with a solution containing pentobarbital 
(100 mg/kg) and transcardially perfused with 25 ml of 0.9% normal saline solution. Brains were 
collected immediately following perfusion. One hemisphere was collected for mitochondrial 
assays and the second hemisphere was frozen for Western blot analysis. The results from the 
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Western blot analysis assaying tau levels and phosphorylation status are presented in (Brownlow, 
Joly-Amado et al. 2014). 
 
Mitochondrial isolation 
Single mouse cerebral hemispheres were placed in 3 ml of ice cold mitochondrial 
isolation buffer (MIB) (75 mM sucrose, 0.1% BSA, 1 mM EGTA, 215 mM mannitol, 20 mM K
+
 
HEPES, pH 7.2) immediately after brain extraction. Cerebral hemispheres were quickly minced 
using a surgical scalpel, scooped into a spatula, and transferred to a glass dounce homogenizer. 
After homogenization using 3-4 slow strokes, the homogenate was aliquoted into 4 
microcentrifuge tubes and spun at a speed of 1,300 x g for 5 minutes at 4⁰C. The supernatant was 
transferred to new microcentrifuge tubes and centrifuged at 13,000 x g for 10 minutes at 4⁰C 
pelleting the mitochondria. The pellet was re-suspended in 500 µl of ice cold mitochondrial 
isolation buffer without EGTA yielding roughly 6 mg protein/ml of mitochondrial suspension. 
The tube was kept on ice for up to 2 hours for the experiments. 
  
Oxygen consumption analysis 
From the mitochondrial suspension, 50 µl was placed into a Strathkelvin Mitocell 
MT200A respiratory chamber with Clark type electrode, containing 300 µl of respiratory buffer 
(125 mM KCl, 1 mM MgCl2, 2 mM KH2PO4, 5 mM pyruvate, 2.5 mM malate, 500 μM EGTA, 
20 mM HEPES, pH 7.2) at 37⁰C with a stir bar. Respiratory state 2 (mitochondria in buffer with 
respiratory substrates), state 3 (with the addition of 1 mM ADP), state 4 (with the further 
addition of 11 µM oligomycin), and state 5 (with the further addition of 457 nM FCCP) were 
obtained. Each state was recorded for 2 minutes. The middle 1 minute was chosen for slope 
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analysis. 1 mM ADP, 457 nM FCCP, and 11 µM oligomycin (final concentrations) were added 
through the injection port using a Hamilton syringe. 
 
Reactive oxygen species level measurements 
2’,7’-dichlorodihydrofluorescein diacetate was used to detect reactive oxygen species 
(ROS) levels. Following hydrolysis of the acetate esters by mitochondrial esterases, 
dichlorodihydrofluorescein is produced.  Dichlorodihydrofluorescein, when oxidized by ROS 
becomes the highly fluorescent compound dichlorofluorescein (DCF). A 2’,7’-
dichlorodihydrofluorescein diacetate stock solution of 500 µM was made up in 2% DMSO in 
PBS and the tube was wrapped in foil to prevent exposure to light.  An assay concentration of 50 
µM was obtained by mixing 10 µl of the stock solution with 80 µl of mitochondrial respiratory 
buffer plus 10 µl of the mitochondrial suspension per well in a 96-well plate. In some assays, 5 
mM pyruvate was omitted and replaced with 5 mM DL-beta-hydroxybutyrate (βHB).  As a 
positive control, 0.5 µl of 100% EtOH was added, as it can greatly stimulate mitochondrial ROS 
production at complexes I and III (Cunningham and Bailey 2001).  The plate was incubated in 
the dark at 37°C for 30 minutes. The fluorescence was then measured using a Biotek Synergy-2 
microplate reader with an excitation filter of 485/20 nm and emission filter of 528/15 nm. 
 
Mitochondrial membrane potential determination  
The cationic carbocyanine dye JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl-
benzimidazolycarbocyanine iodide) was used to monitor the mitochondrial membrane potential. 
JC-1 selectively accumulates in mitochondria based on the membrane potential where its 
emission shifts from green (~530 nm) to red (~600 nm). A 10 M stock solution of JC-1 was 
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made in PBS.  The mitochondrial sample was incubated with 1 M JC-1 in mitochondrial 
respiratory buffer for 10 minutes at room temperature. For the negative control the mitochondrial 
membrane potential was dissipated by including 457 nM of the protonophore carbonyl cyanide 
4-(trifluoromethoxy) phenylhydrazone (FCCP) in the suspension. Following the incubation 
mitochondria were spun down for 10 minutes at 4°C at 13,000 rpm in a microcentrifuge.  
Mitochondria were washed twice with mitochondrial isolation buffer and then suspended in 450 
µl of PBS, and aliquoted into a 96 well microplate in triplicate (100 µl per well). The microplate 
was read using a Biotek Synergy-2 microplate reader using an excitation filter of 485/20 nm and 
an emission filter of 528/15 nm for green fluorescence and an excitation filter of 530/20 nm and 
an emission filter of 590/35 nm for red fluorescence. We report the signal as red fluorescence 
(polarized) / green fluorescence (depolarized). 
   
ATP synthesis assays in isolated mitochondria 
CellTiter-Glo (Promega, Madison, WI) ATP detection reagent was used to determine the 
levels of medium ATP following a 10 minute 37°C incubation of isolated mitochondria at a 
concentration of ~ 2 mg/ml in respiratory buffer with  10 mM ADP.  CellTiter-Glo reagent was 
combined with the mitochondrial suspension in a 1:1 ratio in a 96-well microplate and then 
shaken for 2 minutes. Luminescence was read using a Biotek Synergy 2 microplate reader. 
 
F0F1-ATPase activity measurements 
A molybdenum-based assay measuring free phosphate was used to determine the F0F1-
ATPase hydrolytic activity of frozen-thawed isolated mitochondria. The reaction buffer 
consisted of 80 mM KCl, 3 mM MgCl2, 5 mM sodium azide, 0.2 mM EGTA, 0.2 mM CaCl2, 
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and 25 mM MOPS. The pH was adjusted to 7.0 using Tris base.  2 µM oligomycin was added to 
control samples to obtain the F0F1-ATPase-independent rate of phosphate release, which was 
subtracted off.  The coloring solution consisted of 0.7 mM ammonium heptamolybdate, 3 mM 
ascorbic acid, 100 µM potassium antimony tartrate, and 140 mM H2SO4 made from stock 
concentrations of 0.3 M ascorbic acid, 4 mM potassium antimony tartrate and 24 mM 
ammonium heptamolybdate. 1 mM ATP and 10 µg/ml of mitochondrial protein were added to 
the reaction buffer at 37°C.  After a 10 minute incubation, 270 L of coloring solution was added 
to 30 L of reaction buffer (containing ATP and mitochondrial protein) and the absorbance was 
read at 850 nm on a Biotek Synergy 2 microplate reader 4 minutes later. 
 
ATP synthesis assays in permeabilized N2a and HEK293 cells 
N2a and HEK293T cells stably expressing human P301L tau were grown in T-75 flasks 
using M10 culture media (DMEM with 10% FBS, 30 µg/ml penicillin, 50 µg/ml streptomycin, 
and 2 mM glutamine). Following trypsinization, cells were pelleted and re-suspended in buffer A 
(150 mM KCl, 25 mM Tris-HCl, 2 mM EDTA, 0.1% BSA, 10 mM potassium phosphate, 0.1 
mM MgCl2, pH 7.4) containing 75 µg/ml digitonin. Cells were incubated for 2 minutes at room 
temperature while gently tapped in a 1.5 ml microcentrifuge tube. The permeabilized cells were 
spun down by centrifugation at 1,200 x g for 5 min. The permeabilized cells were washed with 
buffer A (without digitonin), spun down again, and then suspended in 1.4 ml of  buffer A with 5 
mM malate and 10 mM pyruvate or 5 mM succinate and 5 µM rotenone. 140 µl of a 3 mM di-
adenosine pentaphosphate stock solution yielding a final concentration of 267 µM was added to 
tubes containing the permeabilized cell suspensions.  25 ul of the suspension was placed into 
each well of a 96-well microplate. 2.6 µl of 1 mM oligomycin (made up in DMSO) yielding a 
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final concentration of 94 µM was added to control wells. The plate was then incubated for 1 
minute at room temperature. 25 µl of 0.2 mM ADP yielding a final concentration of 0.1 mM was 
added to all wells. 50 µl of CellTiter-Glo solution was added to each well at 1 minute intervals 
quenching the reaction. The luminescence was read using a Biotek Synergy 2 microplate reader 
10 minutes later. Control values, those obtained in the presence of oligomycin, were subtracted 
off those obtained in the absence of oligomycin.  Best fit straight lines through the 0, 1, and 2 
minute data points were used to obtain the initial mitochondrial ATP synthesis rates. 
  
Western blots 
For the western blots, the mitochondrial fraction was centrifuged 10,000 x g for 10 min at 
4°C. The supernatant was poured off and the mitochondrial pellet was resuspended in 8.2 μl/10 
mg protein of buffer B, consisting of 10 mM HEPES, 420 mM NaCl, 0.5 mM dithiothreitol,  
protease inhibitor cocktail (Sigma), and phosphatase inhibitor cocktails I & II (Sigma).  15 µg of 
protein for each sample was loaded and ran on an SDS-PAGE gel. The protein was transferred to 
a 0.2 µm pore size nitrocellulose membrane and immuno-blotted using mouse monoclonal 
antibodies against ATP synthase subunit alpha and ATP synthase subunit beta, which were 
obtained from Life Technologies and used at 1:1,000 and 1:2,000-fold dilution, respectively.  
Fluorescently tagged goat anti-mouse secondary antibodies (IRDye 800CW, LI-COR 
Biosciences) were used at a dilution of 1:10,000.  Band intensities were quantified by 
densitometric analysis and normalized to the band intensity of β-actin (antibody obtained from 
Sigma and used at a dilution of 1:1000) used as a loading control. 
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Protein assays 
A determination of the protein concentration was performed using the BCA protein assay 
(Thermo Scientific Pierce). All results were normalized using the protein concentrations present 
for the assays. 
 
Statistical analysis 
Error bars represent the standard error of the mean.  Two-way ANOVA tests were 
performed with genotype and diet as variables, followed by Fisher’s LSD post hoc means 
comparison on all samples.  * indicates a p value of < 0.05, ** indicates a p-value < 0.005, and 
*** indicates a p-value < 0.001.  Stat View software version 5.0 (SAS Institute Inc., Cary, NC) 
was used for statistical analysis. Graphs were generated using GraphPad Prism version 5.01 (La 
Jolla, CA). 
 
Results 
 
Mitochondria from Tg4510 mice show decreased state 3 oxygen consumption rates 
and respiratory control ratios  
Cerebral mitochondria were isolated from Tg4510 (expressing P301L tau) and 
nontransgenic (Ntg) control mice fed either an ad libitum or CR diet.  State 2, state 3, state 4, and 
state 5 oxygen consumption rates (as outlined in Table 2) were measured using the isolated 
mitochondria. The results are shown in Fig. 3 A. No genotype or diet differences were found in 
the state 4 and state 5 respiratory rates. However, we did find that Tg4510 mice had slightly 
lower state 2 and state 3 (ADP-stimulated) respiratory rates than Ntg controls (ANOVA 
genotype effect, p<0.05), regardless of diet.  Fig. 3 B shows the respiratory control ratios (RCRs) 
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defined as the ratio of state 3 to state 4 respiration, as well as the ratios of state 5 to state 4 
respiration.  These ratios provide an excellent indication of both electron transport chain activity 
and the impermeability of the inner mitochondrial membrane to protons as a direct indicator of 
the ATP synthesizing capability of the organelle. The Tg4510 mice showed a decreased RCR 
compared to the Ntg mice (ANOVA genotype effect, p=0.02), as shown previously (David, 
Hauptmann et al. 2005).  The CR diet had no appreciable effect on the RCRs.  No genotype or 
diet-induced differences in the state 5 to state 4 respiratory ratios were observed as well. 
 
Mitochondria from Tg4510 mice show increased ROS production in the presence of 
ethanol stress 
We next measured reactive oxygen species (ROS) production from the mitochondria. 
Either malate plus pyruvate or malate plus beta-hydroxybutyrate (βHB) were used as respiratory 
substrates.  βHB was used because it is a respiratory substrate present at higher levels during CR 
conditions when pyruvate and glucose levels are low. Under standard conditions, no genotype or 
diet-induced differences in ROS production were observed when using either malate plus 
pyruvate or malate plus βHB as respiratory substrates (Fig. 4 A), although there were trends 
toward increased ROS production when assaying mitochondria from the ad libitum fed Tg4510 
mice. However, following incubation with 0.5% ethanol, which stimulates ROS production at 
electron transport chain (ETC) complexes I and III (Bailey, Pietsch et al. 1999), genotype 
dependent differences were revealed (ANOVA genotype effect, p =0.01, Fig. 4).  Under the 
ethanol stress, the Tg4510 mitochondria produced more ROS than Ntg controls independent of 
the respiratory substrates oxidized. This is consistent with the results from a previous study 
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(David, Hauptmann et al. 2005).  In addition, the presence of βHB instead of pyruvate in the 
respiratory buffer consistently led to substantially increased ROS production (p=0.001). 
    
Mitochondria from Tg4510 mice show increased membrane potential 
A mitochondrial membrane potential assay was performed using the potentiometric 
fluorescent probe JC-1.  Surprisingly, mitochondria from Tg4510 mice showed a trend for higher 
membrane potential than Ntg controls (ANOVA genotype effect, p=0.09) and this effect was 
independent of the diet (Fig. 5). In addition when comparing only mice on the CR diet, Tg4510 
mitochondria had a higher membrane potential than Ntg controls (t-test, p<0.05).  The uncoupler 
FCCP was used as a negative control to dissipate the membrane potential. 
 
CR does not restore the reduced mitochondrial ETC complex I activity in Tg4510 
mitochondria 
We next determined ETC complex I activity from the mitochondrial extracts.  As shown 
in Fig. 6, mitochondria from Tg4510 mice showed a decreased complex I activity (ANOVA 
genotype effect, p=0.001). This finding is similar to the findings in previous reports (Rhein, 
Song et al. 2009; Lasagna-Reeves, Castillo-Carranza et al. 2011).  Consistent with the inability 
of CR to restore other mitochondrial functional parameters in this study, the CR diet did not 
prevent the decreased complex I activity in the Tg4510 mice. 
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No change in the levels of the alpha and beta subunits of ATP synthase in isolated 
mitochondria from Tg4510 mice 
The fact that ADP-stimulated (state 3) respiratory rates were lower in mitochondria from 
the Tg4510 mice than controls, but uncoupler-stimulated (state 5) respiratory rates were not 
lower in the Tg4510 mice suggests a possible P301L tau-induced deficiency of mitochondrial 
ADP transport or ATP synthesis.  Therefore, Western blot analysis was performed on the alpha 
and beta subunits of the F0F1-ATP synthase complex to determine if lower levels were present in 
isolated Tg4510 mitochondria. No difference in the amount of these subunits was detected in any 
of the mitochondrial samples (Fig. 7 A and 7 B). In addition, no tau band could be detected on 
the blots from the mitochondrial fractions (data not shown). Therefore, a direct interaction 
between tau and complex I is not likely responsible for the decreased complex I activity present. 
 
No change in isolated mitochondrial ATP production in Tg4510 mice or in CR mice 
To obtain further data regarding the ability of mitochondria from Tg4510 mice to 
transport and phosphorylate ATP, we performed assays measuring the ATP synthesizing 
capacity of the isolated mitochondria using malate plus pyruvate (Fig. 8 A) or malate plus βHB 
(data not shown) as respiratory substrates. For this assay, energized mitochondria were incubated 
in the presence of ADP and phosphate for 10 minutes and then the ATP in the suspension was 
measured. Due to experimental constraints, time course experiments were subsequently 
performed in immortalized cells. No genotype or diet-induced differences in ATP levels were 
observed between groups. However, mitochondria oxidizing malate plus pyruvate produced 
significantly more ATP than mitochondria oxidizing malate plus BHB (p < 0.05) (data not 
shown).   
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A decreased rate of mitochondrial ATP synthesis in digitonin-permeabilized N2a-
P301L tau cells 
To further determine if mutant tau expression has an effect on mitochondrial ATP 
synthesis, we used cell culture models and measured the rate of oligomycin-sensitive ATP 
synthesis in digitonin-permeabilized N2a (Fig. 8 B) or HEK293T (Supplementary Fig. 10) cells 
with or without stable expression of P301L tau.  The permeabilized cells were given the 
respiratory substrates malate plus pyruvate that primarily generate NADH, which is oxidized 
through ETC complex I.  Strikingly, P301L tau expression decreased the rate of ATP synthesis 
in the neural N2a cell line, but not in the non-neural HEK293T cell line.  To determine if the 
decreased rate of ATP synthesis in the N2a-P301L tau cells was primarily due to decreased 
complex I activity, a similar ATP synthesis experiment was performed, but this time 
administering succinate, an ETC complex II linked respiratory substrate instead of malate plus 
pyruvate.  Rotenone, an ETC complex I inhibitor was also added to prevent oxidation of 
endogenous complex I-linked respiratory substrates.  As shown in Fig. 8 B, the cells in both 
succinate treated groups generated ATP at a much lower rate than when oxidizing malate and 
pyruvate.  In addition, there was no significant difference in the rate of ATP synthesis when 
comparing digitonin-permeabilized N2a and N2a-P301L tau cells indicating that complex I 
dysfunction was the major determinant for the decline in ATP synthesis in these cells when 
oxidizing NAD-linked respiratory substrates.  The data do not suggest that there is a functional 
deficit in mitochondrial ADP/ATP transport or F0F1-ATP synthase activity in the P301L tau-
expressing cells.   
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Mitochondria from CR mice show decreased F0F1-ATPase activity 
One last assay was performed on isolated brain mitochondria to determine if any 
alteration of mitochondrial F0F1-ATPase activity was induced by P301L tau expression.  
Mitochondria samples were frozen and thawed several times to disrupt the membrane integrity, 
ATP was added, and oligomycin-sensitive ATPase activity was measured by monitoring the 
release of free phosphate. We found no difference in F0F1-ATPase activity as a result of P301L 
tau expression. But surprisingly, there was a significant decrease in oligomycin-sensitive ATPase 
activity in mitochondrial homogenates from mice on the CR diet regardless of the genotype 
(ANOVA, diet effect p=0.0003) (Fig. 9). 
 
Discussion 
In this study we found that 4 months of CR did not restore cerebral mitochondrial ETC 
complex I deficits mediated by P301L tau overexpression. In addition there was a strong 
decrease in cerebral mitochondrial F0F1-ATPase activity in mitochondria from mice of all 
genotypes on the CR diet. 
   
Tau inhibition of mitochondrial ETC complex I 
Consistent with published data (David, Hauptmann et al. 2005), we observed P301L tau 
expression to decrease mitochondrial ETC complex I activity.  Somewhat unexpectedly, this 
reduced activity was not prevented by CR (as shown in Fig. 2.4), as CR has previously been 
shown to decrease phospho-tau levels (Halagappa, Guo et al. 2007).  In our study, since the 
uncoupled respiration of mitochondria oxidizing the complex I-dependent substrates malate and 
pyruvate was not affected by tau expression, but tau expression decreased complex I activity,  
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there must be spare respiratory capacity in complex I so that the activity of complex I does not 
limit the maximal (uncoupled) respiratory rate. 
 
Tau expression does not decrease F0F1-ATPase activity or the levels of two ATP 
synthase subunits 
The mitochondrial levels of the alpha and beta subunits of the F0F1-ATPase did not 
change with mutant tau expression or following a CR diet (Fig. 7 A and 7 B) suggesting that in 
our model, neurofibrillary tangles (NFTs) did not prevent F0F1-ATPase subunit translocation into 
the mitochondrion, in contrast to a report that found the accumulation of the ATP synthase alpha 
subunit in the cytoplasm in association with neurofibrillary tangles (Sergeant, Wattez et al. 2003) 
. In mammals all but two of the F0F1-ATPase subunits are encoded by nuclear DNA, synthesized 
by cytosolic ribosomes, and translocated into the mitochondria.  We did not find any evidence of 
mitochondrial F0F1-ATPase deficiency induced by P301L tau expression, while others have 
found mutant tau expression to decrease ATP levels and the levels of ATP synthase D chain 
(David, Hauptmann et al. 2005).  However, we did not measure the level of this subunit. 
 
Behavior of Tg4510 mice on the CR diet 
We have recently published the results of a thorough behavioral characterization of the 
mice used in this study (Brownlow, Joly-Amado et al. 2014).  The Tg4510 mice had decreased 
body weight even though they consumed more food, likely due to increased locomotor activity.  
The CR diet was shown to increase short term memory in the Tg4510 mice in the novel object 
recognition test and there was a trend for improvement in contextual memory with mice 
undergoing CR.  However, there were no improvements in spatial memory deficits as well as no 
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effect on tau deposition markers in the Tg4510 mice on the CR diet.  Since the CR diet did not 
improve mitochondrial respiratory function of the mice as shown here, some other positive 
effects of CR are likely responsible for the improved behavior.  In this regard mutant tau is 
known to both inhibit mitochondrial transport and alter mitochondrial fission and fusion 
dynamics (Eckert, Nisbet et al. 2014), which could potentially be normalized by the CR diet.  In 
addition, CR decreases neuroinflammation (Morgan, Wong et al. 2007) and increases 
neurogenesis (Levenson and Rich 2007),  which may also be responsible for the protective 
effects of CR on the behavior. 
 
Possible mechanisms for the decreased state 3, but not state 5 respiration rate in 
mitochondria from Tg4510 mice 
Another group studying mitochondrial function in P301 tau transgenic mice found 
defects in both the state 3 (ADP-stimulated) and the state 5 (uncoupler-stimulated) respiratory 
rates (David, Hauptmann et al. 2005), where we only found a deficit in the state 3 respiratory 
rate.  This is likely due to the different strains of mice used in the two studies. In the previous 
study tau expression in the mice was driven by the neuron-specific mThy1.2 promoter, while in 
our study tau expression is driven by the CAM kinase II promoter.  The decreased state 3 but not 
state 5 respiratory rates in the Tg4510 cerebral mitochondria used here (Fig. 3), suggests that 
either ADP transport into mitochondria is reduced or that the F0F1-ATP synthase activity is 
decreased in these mice. 
We found the F0F1-ATPase (ATP-hydrolyzing) activity to be normal in the Tg4510 mice.  
However, a limitation to our study is that we did not directly measure the reverse reaction, the 
ATP synthase activity or the rate of ADP/ATP transport into and out of the isolated 
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mitochondria.  In addition, the RCR of the isolated mitochondria was low, even in the Ntg 
controls, possibly indicating damage during the isolation procedure that could have affected our 
results.  A further limitation is that our measurement of ATP synthesis in isolated brain 
mitochondria only captured a single time point and did not measure a rate, so small changes in 
ATP synthesis activity could easily have been missed.  So, we cannot rule out the possibility that 
Tg4510 brain mitochondria possess a slightly decreased F0F1-ATP synthase activity with a 
normal F0F1-ATPase activity that could explain the decreased state 3, but normal state 5 
respiratory rates in the Tg4510 mitochondria in our study. 
Another possible explanation for the decreased ADP-stimulated respiratory rate in 
Tg4510 mitochondria is hindered transport of ADP and ATP into or out of the mitochondria. The 
adenine nucleotide translocase (ANT) is responsible for the reversible exchange of ADP/ATP 
into and out of the mitochondrial matrix, while VDAC (voltage-dependent anion channel) 
proteins are responsible for the transport of nucleotides and other solutes across the outer 
mitochondrial membrane. Adenine nucleotide translocase-1 (ANT-1) has been shown to be 
inhibited by a caspase-cleaved, truncated form of tau (Amadoro, Corsetti et al. 2012).  A tau 
mediated inhibition of ANT function may also be responsible for the increased mitochondrial 
membrane potential observed in mitochondria from Tg4510 mice.  The ANT can mediate both 
basal and fatty acid-mediated mitochondrial uncoupling (Brustovetsky and Klingenberg 1994; 
Shabalina, Kramarova et al. 2006), which decreases mitochondrial membrane potential.  Another 
possible explanation for the decreased state 3 respiratory rate is that tau associates with VDAC 
and inhibits ADP and ATP transport across the outer mitochondrial membrane in neural 
mitochondria.  In this regard, tau has been shown to associate with VDAC1 and high levels of 
VDAC1 occur in AD brain (Manczak and Reddy 2012).   
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Possible mechanisms through which CR decreases F0F1-ATPase activity 
CR has previously been shown to slightly decrease F0F1-ATP synthase activity in rat 
heart (Colom, Oliver et al. 2007). We have shown a much larger decrease in F0F1-ATPase 
activity in cerebral mitochondria as a result of CR in both mice expressing mutant tau and age-
matched Ntg counterparts.  Since the ADP-stimulated respiratory rate was not altered in Ntg CR 
mice, the rate of the forward reaction of F0F1-ATP synthase is not likely altered by CR, but the 
reverse F0F1-ATPase reaction appears greatly slowed by the CR diet.  We predict that the 
decreased F0F1-ATPase activity plays a protective role in neural cells during CR.  In times of low 
glucose in the brain such as in times of CR, the TCA cycle and mitochondrial NADH and 
FADH2 levels may decline due to respiratory substrate limitation resulting in decreased ETC-
mediated proton pumping and a decreased mitochondrial membrane potential (MMP).  To 
compensate for the decreased MMP, the F0F1-ATP synthase likely reverse its normal direction 
and hydrolyzes ATP to pump protons.  This reversal could potentially deplete cellular ATP 
levels resulting in bioenergetic collapse and cell death.  Limiting mitochondrial F0F1-ATPase 
activity under these conditions would minimize loss of ATP, maintaining cellular energy 
reserves, thus protecting from cell death.  But the MMP must not be totally dissipated under 
these conditions as it is required for protein import and other essential mitochondrial functions. 
There are several mechanisms through which CR may lead to decreased F0F1-ATPase 
activity. One possibility is through alteration of F0F1-ATP synthase post-translational 
modification such as by protein acetylation.  In this regard, the majority of ATP synthase 
subunits are acetylated, with many of them being acetylated at multiple residues (Foster, Liu et 
al. 2013).  For example ATP synthase subunit alpha was found to have 26 acetylation sites, the 
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most of any mitochondrial protein. The mitochondrial protein deacetylase SIRT3 is upregulated 
by CR (Someya, Yu et al. 2010).  The deacetylation of the OSCP (oligomycin-sensitivity 
conferring protein) subunit of ATP synthase was shown to stimulate ATP synthase activity in 
muscle (Vassilopoulos, Pennington et al. 2014).  In liver, even though SIRT3 deacetylase was 
upregulated by CR, there was an increase in total protein acetylation levels (Hebert, Dittenhafer-
Reed et al. 2013; Nakamura, Kawakami et al. 2013). SIRT3-mediated deacetylation of ATP 
synthase beta subunit was also shown to increase ATP synthase activity (Rahman, Nirala et al. 
2014). 
Another possible mechanism as to how CR may decrease F0F1-ATPase activity is through 
increasing the levels or activity of its natural inhibitor, mitochondrial ATPase Inhibitor Factor 1 
(IF1).  IF1 overexpression has been described to promote cell survival through transcriptional 
activation of the NFκB pathway (Formentini, Sanchez-Arago et al. 2012).  CR may induce IF1 
expression or increase its activity through post-translational modification. Overexpression of IF1 
has been shown to preserve mitochondrial morphology and inner membrane architecture and 
prevent apoptotic signaling (Faccenda, Tan et al. 2013). IF1 is found to be acetylated under 
normal physiological conditions in Hartley guinea pig hearts (Foster, Liu et al. 2013), so we 
speculate that deacetylation of IF1 by SIRT3 could play an active role in its regulation during 
CR. 
 
Conclusions 
Four months of CR did not rescue the decreased cerebral ETC complex I activity in mice 
expressing P301L tau. Since mutant tau expression caused decreased ADP-stimulated, but not 
uncoupler-stimulated respiratory rates, hyperphosphorylated tau may induce functional deficits 
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in mitochondrial ANT, VDAC, or ATP synthase activities in brain.  Future studies will focus on 
determining the effects of P301 tau expression on the transport of ADP and ATP across 
mitochondrial membranes and the effects of P301 tau expression on the rate of ATP synthase 
activity in freshly isolated brain mitochondria.  In addition, CR significantly reduced F0F1-
ATPase activity in brain, which is likely an important neuroprotective mechanism under these 
conditions.  Therefore, future studies will determine the CR-induced changes in the post-
translational modifications of IF1 and the many subunits of the mitochondrial F0F1-ATP synthase 
and the consequence of these modifications on function.  
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Table 1 Calorie restriction diet information 
 
 
 
 
 
Table 2 Definitions of mitochondrial respiratory states 
State  Definition                            Note: RCR= State 3/State 4 
2 Mitochondria and respiratory substrate present 
3 ADP added 
4 Oligomycin (ATP synthase inhibitor) added 
5 FCCP  (uncoupler) added 
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Figure 3 Respiratory states 
Decreased state 2 and 3 respiratory rates and respiratory control ratio (RCR) in Tg4510 
mitochondria.  A) Respiratory rates and B) RCRs of isolated mouse cerebral mitochondria from 
Tg4510 and Ntg control mice.  Mitochondria were suspended in a buffer containing malate and 
pyruvate (Mal/Pyr).  1 mM ADP, 11 M oligomycin (Oligo), and 457 nM FCCP were added 
sequentially.  The state 2 and state 3 respiratory rates of Tg4510 mitochondria were less than Ntg 
controls (ANOVA genotype effect, * p < 0.05).  The RCR (state 3/state 4) of Tg4510 
mitochondria was also less than Ntg controls (ANOVA genotype effect, * p = 0.02).  AL =fed an 
ad libitum diet. CR= fed a calorie restricted diet. 
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Figure 4 ROS production 
ROS production from Tg4510 or Ntg cerebral mitochondria. Mitochondria were given either 
malate plus pyruvate or malate plus BHB as respiratory substrates in the presence or absence of 
0.5% ethanol and DCF fluorescence was measured. Ethanol induces ROS production at 
complexes I and III.  In the presence of ethanol, Tg4510 mitochondria produced more ROS 
irrespective of the respiratory substrates oxidized (ANOVA genotype effect, * p < 0.05).  In the 
presence of ethanol, mitochondria oxidizing malate plus BHB produced more ROS than those 
oxidizing malate plus pyruvate (ANOVA respiratory substrate effect, *** p < 0.001). 
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Figure 5 Mitochondrial membrane potential 
Mitochondrial membrane potential of Tg4510 or Ntg cerebral mitochondria.  Membrane 
potential was measured by JC-1 fluorescence either in the absence or presence of an uncoupler of 
oxidative phosphorylation, FCCP.  There was an overall trend for increased membrane potential 
in Tg4510 mitochondria (ANOVA genotype effect, p = 0.09).  And specifically, Tg4510 CR 
mitochondria had a higher membrane potential than Ntg CR mitochondria (t-test, * p < 0.05). 
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Figure 6 ETC complex I activity 
CR does not restore decreased complex I activity in mitochondria from Tg4510 mice.  Tg4510 
mitochondria had lower complex I activity than Ntg mitochondria (ANOVA genotype effect, * p 
< 0.05). 
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Figure 7 ATP synthase alpha and beta subunits 
No change in the levels of ATP synthase subunits in Tg4510 mice.  A) Western blot for the 
alpha-subunit of ATP synthase using cerebral mitochondrial lysates from Tg4510 and Ntg 
control mice.  B) Western blot for the beta-subunit of ATP synthase using cerebral mitochondrial 
lysates from Tg4510 and Ntg control mice.  
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Figure 8 ATP levels and ATP production 
The effect of P301 tau expression on mitochondrial ATP synthesis rates. (A) Medium ATP 
levels following administration of ADP to isolated Tg4510 and Ntg mouse cerebral 
mitochondria.  (B) Medium ATP levels in the presence of digitonin-permeabilized stably 
transfected P301L tau and control N2a cells given ADP, Pi and either malate and pyruvate or 
succinate and rotenone. The 2 bar graphs on the right show the rates of ATP synthesis over the 
first 2 minutes of the reaction. 
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Figure 9 FoF1-ATPase activity 
Decreased F0F1-ATPase activity in mitochondria from mice undergoing CR.  Mice on a CR diet 
had decreased mitochondrial F0F1-ATPase activity (ANOVA diet effect, p < 0.001).  When 
comparing genotypes separately, Ntg CR mice had lower F0F1-ATPase activity than Ntg AL 
controls (t-test, p < 0.005) and Tg4510 CR mice also had lower F0F1-ATPase activity than 
Tg4510 AL controls (t-test, p < 0.05). 
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Figure 10 supplemental Mitochondrial ATP production 
No effect of P301 tau expression on mitochondrial ATP synthesis in digitonin-permeabilized 
HEK293T cells. Levels of mitochondria-synthesized ATP in digitonin-permeabilized control and 
stably transfected P301L tau N2a cells administered ADP, Pi and malate and pyruvate as 
respiratory substrates. The complete method is described in the Material and Methods section. 
The amount of ATP measured in the presence of oligomycin, a mitochondrial F0F1-ATP 
synthase inhibitor, was subtracted off to obtain the level of mitochondria-synthesized ATP. No 
statistical difference was obtained between groups following calculation of the best fit straight 
lines through the data points as a measurement of the rate of ATP synthesis.   
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CHAPTER THREE: MELATONIN’S MITOCHONDRIAL PROTECTIVE ROLE IN 
ALZHEIMER’S MICE: ROLE OF MELATONIN RECEPTORS  
 
Note to Reader: This chapter was published in Melatonin: Therapeutic Value and 
Neuroprotection CRC Press, Oct 31, 2014. This chapter has been reproduced with permission 
from the publisher. The lead author was responsible for enrichment of mouse brain samples for 
mitochondria and complex IV assay optimization. The lead author was also responsible for 
training and supervising the execution of 2 different complex IV assays in this study. The lead 
author was also responsible for generating figures, statistical analysis, and contribution to writing 
of the manuscript. 
  
Abstract 
Melatonin is a powerful antioxidant that has been shown to be cytoprotective in cell 
models and neuroprotective in mouse models of neurodegenerative diseases such as Alzheimer’s 
disease (AD).  But the role, if any that the MT1 and MT2 melatonin receptors play in this 
protection in AD models has not been well studied.  Three to six months of treatment with the 
MT1/MT2 receptor agonist ramelteon (3 mg/kg/day) showed little to no benefit in the 
improvement of cognition or amyloid plaque pathology in AD mice. But piromelatine (Neu-
P11), which functions both as an MT1/MT2 receptor agonist and as a serotonin 5-HT1A/1D 
receptor agonist, was even more protective than melatonin in the prevention of cognitive 
performance decline and the prevention of hippocampal cell loss in rats following hippocampal 
injection of amyloid-beta, the major component of plaques found in AD brain. Hippocampal and 
cortical brain regions from AD patients and animal models are often characterized by 
mitochondrial dysfunction, which may include cytochrome c oxidase deficiency, other oxidative 
phosphorylation (such as complex I and complex V) defects, dysregulation of components of the 
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TCA cycle, and impaired mitochondrial dynamics. Melatonin protected against the aging-
induced decline and the amyloid-beta-mediated dysregulation of brain mitochondrial function in 
a mouse model of AD, with the protection being partly dependent and partly independent of the 
MT1 and MT2 melatonin receptors.   Therefore melatonin receptors likely play a critical role in 
the preservation of mitochondrial function during aging and AD.  
 
Alzheimer’s Disease 
Dementia affects 35 million people worldwide and this total is predicted to increase to 
over 60 million people in 2030 and over 100 million people by 2050.  Due to this sharp increase 
in prevalence and the high cost for healthcare for these individuals, treatments that prevent or 
even delay the onset of dementia are highly sought.  In this regard melatonin has been identified 
as a compound that may delay the onset of certain types of dementia.  In this chapter we will 
discuss the potential of melatonin as a treatment for Alzheimer’s disease (AD), the most 
prevalent form of dementia and the role that melatonin and its cellular receptors play in this 
process. 
AD is characterized clinically by memory and functional deficits culminating in 
progressive cognitive decline. The vast majority of individuals with AD are 65 years of age or 
older. The likelihood of developing Alzheimer’s doubles roughly every five years after age 65. 
The risk reaches nearly 50 percent after the age of 85.  Another strong risk factor is family 
history as both genetics and environmental factors play a role in disease development. 
In the brain, AD mostly affects the hippocampal and cerebral cortical regions and is 
characterized by the presence of extracellular amyloid beta (Aß) plaques, intracellular soluble 
Aß, and also by the presence of intracellular neurofibrillary tangles (NFTs) caused by the 
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hyperphosphorylated microtubule-associated tau protein. Familial or early onset forms of AD 
exist, make up around 5% of total AD cases, and are generally caused by mutations in by 
mutations in the presenilin-1 (PS1) or presenilin-2 (PS2) genes located on chromosome 14 or the 
amyloid precursor protein (APP) gene located on chromosome 21. The most prevalent (~ 85%) 
of these familial forms are caused by mutations in PS1.   95% of AD cases are sporadic, with age 
being the largest risk factor. The single largest genetic factor associated with late onset 
Alzheimer’s disease (LOAD) is the ε4 allele of the apolipoprotein E (APOE) gene (Corder, 
Saunders et al. 1993; Strittmatter, Saunders et al. 1993). It likely contributes to 20-25 percent of 
LOAD cases.  The APOE gene, coding for the major cholesterol binding protein in the human 
brain, apoliprotein E, exists as three polymorphic alleles (ε2, ε3 and ε4) resulting in 6 different 
genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4) (Mahley 1988; Bu 2009). The presence of 
one ε4 allele increases the likelihood of a person developing AD by three to four times (Corder, 
Saunders et al. 1993; Bertram and Tanzi 2008). Antecedent factors influencing AD progression 
are cardiovascular disease, smoking, hypertension, type II diabetes, obesity, and traumatic brain 
injury (TBI) (Mayeux and Stern 2012).  
 
Mitochondrial dysfunction as a contributing factor in AD 
Mitochondrial dysfunction occurs with aging (Harman 1972; Chomyn and Attardi 2003; 
Kujoth, Hiona et al. 2005; Wallace and Fan 2009) and also contributes to the pathophysiology of 
many diseases that occur as a normal part of aging.  An association between mitochondrial 
dysfunction and AD is well established (Perry, Perry et al. 1980; Sorbi, Bird et al. 1983; Parker 
1991). Redox imbalance and oxidative stress, which frequently develop as a result of 
mitochondrial dysfunction, have been observed in aging and neurodegenerative disorders such as 
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AD. This oxidative stress may lead to damage of important mitochondrial components such as 
mitochondrial DNA, mitochondrial proteins such as the electron transport chain (ETC) 
components, and mitochondrial phospholipids, especially to cardiolipin, which contains a high 
percentage of unsaturated fatty acids. Damage to the ETC proteins or cardiolipin, required for 
ETC complex function, may result in decreased ETC oxygen consumption, ATP production, and 
mitochondrial membrane potential, and also increased ROS production. This damage to 
mitochondria has also been shown to result in dysregulation of mitochondrial dynamics (e.g. 
fission, fusion, transport, mitochondrial biogenesis, and mitophagy) and if severe enough results 
in mitochondrial-mediated apoptosis. The mitochondrial damage has been shown to be most 
severe in areas adjacent to amyloid plaques (Xie, Guan et al. 2013). 
Mitochondrial dysfunction can have varying effects depending on the degree.  Small 
amounts of mitochondrial dysfunction, which typically slightly increase ROS production or 
decrease ATP levels can activate retrograde signaling and be compensated for by increased 
mitochondrial biogenesis. Two signals for mitochondrial biogenesis which occur as a result of 
mitochondrial dysfyunction include increased ROS production and AMP-activated protein 
kinase (AMPK) activation. Both of these signals can lead to the activation of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), which binds nuclear 
respiratory factors-1 and 2, estrogen related receptor-alpha and other transcription factors which 
increase expression of proteins targeted to mitochondria.   When damage to mitochondria 
becomes too great to be compensated by increased mitochondrial biogenesis and/ or degradation 
of damaged mitochondria through mitophagy, mitochondrial dysfunction arises that can lead to 
cell death. 
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Due to the fact that amyloid plaques are one of the two major phenotypic markers of AD, 
many strategies have been employed to pharmacologically decrease their formation, or once they 
have formed, to break them down and remove the plaque components from the brain.   
Unfortunately, anti-amyloid drugs have shown little success in AD treatment (Herrmann, Chau et 
al. 2011). Therefore, novel multi-pronged research strategies need to be employed that attack 
other phenotypes of AD.  With this in mind, much scientific evidence links mitochondrial 
dysfunction with Alzheimer’s disease (AD), yet therapies targeting mitochondrial dysfunction in 
AD have yet to be methodically tested in human patients.  Several research groups have 
discovered altered activities of the mitochondrial citric acid cycle enzymes and electron transport 
chain complexes, predominately complex IV, in the brains from postmortem AD patients 
(Bubber, Haroutunian et al. 2005) and in transgenic mouse models of familial AD (Hauptmann, 
Scherping et al. 2008). Mitochondrial ATP synthase levels have also been found to be low in AD 
brain (Schagger and Ohm 1995).  Specifically, mitochondrial dysfunction is one of the earliest 
symptoms in double mutant London and Swedish APP transgenic mice (Hauptmann, Scherping 
et al. 2008).  Mitochondrial dysfunction occurs in these mice at 3 months of age, at an age before 
extracellular deposits of amyloid beta peptide (Aß), and much earlier than memory impairment.  
Therefore mitochondrial dysfunction may be an initiating event in AD, an idea which has been 
formalized in the mitochondrial cascade hypothesis of AD (Swerdlow and Khan 2004; 
Swerdlow, Burns et al. 2013).  
An oligomeric form of Aß likely dimeric Aß has been described to inhibit cytochrome c 
oxidase of the mitochondrial electron transport chain (Crouch, Blake et al. 2005). Through this 
interaction, as well as through an interaction with complex I (Munguia, Govezensky et al. 2006), 
Aß stimulates increased reactive oxygen species production from the ETC, which may ultimately 
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lead to cell death through opening of the mitochondrial permeability transition pore in the inner 
mitochondrial membrane.  This event uncouples mitochondrial oxidative phosphorylation and 
releases mitochondrial factors such as cytochrome c and apoptosis inducing factor (AIF) into the 
cytoplasm, where caspases execute the apoptotic program.  Knockout of cyclophilin D, a 
mitochondrial matrix peptidylprolyl cis-trans isomerase and Aß-binding protein (Du, Guo et al. 
2008) that facilitates mitochondrial permeability transition pore opening, increases learning and 
memory and synaptic function in a mouse model of AD (Du, Guo et al. 2008).  In this regard, 
APPswe overexpression upregulates mitochondrial cyclophilin D (Manczak, Mao et al. 2010), 
which facilitates mitochondrial permeability transition pore opening and cell death. High Aß 
levels, in addition to inhibiting the mitochondrial ETC, have been shown to decrease TCA cycle 
enzyme activities (Bubber, Haroutunian et al. 2005), alter the rates of mitochondrial fission and 
fusion (Manczak, Calkins et al. 2011), decrease the rate of mitophagy (Santos, Correia et al. 
2010), and decrease axonal transport of mitochondria (Calkins, Manczak et al. 2011). 
But whether mitochondrial dysfunction plays an initiating role in human AD disease 
pathogenesis, specifically in the synaptic or neuronal loss associated with the late onset form of 
AD is controversial. It may as yet prove that mitochondrial dysfunction is a result of other AD 
pathology. In this regard some reports of normal mitochondrial function in AD models have been 
published.  For example, mitochondrial function appeared mostly normal in presynaptic nerve 
terminals in mouse models of AD (Choi, Gerencser et al. 2012). But the ability of Aß, a common 
component of AD plaques (Pereira, Santos et al. 1998); hyperphosphorylated tau, a component 
of neurofibrillary tangles (David, Hauptmann et al. 2005); and apolipoprotein E4 (Chang, ran Ma 
et al. 2005), a major risk factor for late-onset AD, to each cause mitochondrial dysfunction lends 
strong support for a mitochondrial etiology for AD. 
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Melatonin protects mitochondrial, cell, and brain function in AD mice in many ways.  
Melatonin has long been used to alleviate jet lag and to modify circadian rhythms.  
However, its potential use as an antioxidant in the treatment of disease is gaining momentum, 
especially since controlled release formulas having a more favorable pharmacokinetic profile 
have been developed (Lemoine and Zisapel 2012). Melatonin can be used to increase the amount 
of total and REM sleep (Dijk and Cajochen 1997). Sleep itself can protect against AD as Aß and 
other metabolic waste products are more quickly cleared from brains in the sleeping state than 
during wakefulness (Xie, Kang et al. 2013). This has led some to suggest that disrupted circadian 
rhythms may be partly a cause instead of a result of AD (Bedrosian and Nelson 2012).  
Melatonin has an advantage over many other antioxidants such as Vitamin E in that it is freely 
permeable to the brain (Lahiri, Ge et al. 2004).  Melatonin has been reported to extend the 
lifespan of APP transgenic mice (Matsubara, Bryant-Thomas et al. 2003) and prevent cognitive 
dysfunction in APP/PS1 mice (Olcese, Cao et al. 2009), although it failed to reverse cognitive 
dysfunction if melatonin treatment was initiated after the initiation of cognitive impairment (G. 
Arendash, unpublished data).  Others also found little to no positive effect of melatonin on 
oxidative stress or amyloid burden when treatment was initiated late in life in a mouse AD model 
(Quinn, Kulhanek et al. 2005).  Melatonin was also shown to decrease immunoreactive Aß levels 
(Olcese, Cao et al. 2009) and protein nitration (Matsubara, Bryant-Thomas et al. 2003) in the 
brain of AD mouse models.  Melatonin is hypothesized to delay AD in mice through preventing 
Aß oligomerization (Pappolla, Bozner et al. 1998; Olcese, Cao et al. 2009), preventing reactive 
oxygen species-mediated damage (Ionov, Burchell et al. 2011), and by stabilizing mitochondrial 
function in the presence of increased levels of Alzheimer’s amyloid (Dragicevic, Copes et al. 
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2011) or phosphorylated tau (Peng, Hu et al. 2013).  One study found that supplementation of 
Tg2576 mutant amyloid precursor protein-expressing Alzheimer’s mice with melatonin from 8-
12 months of the lifespan was critical, because treating the mice with melatonin from 4-8 months 
of life was ineffective (Peng, Hu et al. 2013). 
 
Melatonin receptors 
In the plasma membrane, two receptors for melatonin, MT1 and MT2 have been 
identified.  These melatonin receptors are seven-pass G-protein coupled receptors (GPCR) that 
can homo- or heterodimerize and can signal through multiple signaling pathways in different 
cells by using distinct G-protein alpha subunit isoforms.  Melatonin has sub-nanomolar affinity 
for these receptors (Dubocovich and Markowska 2005), which allows the receptors to be 
activated when melatonin levels rise due to increased pineal gland secretion at night. The MT1 
and MT2 genes, located on chromosomes 4q and 11q, respectively show 55% identity and 
encode proteins of 350 and 365 amino acids in length.  The intracellular portions of the receptors 
contain casein kinase 1 and 2, protein kinase A, and protein kinase C phosphorylation sites. MT1 
and MT2 are especially found at high density in the suprachiasmatic nucleus in the brain (Liu, 
Weaver et al. 1997) where they are bound by melatonin and influence the diurnal rhythm. 
mRNA levels of the MT1 receptor have also been shown to undergo diurnal variation (Guerrero, 
Gauer et al. 1999). The classic action of melatonin receptor signaling is to dissociate 
heterotrimeric G proteins where the Gα and Gßγ subunits interact with various signaling 
pathways.  In the suprachiasmatic nucleus following melatonin binding, the Gαi2 and Gαi3 
isoforms have been described to inhibit adenylate cyclase activity (Brydon, Roka et al. 1999).  
This event decreases cAMP levels and decreases pituitary adenylate cyclase-activating protein 
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(PACAP)-mediated CREB activation affecting the circadian clock (Travnickova-Bendova, 
Cermakian et al. 2002). 
In addition to inhibiting cAMP mediated signaling, melatonin receptors can activate 
phospholipase C signaling through Gq-coupling (Chan, Lai et al. 2002).   This activates Ca
2+
-
mediated and protein kinase C (PKC) phosphorylation cascades. These signals activate 
calmodulin kinase and mitogen-activated protein kinase (MAPK) signaling kinases including 
p38, JNK, and ERK.  There is also evidence that melatonin receptor activation may lead to  
stimulation of the PI3 kinase/Akt pathway or opening of different ion channels such as voltage-
gated calcium channels or large conductance calcium-activated potassium channels (Hardeland 
2009).  In addition to these effects mediated by GPCRs, melatonin can also interact directly with 
quinone reductase 2, orphan nuclear receptors such as retinoid Z receptor (RZR) and retinoid 
acid receptor-related orphan receptor (ROR),  calmodulin, calreticulin, and other proteins 
(Reiter, Tan et al. 2010). The melatonin receptor-related protein GPR50, an orphan GPCR that is 
45% identical to melatonin receptors, can bind to MT1 and function as an antagonist (Levoye, 
Dam et al. 2006). From this collection of data it is apparent that melatonin and melatonin 
receptors act through many different complex signaling mechanisms to affect cellular 
physiology. 
The melatonin MT1 and MT2 receptors play complementary roles in cell function.  MT1 
receptors are found in similar, but not identical locations.  MT1 is located in the suprachiasmatic 
nucleus, cerebellum, hippocampus, substantia nigra, and many other tissues of the body while 
MT2 receptor expression is mostly restricted to brain including the suprachiasmatic nucleus, but 
expression has been found in a few other tissues as well, but not to the extent of MT1 
(Dubocovich and Markowska 2005). In the suprachiasmatic nucleus, MT1 and MT2 receptors 
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appear to play different roles.  MT1 receptor activation leads to acute inhibition of neuronal 
activity, while MT2 activation leads to the phase shift of circadian rhythm (Liu, Weaver et al. 
1997; Hunt, Al-Ghoul et al. 2001).  Some of these studies using brain slices have also been 
confirmed in mice with specific knockout of the MT1 receptor or in mice administered 4P-
PDOT, a specific inhibitor of MT2 (Dubocovich, Hudson et al. 2005).   The phenotypes of the 
MT1 and MT2 receptor knockouts are subtle (Jin, von Gall et al. 2003) and phenotypes have 
mainly been found at the molecular level, with the exception of the lack of phase-shifting effect 
of melatonin in the MT1 receptor knockout mice and a deficit in learning and memory in the 
MT2 receptor knockout mice (Dubocovich, Hudson et al. 2005; Larson, Jessen et al. 2006). 
 
Melatonin receptors and the hippocampus 
The hippocampus plays a key role in memory and is the main site of dysfunction in AD.  
Both MT1 and MT2 receptors are expressed in the hippocampus, specifically in the CA1 and 
CA3 regions, the subiculum, and the dentate gyrus (Musshoff, Riewenherm et al. 2002).  
Administration of melatonin to hippocampal slices was shown to increase the neuronal firing 
rate, which was blocked by luzindole, which shows a slight selectivity for MT2 over MT1.  
Melatonin also showed an inhibition of long term potentiation in hippocampal slices, which was 
inhibited by both luzindole and 4P-PDOT, a more specific inhibitor of MT2 (Wang, Suthana et 
al. 2005).  MT1 and MT2 knockout mice were used to confirm these observations (Dubocovich, 
Hudson et al. 2005; Larson, Jessen et al. 2006).  To verify that MT2 is involved in learning and 
memory, MT2 knockout mice were tested in the elevated plus maze paradigm (Larson, Jessen et 
al. 2006).  A marked inhibition of learning was measured indicating a deficiency in long term 
synaptic plasticity.  
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In human studies it was shown that the time of day that melatonin was administered 
drastically altered the effect of melatonin on learning behavior (Gorfine and Zisapel 2007). 
These studies implicated melatonin and the circadian clock in human memory processing and 
consolidation.  In further neuroimaging studies, it was shown that melatonin administration was 
as effective as a 2-hour nap in increasing performance in a verbal association test (Gorfine, 
Yeshurun et al. 2007).  Future studies should aim to confirm these initial human studies on the 
effects of melatonin on learning behavior and determine other paradigms where melatonin 
treatment may be beneficial. 
 
Mitochondrial localization of the MT1 melatonin receptor in mice 
Melatonin MT1 receptors have been localized to brain mitochondria in mice, whereas 
only a trace amount of MT2 receptors could be found in this subcellular localization (Wang, 
Sirianni et al. 2011).  Interestingly, MT1 receptor levels declined in the R6/2 mouse model of 
Huntington’s disease and this decline, including the decline in mitochondrial levels, was delayed 
by melatonin treatment, which also delayed disease pathology in these mice.  Therefore, the 
decline in MT1 receptors induced by mutant huntingtin protein may be a contributing factor to 
the disease.  It is currently unclear what role, if any, that mitochondrial MT1 receptors play in 
brain physiology and if these declines occur in other neurodegenerative disorders such as AD, 
but identifying the mitochondrial role of MT1 receptors will likely prove instrumental in 
understanding the protective effect of melatonin treatment for neurodegenerative diseases. 
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AD patients have decreased melatonin levels 
Involvement of melatonin in the pathogenesis of AD has been suggested from studies 
indicating that AD patients have decreased blood and cerebrospinal fluid (CSF) levels of 
melatonin (Maurizi 1997).  In AD patients ApoE4 allele status also plays a role in determining 
melatonin levels as APOE4 homozygotes had the lowest melatonin levels (Liu, Zhou et al. 
1999). Unexpectedly, in C6 glioma cells, expression of APOE4, the allele most associated with 
development of AD, expression increased melatonin levels compared to expression of APOE3 or 
APOE2 (Liu, Meng et al. 2012). Perhaps different results would be obtained in neuronal cells or 
in primary, non-transformed cells.  In addition, lower CSF levels of melatonin have been 
strongly correlated with progression of AD neuropathology, and preclinical AD subjects already 
have decreased CSF melatonin levels. In addition to these findings suggesting that decreased 
melatonin levels are an early event in AD pathogenesis, epidemiologic studies have reported that 
melatonin treatment provides cognitive benefit to patients with mild cognitive impairment (MCI) 
as well as AD patients.  The decreased melatonin levels in AD brain may allow oxygen and 
nitrogen free radicals to damage sensitive neurons (Srinivasan, Kaur et al. 2010). 
 
Changes in melatonin receptor levels in aging, Parkinson’s disease, and AD 
MT1 and MT2 receptor levels have been shown to decline with aging in many tissues 
(with the exception of the thymus) in rats (Sanchez-Hidalgo, Guerrero Montavez et al. 2009) and 
mice. There was also a report of the MT1 receptor increasing with age in mice in spleen (Bondy, 
Li et al. 2010).  The level of the MT2 receptor declined in the aged suprachiasmatic nucleus in 
mice (von Gall and Weaver 2008) and humans (Wu, Zhou et al. 2007).  But interestingly the 
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MT2 receptor increased with age in the hippocampus in gerbils (Lee, Choi et al. 2010).  
Therefore, regulation of melatonin receptor levels is likely species specific. 
The MT1 receptor level was shown to increase in hippocampal sections CA-1-4 from AD 
patients (Savaskan, Olivieri et al. 2002), while the MT2 receptor levels declined in these and 
other regions such as the retina in AD patients (Savaskan, Ayoub et al. 2005; Savaskan, Jockers 
et al. 2007).  It is possible that the increased MT1 receptor expression is a compensatory 
mechanism in response to the decreased melatonin levels, while the decreased MT2 receptor 
levels and/or decrease in melatonin levels may contribute to the onset of AD.  In addition to the 
decline in melatonin receptor levels with aging, both MT1 and MT2 receptors have been shown 
to decrease in the substantia nigra and the amygdala in Parkinson’s disease (PD) patients (Adi, 
Mash et al. 2010).  Melatonin has been shown to delay movement problems associated with PD 
in rodent models (Mayo, Sainz et al. 2005).  But the role that the MT1 and MT2 receptors play in 
this protection remains unclear.  
 
Melatonin treatment has shown beneficial effects in AD patients 
Preliminary data with human AD patients showed that melatonin supplementation 
decreased “sundowning”, improved sleep, and slowed disease progression (Maurizi 2001).  A 
slight improvement in cognitive function was observed when melatonin was given to AD 
patients (Brusco, Marquez et al. 1998; Brusco, Marquez et al. 2000; Asayama, Yamadera et al. 
2003).  In addition, a retrospective study showed that melatonin treatment improved cognitive 
performance and sleep quality in patients with MCI (Furio, Brusco et al. 2007).  Several studies 
have also shown that melatonin increases sleep duration and quality in AD patients (Mishima, 
Okawa et al. 2000; Mahlberg, Kunz et al. 2004; Cardinali, Furio et al. 2011).  This data suggests 
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that melatonin may be a beneficial add-on drug for the treatment of AD.  However, there has also 
been a large clinical study showing that melatonin had no effect on sleep or agitation in AD 
patients (Gehrman, Connor et al. 2009).  Therefore larger multi-center double-blind placebo 
controlled studies are needed to clarify these results. 
 
Beneficial effects of melatonin in cell and mouse models of AD 
Cell culture studies using AD model cells have also shown positive results following 
melatonin treatment.  Most of the studies have been performed using mutant amyloid precursor 
protein (APP) overexpression, which is a model of familial AD.  A drawback of these studies is 
that these cells might not address the driving force behind the pathology in LOAD patients.  The 
ApoE4 allele appears to be the strongest determinant of LOAD.  ApoE4 can enhance or inhibit 
toxic fibril formation when bound to Aß depending upon the concentration (Naiki, Gejyo et al. 
1997). Cell culture studies have shown that melatonin can bind to ApoE and inhibit toxic Aß 
fibril formation to a much higher extent than melatonin can inhibit fibril formation by itself 
(Poeggeler, Miravalle et al. 2001).   In culture, melatonin has also been shown to inhibit 
mitochondrial DNA damage and apoptosis induced by Aß (Pappolla, Sos et al. 1997; Pappolla, 
Chyan et al. 1999).  Most of the culture and rodent studies attributed the beneficial effects of 
melatonin to a combination of direct anti-oxidant effects (Ionov, Burchell et al. 2011) and the 
ability of melatonin to prevent toxic Aß fibril formation (Olcese, Cao et al. 2009).  However, 
neither of these explanations satisfactorily explain why melatonin was only able to prevent Aß-
mediated mitochondrial dysfunction in young isolated hippocampal neurons of low (~10) 
passage number, but not in senescent hippocampal neurons of high (~25) passage number (Dong, 
Huang et al. 2010).  A possible explanation for these results is that melatonin receptor expression 
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declined in the senescent neurons and that a portion of the protective effect is mediated by 
melatonin receptor signaling as well. 
Melatonin has shown beneficial effects on cognitive function and plaque formation in 
many rodent studies of amyloid-ß toxicity (Pandi-Perumal, BaHammam et al. 2013). There are 
too many to discuss in this chapter, so we will mention some of the most relevant concerning the 
ability of melatonin to positively impact mitochondrial function. A more detailed examination of 
this topic can be found in the following reviews (Cheng, Feng et al. 2006; Rosales-Corral, 
Acuna-Castroviejo et al. 2012; Cardinali, Pagano et al. 2013; Lin, Huang et al. 2013; Pandi-
Perumal, BaHammam et al. 2013)  First a study showed that both exercise or melatonin 
treatment delayed many of the phenotypes in 3x-Tg AD mice.  But only the combination of 
melatonin and exercise together was able to completely prevent the loss of mitochondrial ETC 
complex protein levels and increase levels of coenzyme Q9, the precursor to the ETC electron 
carrier CoQ10 (Garcia-Mesa, Gimenez-Llort et al. 2012).  Another study showed that 
hippocampal injection of fibrillar Aß into mice led to cellular and mitochondrial uptake that 
increased ROS production and led to a decrease in the respiratory control ratio that was slightly 
increased by the presence of melatonin in the drinking water.  However, an Aß-mediated 
inhibition of the mitochondrial F0F1-ATP synthase was not improved by melatonin 
administration (Rosales-Corral, Acuna-Castroviejo et al. 2012).  Lastly we have shown that the 
ability of a one month melatonin treatment largely reverses mitochondrial dysfunction mediated 
by Aß in Alzheimer’s mice and this restorative effect was blunted in mice receiving melatonin 
and caffeine (Dragicevic, Delic et al. 2012). The mechanism through which caffeine partially 
blocks the effect of melatonin remains unknown, but it is likely through inhibition of melatonin 
receptor signaling.  
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Indole-3-propionamide (IPAM) as an alternative to melatonin for the treatment of 
neurodegenerative disease.  
 Indole-3-propionic acid (IPA) (OXIGON
TM
), a natural metabolite found in almost all 
organisms, and a related indole to melatonin, was reported to be a better anti-oxidant than 
melatonin and just like melatonin showed no pro-oxidant activity (Chyan, Poeggeler et al. 1999).  
However, being an acid, it is hydrophilic and is slow to permeate the blood brain barrier for the 
treatment of neurodegenerative diseases. Nonetheless, a phase II clinical trial using IPA to treat 
Friedreich’s Ataxia was initiated in 2012 (Gomes and Santos 2013).  The same group of 
researchers who discovered the strong antioxidant activity of IPA subsequently published that 
indole-3-propionamide (IPAM) was more effective as an antioxidant than melatonin, but retained 
the hydrophobic nature of melatonin (Poeggeler, Sambamurti et al. 2010). In addition, when i.p. 
injected into rats at 0.5 mg/kg, high IPAM levels could be measured in the brains for over 8 
hours, but melatonin and IPA levels were not even measurable after 1 hour.  IPAM also 
prevented Aß aggregation in a thioflavin T assay just like melatonin and IPA.  Therefore IPAM 
may show the highest potential of any known indole antioxidant for the treatment of 
neurodegenerative diseases. IPAM was also shown to increase the lifespan of a rotifer species by 
300% (Poeggeler, Sambamurti et al. 2010).  IPA treatment had no effect on the lifespan of a 
separate rotifer species (Snell, Fields et al. 2012).  We published that IPA-induced restoration of 
mitochondrial function in N2a-APPswe cells was partially blocked by luzindole (Dragicevic, 
Copes et al. 2011). Therefore, melatonin-related indoles such as IPA and IPAM may be utilizing 
melatonin receptors to protect the cells from the damage-induced by Aß. However, these 
observations should be verified in animal models.  These results suggest IPAM in addition to 
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controlled release melatonin may show beneficial effects in clinical trials for neurodegenerative 
diseases such as AD.  Other melatonin-related compounds, such as the melatonin breakdown 
product AFMK, have also shown promise as a strong antioxidant in the protection of cells from 
oxidative stress induced by Aß (Poeggeler, Miravalle et al. 2001). 
 
Direct effects of melatonin and IPAM on mitochondrial function.  
Melatonin increases mitochondrial function through both direct and indirect mechanisms.  
Binding sites for melatonin have been found on mitochondrial membranes (Yuan and Pang 1991; 
Poon and Pang 1992).  This may be partially explained by the recent localization of the 
melatonin MT1 receptor to mitochondria (Wang, Sirianni et al. 2011).  But melatonin also binds 
mitochondrial complex I with an affinity of 150 pM (Hardeland 2009).  Mitochondrial electron 
transport chain (ETC) complex I and IV activities are stimulated by melatonin in brain (Martin, 
Macias et al. 2000).  Melatonin also preserves mitochondrial respiration in the aging mouse brain 
(Carretero, Escames et al. 2009), in mice given ruthenium red (Martin, Macias et al. 2000), or in 
mice given the ETC complex IV inhibitor cyanide (Yamamoto and Mohanan 2002). Like 
melatonin but more potently, IPAM stimulates complex I and IV activity, and stabilizes 
mitochondrial function in the presence of mitochondrial toxins such as FCCP, doxorubicin, and 
antimycin A (Poeggeler, Sambamurti et al. 2010). 
 
Antioxidant signaling through melatonin receptors 
Melatonin treatment has been shown to increase the mRNA levels of many antioxidants 
in rat brain including Mn-SOD (SOD2) Cu/Zn-SOD (SOD1), and catalase (Kotler, Rodriguez et 
al. 1998; Gunasingh, Philip et al. 2008; Garcia, Esparza et al. 2010). Glutathione peroxidase and 
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glutathione reductase have also been shown to be upregulated by melatonin in certain tissues 
(Carretero, Escames et al. 2009; Limon-Pacheco and Gonsebatt 2010; Pandi-Perumal, 
BaHammam et al. 2013).  It is hypothesized that this upregulation of antioxidant gene expression 
occurs mainly through melatonin receptor signaling as luzindole, an inhibitor of melatonin 
receptors has been shown to partially or completely prevent upregulation of these antioxidant 
genes in various tissues and cell lines (Rezzani, Rodella et al. 2006; Choi, Dadakhujaev et al. 
2011; Adamczyk-Sowa, Sowa et al. 2013).   
 
Superoxide dismutase converts superoxide to hydrogen peroxide and then either catalase 
in the peroxisomes or glutathione peroxidase in the mitochondria or cytoplasm converts the 
hydrogen peroxide to water.  It has been shown that melatonin treatment of rats increased 
mitochondrial superoxide dismutase activity in old rat brain (Ozturk, Akbulut et al. 2012).  It was 
also shown that aging upregulated mitochondrial glutathione peroxidase activity and melatonin 
prevented this response.  Lastly there was an aging-related decline in the superoxide dismutase to 
glutathione peroxidase ratio that was prevented by melatonin treatment.  Therefore, melatonin 
treatment preserves the correct youthful ratio of these enzymes, preventing superoxide increases 
in the cell and oxidative damage.   
Melatonin receptors are not always required for the antioxidant effect of melatonin on 
cells and tissues. In several cases luzindole did not prevent the protective effects of melatonin 
indicating that melatonin’s antioxidant effects can frequently be receptor-independent (Behan, 
McDonald et al. 1999; Lahiri, Singh et al. 2009; Song, Kim et al. 2012).  However, concerning 
the effect of melatonin on neural cells, melatonin was shown to prevent neural ischemic stroke 
injury, partially through a MT2-dependent mechanism as both luzindole and the more selective 
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MT2 antagonist 4P-PDOT (4-phenyl-2-propionamidotetralin) partially blocked melatonin’s 
protective effect (Chern, Liao et al. 2012). Similarly luzindole blocked the protective effect of 
melatonin on the palmitic acid-induced increased in ROS levels and cell death in primary mouse 
astroglial cells (Wang, Liu et al. 2012).  Therefore it will be important to determine if the 
protective effects of melatonin on mitochondrial dysfunction in aging and AD depends on the 
MT1 or MT2 receptors.   
 
Melatonin receptor agonists for the treatment of AD 
There has been in vitro data implicating a role for melatonin receptor signaling in 
mediating a partial protection from Aß-mediated mitochondrial dysfunction (Dragicevic, Copes 
et al. 2011), while two studies showed that AD model mice treated with the melatonin receptor 
agonist ramelteon showed little or no protection from AD pathology. In the first ramelteon 
treatment study, the AD model B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J transgenic mouse strain 
(APP/PS1 mice) was used. The mice were treated with ~3 mg/kg/day of ramelteon and no 
change in cognitive behavior as judged by performance in a water maze was observed after 3 
months of treatment (McKenna, Christie et al. 2012). Even 6 months of ramelteon treatment 
failed to yield reductions in amyloid plaque burden.  The second study, also using an APP/PS1 
mouse strain, determined a lack of effect of ramelteon on spatial memory performance, but did 
find that ramelteon slightly decreased hippocampal protein oxidation in the APP/PS1 mice (Bano 
Otalora, Popovic et al. 2012).  However, a study using the melatonin receptor agonist Neu-P11 
(piromelatine) found that rats which had undergone intrahippocampal injection with Aß 
performed better in novel object recognition and Y-maze tasks and showed less CA1 
hippocampal cell loss when i.p. injected with 50 mg/kg Neu-P11.  The Neu-P11 injected group 
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even outperformed the melatonin injected group (He, Ouyang et al. 2013).  One further piece of 
data that supports the use of melatonin receptor agonists clinically for cognitive dysfunction is 
that ramelteon was shown to improve delirium in five patients after only one day of treatment 
(Furuya, Miyaoka et al. 2012). 
 
The role that melatonin receptors play in protecting AD-associated mitochondrial 
dysfunction 
We have identified melatonin receptors, likely MT2 as being essential for the full 
mitochondrial protective effect of melatonin against Alzheimer’s amyloid (Dragicevic, Copes et 
al. 2011).  We also observed that a low concentration of caffeine or cAMP-dependent or cGMP-
dependent phosphodiesterase inhibitors blocked melatonin from fully protecting against 
amyloid-mediated mitochondrial dysfunction.  Therefore melatonin receptor signaling may 
decrease adenylate cyclase activity to decrease cAMP levels to protect mitochondrial function in 
the hippocampus in AD and inhibiting cAMP-dependent phosphodiesterases may antagonize this 
response by restoring cAMP levels.  Although the mechanism has not yet been fully elucidated, 
direct oxidant scavenging and direct inhibition of amyloid fibril formation are likely not the sole 
mechanisms of melatonin-mediated protection in AD.  Melatonin receptor signaling, therefore, 
likely contributes to the melatonin-mediated prevention of cognitive dysfunction in AD mice.  
Discovering the signal transduction pathway between melatonin receptors and mitochondria is an 
essential next step in determining the suitability of melatonin, melatonin-related indoles, or 
melatonin receptor agonists for clinical trials.  The most straightforward hypothesis is that there 
is increased expression of antioxidant defense proteins as a result of MT2 receptor signaling that 
is protecting mitochondria from oxidative damage in AD model mice and cells. 
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The role that melatonin receptors play in protecting from aging-induced loss of cytochrome 
c oxidase activity in mice 
In data just published at the time of print, we have performed experiments determining 
the role of melatonin receptors in preventing the decline in brain cytochrome c oxidase (COX) 
activity during aging (Fig. 11).  We used striatal tissue from knockout mice deficient in both the 
MT1 and MT2 melatonin receptors.  We found that mice deficient in both MT1 and MT2 
melatonin receptors showed 33% more loss of COX activity at 16 months of age as compared to 
the activity in young mice (67% loss in MT1/MT2 knockout mice compared to 50% loss in WT 
controls).  In addition melatonin treatment completely prevented the loss of COX activity in the 
WT mice, but the melatonin-treated MT1/MT2 receptor knockout mice lost 33% of COX activity 
by 16 months of age.   These data indicate that roughly half of the effect of melatonin in 
preventing aging-related loss of COX activity is MT1 or MT2 receptor-dependent, while the 
other half of the protective effect is receptor-independent.  Future studies will determine which 
of the melatonin receptors is required for the protection from the aging-related loss of COX 
activity. 
 
The role that melatonin receptors play in protecting from AD-induced alteration of COX 
activity in mice 
In further data just published at the time of print, we determined the role that melatonin 
receptors play in protection from APPswe/PS1-induced alteration of COX activity in the striatum 
of mice (Fig. 12).  In contrast to what we were expecting, we did not find a decrease in COX 
activity caused by APPswe expression as we and others have observed when using mice of 
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different genetic backgrounds (Manczak, Anekonda et al. 2006; Dragicevic, Mamcarz et al. 
2010).  In fact we found a striking increase in COX activity from 13 to 16 months of age.  Others 
have also found increased cytochrome c oxidase activity in APP-expressing mice, such as in the 
ventral striatum of APP23 mice partially backcrossed onto a C57B/6 background (Strazielle, 
Sturchler-Pierrat et al. 2003).  This report showed that COX activity increased, but only in 
specific regions of the brain.  COX activity was also shown to increase in Tg2576 mice at 5 
months of age (Poirier, Amin et al. 2011) and in another report in these mice at 7 months of age 
(Cuadrado-Tejedor, Cabodevilla et al. 2013).  Consistent with this data, mitochondrial electron 
transport genes are upregulated in Tg2576 mice (Reddy, McWeeney et al. 2004).  However, 
many others have shown decreased COX activity in different brain regions of Tg2576 mice 
(Manczak, Anekonda et al. 2006; Valla, Schneider et al. 2007; Zhang, Xiong et al. 2010; 
Varghese, Zhao et al. 2011). Decreased COX activity has also been shown in double and triple 
transgenic mouse models of AD combining mutant APP overexpression with overexpression of 
presenilin-1 and/or tau (Rhein, Song et al. 2009; Wolf, Braden et al. 2012).        
We used MT1/MT2 knockout mice crossed with APPswe/PS1 transgenic mice and studied 
the effects on COX activity on striatal extracts from mice treated with or without melatonin.  We 
found that melatonin treatment completely inhibited the APPswe/PS1-mediated increase in COX 
activity under conditions of normal MT1 and MT2 expression and even led to a slight decrease 
in COX activity.  However, in the MT1/MT2 knockout mice, melatonin treatment only led to a 
small non-statistically significant decrease in the APPswe/PS1-mediated increase in COX activity 
(p=0.3).  Therefore, the melatonin receptors play an important role in the ability of melatonin to 
prevent AD-related changes in COX activity.  It will be important to repeat these experiments 
using hippocampal or cerebral cortical tissue or a different genetic background of mice to 
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determine if these trends hold under conditions where COX activity declines as a result of 
APPswe expression. 
 
 Molecular mechanisms through which melatonin receptor signaling protects 
mitochondrial function in aging and disease 
The signaling pathway through which melatonin receptor signaling induces antioxidant 
gene expression and protects mitochondrial function has yet to be convincingly identified in the 
central nervous system (CNS).  However, it is likely to signal through one of the following 
pathways described below.  There are at least 4 examples of melatonin stimulating the Nrf2 
pathway to protect against oxidative damage in the nervous system.  Melatonin was shown to 
decrease okadaic acid-induced memory dysfunction in rats through upregulation of the Nrf2 
signaling pathway and prevention of NF- κB activation, which leads to neuroinflammation 
(Mendes, Lopes et al. 2013).  Nrf2 is normally sequestered in the cytoplasm by Keap1.  During 
oxidative and nitrosative stress, such as shown following ischemic brain injury, tyrosine 473 of 
Keap1 is nitrated, which prevents release of Nrf2 to the nucleus to induce transcription (Tao, 
Huang et al. 2013).  Melatonin treatment prevents damage to Keap1, allowing Keap1 to release 
Nrf2 and Nrf2 to translocate to the nucleus, bind antioxidant response elements (ARE) in DNA 
and transcribe protective genes as a response to the stress.  Melatonin was also shown to activate 
Nrf2 to provide protection from early brain injury in a subarachnoid hemorrhage model in rats 
(Wang, Ma et al. 2012), to protect against high linear energy transfer (LET) carbon ion radiation 
in mouse brains (Liu, Zhang et al. 2012), and to protect the sciatic nerve from increased levels of 
pro-inflammatory cytokines and cell death in streptozotocin-induced diabetic neuropathy in rats 
(Negi, Kumar et al. 2011).   
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Melatonin can also modulate expression of SIRT1, a nicotinamide adenine dinucleotide 
(NAD)-dependent protein deacetylase that deacetylates and activates many substrate proteins 
including PGC-1α, FoxO1, NF-κB, and p53.  There have been several examples of melatonin 
downregulating SIRT1 in cancer cell lines (Cheng, Cai et al. 2013), while there have been at 
least 3 reports of melatonin upregulating or preventing the decline of SIRT1 expression in brain 
in response to a stress (Hardeland 2013).  For example, melatonin prevented the decline in brain 
SIRT1 levels at 10 months of age in the SAMP8 mouse model of accelerated senescence 
(Gutierrez-Cuesta, Tajes et al. 2008), in sleep-deprived rat hippocampus (Chang, Wu et al. 
2009), and in isolated aged neurons from rats (Tajes, Gutierrez-Cuesta et al. 2009).    
Consistent with this activation of SIRT1 by melatonin, melatonin treatment has been 
shown to increase expression of the master mitochondrial transcriptional coactivator α in white 
adipocytes, turning a portion of them into brown adipocytes (Jimenez-Aranda, Fernandez-
Vazquez et al. 2013).  PGC-1α is known to induce gene expression of antioxidant genes such as 
SOD2 and glutathione peroxidase-1 (GPx1) in the brain (St-Pierre, Drori et al. 2006).  However, 
the PGC-1α promoter has a CREB binding site for transcriptional activation (Ashabi, Ramin et 
al. 2012; Sheng, Wang et al. 2012).  So it is possible that ability of melatonin to decrease cAMP 
levels through adenylate cyclase inhibition may lead to decreased PGC-1α transcription.  
However, treating cardiac cells with catecholamines, which increase adenylate cyclase activity to 
increase cAMP levels, decreases PGC-1α activity (Arany, Novikov et al. 2006).  In addition 
there was also an inverse correlation between CREB activation and PGC-1α activation in the 
heart of spontaneously hypertensive rats.  Therefore, there is not always a direct correlation 
between the activities of CREB and PGC-1α. 
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There is diurnal variation in the expression of SIRT1 and PGC-1α in some tissues (Asher 
and Schibler 2011) similar to the cyclic variation in melatonin synthesis in the pineal gland.  In 
liver and skeletal muscle it has been shown that this diurnal expression pattern of PGC-1α 
stimulates the expression of clock genes through the co-activation of the ROR family of orphan 
nuclear receptors. Expression of the Bmal1 and Rev-erb-α genes were notably induced.  This 
diurnal expression of PGC-1α  is likely influenced by the similar cyclic expression pattern of the 
NAD-dependent SIRT1 deacetylase (Asher, Gatfield et al. 2008; Nakahata, Kaluzova et al. 2008) 
and the diurnal variation in NAD levels and the NAD/NADH ratio caused by circadian 
expression of nicotinamide phosphoribosyltransferase (NAMPT)   (Nakahata, Sahar et al. 2009; 
Ramsey, Yoshino et al. 2009).  SIRT1 associates with the CLOCK-BMAL1 heterodimer and 
deacetylates BMAL1 and PER2, which destabilizes PER2 leading to its degradation.  The 
rhythmic PGC-1α expression pattern is also likely influenced by the circadian oscillation of 
CREB activation as shown in both the suprachiasmatic nucleus (O'Neill, Maywood et al. 2008) 
as well as in peripheral tissues (Wang and Zhou 2010).  The relation between the oscillations in 
these metabolic regulators, melatonin action, and AD remain relatively unexplored. 
Since the enzymes that produce melatonin from tryptophan in the pineal gland are 
controlled by the circadian clock and because melatonin receptors are present in the 
suprachiasmatic nucleus in the hypothalamus, it has been speculated that melatonin binding to 
these receptors would influence the circadian clock machinery.  Unexpectedly only a limited 
number of studies have examined the role of melatonin or melatonin receptors on the circadian 
clock genes (Jung-Hynes, Reiter et al. 2010).  One study found that clock genes were 
downregulated in the adrenal cortex of a C57BL melatonin-deficient mouse strain compared to a 
C3H melatonin-proficient strain (Torres-Farfan, Seron-Ferre et al. 2006).  Another study found 
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that melatonin, through binding to MT1 receptors, could decrease expression of PER1 and 
CLOCK, but had no effect on the levels of BMAL1 in primary striatal cultures from mice 
(Imbesi, Arslan et al. 2009).  In addition, a phase-dependent effect of rhythmic melatonin 
administration was found on circadian clock gene expression (Per2 and Bmal1) in the heart of 
hypertensive rats (Zeman, Szantoova et al. 2009), but no effect was observed in the 
suprachiasmatic nucleus (Poirel, Boggio et al. 2003).  Specifically, the authors suggested that 
only melatonin applied during the dark phase of the 24-hour cycle allowed a strong 
synchronization of circadian clock expression in the heart. It will be interesting to determine if 
expression changes or activation of PGC-1α, SIRT1, or CREB play a role in these effects of 
melatonin. 
AMP kinase (AMPK) works upstream and in parallel to SIRT1 in neuro-protective 
pathways.  The two pathways intersect to increase PGC-1α activity and increase mitochondrial 
biogenesis.  AMPK directly phosphorylates PGC-1α at threonine-177 and serine-538 to increase 
PGC-1α-induced activation of the PGC-1α promoter (Jager, Handschin et al. 2007). 
Phosphorylation of AMPK stimulates its kinase activity.  Melatonin has been shown to have 
disparate effects on AMPK in different cancer cell lines (Hardeland 2013). In HT22 
immortalized hippocampal cells, Aß treatment increased AMPK phosphorylation, while 
melatonin prevented this activation.  This AMPK activation was interpreted as being mediated 
by oxidative stress and melatonin presumably prevented the oxidative damage from occurring to 
prevent AMPK activation.  In primary tissues such as in livers undergoing steatosis (Zaouali, 
Boncompagni et al. 2013) and in muscle and livers from aged rats, especially when exercised 
(Mendes, Lopes et al. 2013), melatonin treatment lead to AMPK activation.  The melatonin 
treatment led to increased physiological benefit from exercise in the aged rats. Studies should 
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also be performed in aged and AD brain to determine if melatonin treatment leads to activation 
of AMPK and if melatonin receptors play a role. 
In aging and aging-related disease there is a strong correlation between increased 
inflammation and decreased mitochondrial function.  These two factors appear to be most 
centrally linked to the aging process.  Since these two phenomena are so intricately linked, it is 
likely that one induces the other. Melatonin treatment can decrease chronic and acute 
inflammation by transcriptionally inhibiting iNOS and cyclooxygenase-2 transcriptional 
activation (Cuzzocrea, Zingarelli et al. 1997; Costantino, Cuzzocrea et al. 1998; Deng, Tang et 
al. 2006).  Melatonin has also been shown to directly act on immune cells to decrease production 
of IL-6, IL-8, TNF-α, and adhesion molecules (Esposito and Cuzzocrea 2010). Astrocytes 
become activiated in AD by proinflammatory cytokines and can upregulate iNOS to produce 
excess nitric oxide which binds and inhibits cytochrome c oxidase of the ETC in both neurons 
and glia leading to energy decline and tissue dysfunction.  Melatonin prevents iNOS 
upregulation by inhibiting the p38 MAPK signaling pathway activated by cytokine binding 
(Vilar, de Lemos et al. 2014).  Including melatonin in the diet at 200 ppm for 8 weeks 
normalized the expression of many pro-inflammatory genes that were upregulated in the aged 
mouse brain (Sharman, Sharman et al. 2004).  
Melatonin has been shown to either inhibit or enhance autophagy dependent upon the 
tissue type and disease treatment (Coto-Montes, Boga et al. 2012).  In many pathological 
conditions reactive oxygen species, which may be required for autophagy induction, are 
increased. Under these conditions, melatonin treatment may decrease reactive oxygen species 
levels to decrease autophagic flux.  For example, autophagy increases in a rotenone induced 
Parkinson’s disease model and melatonin treatment decreased autophagy markers and autophagic 
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cell death (Zhou, Chen et al. 2012).  Similar observations were made in methamphetamine-
induced autophagic cell death (Nopparat, Porter et al. 2010).  However, in certain conditions 
melatonin treatment has also been shown to increase autophagy.  One of the mechanisms through 
which melatonin receptor signaling may protect against AD is through modulation of the rate of 
autophagy.  In this regard autophagy is defective in AD brain due to defective lysosomal 
acidification causing an accumulation of autophagosomes in certain AD neurons (Wolfe, Lee et 
al. 2013).  This effect was also observed in presenilin-1 (PS1) knockout and mutant mouse 
neurons and was identified to be caused by a requirement for WT PS1 in the maturation and 
sorting of a v-ATPase subunit to the lysosome. In addition another group showed that the 
unfolded protein response increased autophagy in AD neurons (Scheper, Nijholt et al. 2011).   
Induction of autophagy relies on AMPK activation in many cell types (Meijer and Codogno 
2007) and melatonin may activate AMPK under certain conditions as described above.  
Melatonin-induced autophagy has been shown  to protect against neural cell death in early brain 
injury following a subarachnoid hemorrhage (Chen, Wang et al. 2013). Melatonin-induced 
autophagy has also been shown to provide neuroprotection from prion proteins (Jeong, Moon et 
al. 2012), and protect N2a cells from ischemia-reperfusion-induced cell death (Guo, Wang et al. 
2010).  In addition, melatonin prevented aging-related abnormalities in the autophagosomal-
lysosomal system in brain from the SAMP8 senescence accelerated mouse model (Garcia, Pinol-
Ripoll et al. 2011).  Unfortunately, little is yet known on the effect of melatonin on autophagy in 
AD brain or AD model systems (Coto-Montes, Boga et al. 2012). 
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Conclusion 
The very low toxicity of melatonin versus other potential AD therapeutics makes 
melatonin an obvious choice for human AD therapy if efficacy in slowing cognitive dysfunction 
can be convincingly demonstrated.  Melatonin is more versatile than other antioxidants such as 
vitamin C or vitamin E because it can scavenge peroxynitrite as well as reactive oxygen species 
(Korkmaz, Reiter et al. 2009).  Melatonin is also a candidate therapy for many other 
neurodegenerative and aging-associated disorders. Novel studies on the molecular mechanisms 
of mitochondrial protection mediated by melatonin receptor signaling will lead to a better 
understanding of how melatonin can be used to hinder disease progression in AD.    
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Figure 11 Effects of age on COX activity in mice 
The rate of cytochrome c oxidase oxygen consumption was determined using the Clark type 
electrode, and buffer conditions containing reduced bovine cytochrome C. Members of the initial 
cohort of mice were sacrificed at 6 months, 13 months, and 16 months.  There was an age 
dependent decline in COX activity across all genotypes, except at 16 months, where AD mice 
maintained high levels of COX activity.  
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Figure 12 Effects of age and melatonin treatment on COX activity in mice 
The rate of cytochrome c oxidase oxygen consumption was determined using the Clark type 
electrode, with the buffer containing reduced bovine cytochrome c and antimycin A to prevent a 
backflow of electrons. Members of the initial cohort of mice were sacrificed at 6 months, 13 
months, and 16 months.  There was an age-dependent decline in COX activity across all 
genotypes, except at 16 months, where AD mice maintained high levels of COX. Melatonin 
treatment fully restored COX activity only in the presence of melatonin receptors and only in in 
WT-WT, WT-KO, and AD-WT genotypes. No protective effect was observed in AD-KO 
genotype at 16 months.  
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CHAPTER FOUR: AMINO ACIDS PROTECT AGAINST OXIDATIVE STRESS IN 
CELLS OVEREXPRESSING ALPHA-SYNUCLEIN MODELING PARKINSON’S 
DISEASE 
 
Abstract 
Parkinson’s (PD) disease is a neurodegenerative disorder characterized by alpha-
synuclein (α-syn) accumulation and the loss of dopaminergic neurons in the substantia nigra 
(SN) region of the brain. Increased levels of α-syn in PD promote oxidative stress leading to 
mitochondrial electron transport chain (ETC) and tricarboxylic acid cycle (TCA) dysfunction.  
To model the high iron milieu of the SN and the increased levels of α-syn contributing to PD, 
WT α-syn was overexpressed in M17 neuroblastoma cells and the cells were supplemented with 
ferrous sulfate (FeSO4).  Mitochondrial oxygen consumption was greatly decreased by WT α-syn 
overexpression almost to the extent observed following overexpression of the pathogenic A30P, 
A53T, and E46K α-syn mutants. Overexpression of WT α-syn resulted in increased levels of a 
higher order α-syn conformer, but not monomer levels.  Compared to control cells, cells 
overexpressing WT α-syn were more susceptible to oxidative stress caused by FeSO4 treatment 
resulting in increased reactive oxygen species (ROS) production and decreased oxygen 
consumption and ATP levels.  Overexpression of α-syn also resulted in decreased ATP levels in 
response to paraquat, a ROS inducer.  Amino acids, TCA cycle intermediates and their ester 
forms were screened and several, such as serine, proline, aspartate, and succinate were found to 
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protect mitochondria against FeSO4 or paraquat-induced ROS production, while valine addition 
consistently increased ATP levels. Mass spectrometry based proteome analysis indicated that 
monoamine oxidase-A was increased and superoxide dismutase-2 was decreased in abundance 
by α-syn overexpression.  Potential mechanisms of iron and α-syn-mediated mitochondrial 
dysfunction in PD pathogenesis are discussed. 
 
Introduction 
In Parkinson’s disease (PD) neurons in the substantia nigra region of the brain show 
aging-induced mitochondrial dysfunction resulting in increased reactive oxygen species (ROS) 
production leading to increased oxidative damage. Mitochondrial involvement in the 
pathophysiology of PD is well established (Martin, Pan et al. 2006; Beal 2007; Keane, Kurzawa 
et al. 2011). Although a genetic component exists in ~ 10 % of the PD cases, the disease is 
predominately idiopathic. Dysregulation of mitochondrial dynamics in neurons (e.g. fission, 
fusion, transport, biogenesis, and mitophagy) has been linked to both genetic and toxin-induced 
models of PD (Li, Yang et al. 2007; Dickey and Strack 2011; Gegg and Schapira 2011; Martinez 
and Greenamyre 2012). Dysregulation of these mitochondrial events is in part accompanied by 
reductions of ATP levels, increased ROS production, and decreased oxygen consumption. 
Involvement of alpha-synuclein (α-syn) in both familial and sporadic types of PD is also 
well established (Zarranz, Alegre et al. 2004; International Parkinson Disease Genomics, Nalls et 
al. 2011). Common α-syn mutations known to cause the familial forms of PD and induce 
mitochondrial dysfunction are A30P, A53T, and E46K (Li, Uversky et al. 2001; Zarranz, Alegre 
et al. 2004; Protter, Lang et al. 2012; Cannon, Geghman et al. 2013).  Recently, a dinucleotide 
polymorphism, REP1, found in the promoter region of the α-syn gene (SNCA) has been linked 
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with the sporadic form of PD (Chiba-Falek and Nussbaum 2001; Maraganore, de Andrade et al. 
2006). Some polymorphisms in REP1 result in higher expression of α-syn. Even small increases 
in α-syn over a lifetime could potentially have detrimental effects that lead to PD or in the very 
least a predisposition to developing PD. Higher order oligomers and aggregates of α-syn form 
when α-syn levels increase (Parihar, Parihar et al. 2009).  Certain oligomeric species of α-syn 
can form amyloid pores, which can disrupt the permeability properties of organelle and plasma 
membrane phospholipid bilayers (Volles and Lansbury 2002; Maries, Dass et al. 2003). α-syn 
can disrupt electron transport chain (ETC) function and permeabilize organelle membranes 
releasing iron and calcium into the cytoplasm, which can be taken up by mitochondria. This may 
promote the observed mitochondrial deficits in PD and lead to increased ROS production and 
eventual neuronal cell death. In addition to lysosomes (Bourdenx, Bezard et al. 2014), 
mitochondria are a major subcellular storage site for iron.  Failure to chelate and process free 
iron properly can lead to production of reactive oxygen species (ROS) via Fenton chemistry. A 
detailed review on iron metabolism and its role in the progress of PD and other 
neurodegenerative diseases is found in (Horowitz and Greenamyre 2010). ROS can irreversibly 
oxidize proteins and membrane phospholipids, which compromise their function and promote 
Lewy body inclusion formation.  (Zaleska and Floyd 1985; Keeney, Xie et al. 2006). In one 
proteomic study, approximately 550 different proteins were identified in the LB fraction, and of 
those 40 were verified as true components of LBs (Xia, Liao et al. 2008).  
The mechanisms through which α-syn specifically decreases ETC function in the SN in 
PD are unknown, but increased α-syn levels are associated with decreased activity of ETC 
complex I (Stichel, Zhu et al. 2007).  A recent study has also found that α-syn gets inserted into 
the mitochondrial inner membrane directly inhibiting ETC complex I function promoting ROS 
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production that, together with the high calcium and iron levels in the substantia nigra, induce 
opening of the mitochondrial permeability transition pore releasing cytochrome c to activate 
caspases and induce cell death (Luth, Stavrovskaya et al. 2014).  Overexpression of α-syn in a 
transgenic mouse model has also been shown to decrease the activities of ETC complexes II, IV, 
and V (Subramaniam, Vergnes et al. 2014), perhaps from ROS-mediated damage as a 
consequence of complex I inhibition. 
Deficits in TCA cycle enzyme activities have been shown to occur in both Alzheimer’s 
disease and PD (Gibson, Kingsbury et al. 2003; Gibson, Karuppagounder et al. 2008).  
Decreased TCA cycle enzyme activities are most likely secondary to the oxidative damage of the 
ETC proteins and to cardiolipin, a phospholipid in the mitochondrial inner membrane required 
for ETC function. The TCA cycle enzyme aconitase is an iron-containing enzyme, especially 
sensitive to oxidative damage (Lushchak, Piroddi et al. 2014).  ETC complexes are the main 
producers of free radicals in neurons, producing over 90% of cellular ROS.  Decreased TCA 
cycle enzyme activities yield lower amounts of NADH affecting oxidative phosphorylation 
leading to imbalanced levels of TCA cycle intermediates affecting the many anabolic pathways 
relying on TCA cycle intermediates (i.e. amino acid and fatty acid biosynthesis).  Although 
therapeutic treatments to lower α-syn levels in PD patients have not yet been clinically approved, 
the bioenergetic deficits and increased ROS production from overexpression of α-syn could 
potentially be treated through supplementation with antioxidants and TCA cycle intermediates.  
In this regard succinate bypasses complex I deficits and deliver electrons to complex II of the 
ETC, which showed benefits in a PD model (Ved, Saha et al. 2005).  Restoring bioenergetic 
function while simultaneously reducing ROS may be the most effective way of delaying 
neuronal cell death in PD.  In particular, ester forms of metabolic intermediates have a lower 
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charge and increased hydrophobicity so they more readily diffuse across the blood brain barrier, 
and enter cells in the brain without the need for active transport. Upon cell entry these 
compounds are processed by esterases back to their physiological form to be metabolized.  
Another possible treatment is to supplement with melatonin, a strong antioxidant previously 
described to delay α-syn aggregation and protect in several rodent models of PD (Singhal, 
Srivastava et al. 2012). 
To model sporadic PD we stably overexpressed wild type α-syn in human immortalized 
M17 neuroblastoma cells. The cells were grown in an iron-rich environment to model the 
environment of the substantia nigra (SN).  TCA cycle intermediates, their ester forms, amino 
acids, and other compounds known to stimulate metabolism were supplemented to the cells and 
assays of mitochondrial function were performed.  Metabolites found to be protective against 
FeSO4 insult were further tested for protection against paraquat, another inducer of ROS 
production.  
 
Materials and methods 
Cell culture  
M17 cells stably overexpressing human α-syn using a cytomegalovirus (CMV) promoter 
were grown using M10 culture media (DMEM with 10% FBS, 30 µg/ml penicillin, 50 µg/ml 
streptomycin, and 2 mM glutamine). Stably transfected M17 cell lines overexpressing WT or 
mutant α-syn were created using the pcDNA3a vector containing a neomycin resistance cassette 
(Life TechnologiesⓇ) following selection with G418. Cells were grown in either 96 well plates 
or 10 cm culture dishes. Cells were grown in media containing ferrous sulfate (FeSO4) for 24, 48 
or 72 hours with and without metabolite treatments. Treatments consisted of either TCA cycle 
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intermediates, esterified TCA cycle intermediates, amino acids, or compounds such as 
melatonin, rapamycin, and AICAR previously found to be neuroprotective. In some cases 
titrations were performed for the most effective concentrations. Compounds found to be 
protective against FeSO4 insult in the initial screen were also tested for evidence of 
mitochondrial protection using a 24 hour insult with 600 μM paraquat. 
 
ATP assays 
CellTiter-Glo (Promega, Madison, WI) ATP detection reagent was used to determine the 
levels of medium ATP following a 10 minute 22°C incubation of cells with CellTiter-Glo 
reagent. CellTiter-Glo reagent was combined with a cell suspension in a 1:1 ratio in a 96-well 
microplate and then shaken for 2 minutes. Luminescence was read using a Biotek Synergy 2 
microplate reader after the contents of the 96 well plates were transferred to white opaque 
bottom plates for increased signal and incubated at room temperature for 10 minutes. 
 
Oxygen consumption analysis 
Following growth in 10 cm culture dishes, cells were trypsinized, the trypsin was 
deactivated with five times the volume of culture media, and the cells were spun down and 
resuspended in 1 mL of fresh culture media.  From the 1 ml cell suspension, 350 µl was placed 
into a Strathkelvin Mitocell MT200A respiratory chamber with a Clark type electrode at 37⁰C 
with a stir bar. The basal respiratory rate was recorded for 4 minutes. The middle 1 minute was 
chosen for slope analysis. Oxygen consumption was normalized to the total cell number in the 
chamber. Cell counts were obtained using a hemocytometer.  
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Reactive oxygen species measurements 
2’,7’-dichlorodihydrofluorescein diacetate was used to detect the rate of reactive oxygen 
species (ROS) production. Following hydrolysis of the acetate esters by intracellular esterases, 
dichlorodihydrofluorescein is produced.  Dichlorodihydrofluorescein, when oxidized by ROS 
becomes the highly fluorescent compound dichlorofluorescein (DCF). A 2’,7’-
dichlorodihydrofluorescein diacetate stock solution of 500 µM was made up in 2% DMSO in 
PBS and the tube was wrapped in foil to prevent exposure to light. Media was aspirated from the 
cells and the cells were washed once with 100 µl PBS.  An assay concentration of 50 µM was 
obtained by mixing 10 µl of the stock solution with 90 µl of PBS and added to the monolayer of 
cells in a 96-well plate. The plate was incubated in the dark at 37°C for 30 minutes. The 
fluorescence was then measured using a Biotek Synergy 2 microplate reader with an excitation 
filter of 485/20 nm and emission filter of 528/15 nm. Values were normalized to the total amount 
of protein in each well. Cells were lysed using RIPA buffer without SDS.  
 
Protein assays 
A determination of the protein concentration was performed using the BCA protein assay 
(Thermo Scientific Pierce). All results were normalized using the protein concentrations present 
for the assays. 
 
Western blot analysis 
Cells were solubilized in (non-denaturing) RIPA (Tris-HCl 50 mM, 150 mM NaCl, 
sodium deoxycholate 12 μM, 1 % Triton X-100) buffer without SDS.  Invitrogen- Novex 4-20% 
tris-glycine standard protein gels were used for polyacrylamide gel electrophoresis. Novex® 
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Tris-Glycine gels do not contain SDS and were used to run proteins under denaturing conditions. 
To run denatured proteins, Novex® Tris-Glycine SDS Sample Buffer and Novex® Tris-Glycine 
SDS Running Buffer were used. The gel was transferred to a PVDF membrane. The membrane 
was blocked in blotto blocking solution with 1x TBS (Fisher scientific) for 1 hour. The 
membrane was probed with the mouse anti-alpha- synuclein IgG from BD Biosciences antibody 
using new blotto solution. The GAPDH loading control antibody was from Meridian Life 
Science Inc. LumiGOLD ECL detection kit was used for secondary antibody luminescence and 
the signal was captured on autoradiography film.  The densitometry values obtained using 
imageJ software were normalized to those of the GAPDH loading control. 
 
SILAC Labeling and LC-MS/MS Analysis 
M17 control and WT ɑ-syn stably transfected cell lines were thawed in standard M10 
culture media described above. The next day the media was changed and M17 cells were grown 
in SILAC media supplemented with “heavy” 13C6-
15
N4-Arginine and 
13
C6 L-Lysine, and WT ɑ-
syn cells were grown in SILAC media supplemented with normal “light” L-Arginine and L-
Lysine. Cells were grown for approximately 6 doublings in order to maximize the incorporation 
of labeled amino acids.  Cells were lysed in 100mM Tris-HCl (pH 7.6) with  4% SDS, 100mM 
DTT, and Halt protease inhibitor cocktail (Pierce) at 95˚C for 5 minutes, and briefly sonicated.  
Protein concentrations were determined using the Pierce 660 nm protein assay with ionic 
detergent compatibility reagent (Pierce).  Cell lysates were processed using filter-aided sample 
preparation (FASP) (Wisniewski, Zougman et al. 2009; Chaput, Kirouac et al. 2012). Proteins 
were digested with Trypsin/Lys-C (Promega) at 1:50 (w:w; protease:protein) overnight at 37˚C.  
Peptides were desalted using Pierce C-18 SPE columns with a Supelco vacuum manifold and 
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dried using a vacuum concentrator (Thermo).  Peptides were then fractionated on a Dionex 
U3000 HPLC system with a 15cm x 1.0mm i.d. strong cation-exchange (SCX) column (PolyLC 
Inc.) packed with 5µm 300Å polySULFOETHYL A-SCX material.  Two minute fractions were 
collected using a 30 minute gradient (15-200mM ammonium formate in 25% acetonitrile,  ten 
fractions selected for LC-MS/MS analysis based on the UV 280nm trace were again dried in a 
vacuum concentrator and resuspended in 0.1% formic acid in H2O.   Peptides were analyzed on a 
Q-Exactive Plus mass spectrometer (ThermoFisher Scientific) with a 75um x 50cm UPLC 
column (Dionex) using a 2 hour gradient (2-40% acetonitrile) on an EASY-nLC 1000 system.   
Raw files were searched against the 2014 UniprotKB human protein sequence database using 
Maxquant software (version 1.5.0.30, maxquant.org). Statistically significant differentially 
expressed proteins were determined using Significance A, an outlier test with a p value < 0.05, in 
Perseus (version 1.5.031, http://141.61.102.17/perseus_doku/).  Statistically significant 
differentially expressed proteins were used for bioinformatic analysis (Ingenuity Pathway 
Analysis) to determine over-represented biological functions and predicted pathway/upstream 
regulator activity changes. 
 
Results 
Overexpression of alpha-synuclein results in decreased oxygen consumption.  
Following the generation of stably transfected WT α-syn and A30P α-syn, A53T α-syn, 
E46K α-syn M17 cell lines, oxygen consumption was determined using cells suspended in 
DMEM-based culture media.  In all cases, the stable transfection led to large declines in oxygen 
consumption (Figure 4.1) (one-way ANOVA, P<0.005). The rate of oxygen consumption was 
decreased by 56% in cells overexpressing wild type α-syn. The reduction in oxygen consumption 
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in the α-syn mutants A30P, A53T, E46K was 80.1%, 93.1%, and 66.0% percent respectively. 
Therefore, overexpression of the WT α-syn had a slightly less severe effect on mitochondrial 
function than overexpression of the mutant forms (Fig. 13).  Overexpression of the α-syn 
mutants even led to a greatly decreased rate of cell division in standard high glucose DMEM 
media. The cells were observed to have a doubling rate of approximately 4 days (data not 
shown). Cells overexpressing WT α-syn did not show this greatly decreased rate of cell division, 
therefore, we decided to characterize other phenotypes in these cells. 
Alpha-synuclein aggregates into tetramers when overexpressed 
We next wished to determine the level of WT α-syn overexpression that led to the 
decreased oxygen consumption. Therefore we performed Western blot analysis of the cells using 
mild sample solubilization conditions able to identify α-syn oligomers. Small α-syn A53T 
mutant oligomers were previously reported to be SDS, temperature and detergent stable (Tsika, 
Moysidou et al. 2010; Marques and Outeiro 2012). Therefore, we wanted to determine if over 
expression of WT α-syn resulted in the same type of aggregation as in α-syn A53T. We were 
also interested in determining if limiting SDS exposure and excluding heating from sample prep 
would result in a clearer picture of which higher order oligomers are also most likely to be 
thermodynamically stable in vivo.   Following overexpression of WT α-syn, there was, 
surprisingly, no increase in the intensity of the α-syn band running at 16 kDa on the gel 
representing monomeric α-syn, but a multimeric form of α-syn running at approximately 60 kD 
was increased by 55% (Fig. 14). The human brain contains both monomers and other conformers 
of α-syn such as dimers, trimers, tetramers, and perhaps pentamers (Gould, Mor et al. 2014), 
with the tetrameric form of α-syn being very stable in the human brain (Bartels, Choi et al. 
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2011).  The tetramer may be stabilized by a lipid or other small molecule, as the monomer re-
forms upon full purification of the protein (Luth, Bartels et al. 2015). 
   
FeSO4 decreases oxygen consumption  
As the substantia nigra contains high levels of iron, we incubated the M17 control and 
WT α-syn-expressing cells with 4 mM FeSO4 and determined the rate of oxygen consumption. 
This concentration was determined by titrating FeSO4 until deficits in WT α-syn were observed 
and M17 control cell remained unaffected. As expected, the rate of oxygen consumption 
declined following incubation with 4 mM FeSO4 in WT α-syn-expressing cells. Oxygen 
consumption also declined in M17 control cells, although this effect did not quite reach statistical 
significance (Fig. 15). 
 
 
 
α-syn overexpression decreases ROS production in the absence of FeSO4, but 
increases ROS production in the presence of FeSO4  
It has long been known that α-syn overexpression sensitizes to peroxide and iron-
mediated cell death and iron and free radicals stimulate α-syn aggregate formation (Ostrerova-
Golts, Petrucelli et al. 2000).  So we next determined the effect of WT α-syn overexpression on 
ROS production in the absence and presence of FeSO4 treatment to the cells.  As shown in Fig. 
16, in the absence of FeSO4 WT α-syn-overexpressing cells produce less ROS than M17 
controls. However, once FeSO4 is introduced, ROS levels of α-syn-overexpressing cells exceed 
those of cells not overexpressing α-syn. 
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Overexpression of a-syn results in FeSO4 or paraquat-induced decreases in ATP 
levels 
We next determined the effect of WT α-syn overexpression and FeSO4 treatment on 
cellular ATP levels.  As shown in Fig. 17, WT α-syn overexpression, increased ATP levels in the 
untreated M17 cells, which is surprising considering that the overexpression also reduced 
mitochondrial oxygen consumption.   However, WT α-syn-overexpressing cells showed a 45% 
decrease in ATP levels upon FeSO4 treatment, while there was no change in ATP levels in M17 
control cells following FeSO4 treatment.  Therefore, it appears that there is a compensatory 
increase in glycolysis or a decrease in ATP consumption that compensates for the α-syn-induced 
decrease in oxygen consumption to maintain or even slightly increase cellular ATP levels in the 
absence of FeSO4.  However, this compensatory mechanism is unable to be maintained in the 
presence of FeSO4 leading to a large decrease in ATP levels. 
We also performed a similar experiment, but this time instead of treating the cells with 
FeSO4, we treated the cells with paraquat, an herbicide and ROS generator known to cause 
Parkinson’s-like symptoms when ingested by humans.  As shown in Fig. 18, very similar results 
were obtained as with FeSO4 treatment, paraquat treatment decreased ATP levels in the α-syn-
overexpressing cells and slightly increased ATP in WT cells. 
 
Some amino acids and TCA cycle intermediates rescue ATP production deficits and 
decrease ROS following oxidative insults 
Since α-syn overexpression leads to mitochondrial dysfunction, especially in the presence 
of FeSO4, we decided to perform a small-scale screen of 32 compounds, mostly metabolites or 
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cell-permeable metabolite esters that may be able to delay or compensate for the decreased 
mitochondrial function.  We first tested the compounds on ATP levels and ROS production in 
the absence and presence of FeSO4.  We then went on to test the best candidates on α-syn-
expressing cells in the presence of paraquat.  We performed this second analysis as it was likely 
that many of the hits from the FeSO4 screen were decreasing ROS by chelating the iron in the 
culture media and we wished to determine which compounds decreased ROS production 
independently of their chelating abilities.  Amino acids and metabolic intermediates found to 
statistically increase ATP and/or decrease ROS, including the results from the paraquat insult, 
are shown in Table 3 and presented as percent increase. 
We believe that criteria for a useful therapeutic compound include increasing ATP levels 
without increasing ROS production or decreasing ROS production without decreasing ATP 
levels.  A compound that satisfied these criteria under all 3 conditions tested is serine.  Serine 
decreased ROS production without affecting ATP levels.  When examining the results of the 
paraquat data, it is shown that succinate and melatonin, a tryptophan-related hormone known to 
be a strong antioxidant, also satisfied these criteria by decreasing ROS production without 
decreasing ATP levels.  Although not satisfying the criteria due to increased ROS production, the 
compounds that increased ATP levels to the greatest extent in the presence of paraquat were 
valine and diethyl oxaloacetate, likely through increasing mitochondrial biogenesis (Valerio, 
D'Antona et al. 2011; Wilkins, Harris et al. 2014).  Likely due to their chelating ability, many of 
the compounds satisfied these criteria when examining the data from the FeSO4 treatment. 
Valine, serine, fumarate, aspartate, rapamycin (an mTOR kinase inhibitor), and proline 
treatments both increased ATP levels and decreased ROS production, while glutaric acid, 
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alanine, asparagine, succinate, and isoleucine increased ATP levels without affecting ROS 
levels. Glutaric acid was particularly potent, as it may be the best iron chelator administered. 
 
Proteomic analysis of α-syn overexpression following SILAC labeling  
In attempt to understand the mechanisms of mitochondrial dysfunction in WT α-syn-
overexpressing cells, we performed proteome analysis on cells lysates following SILAC 
labeling. A total of 211 proteins were identified with significant fold changes in at least 2 of the 
3 biological replicates (appendix A). The entire data set was analyzed by Perseus software using 
the significance A setting. Several proteins relevant to mitochondrial function showed either 
significantly increased or decreased abundance (Fig. 19).   For example, the mitochondrial ETC 
complex I subunits NDUFA13 and NDUFB4 and the mitochondrial ETC complex IV assembly 
protein SURF1 showed increased abundance.  α-syn has been shown to directly interact with 
ETC complex IV (Elkon, Don et al. 2002), although the significance of this interaction is still 
unknown.  NDUFA13 can bind the transcription factor STAT3 and serve as a tumor suppressor.   
In addition monoamine oxidase-A, MAO-A, a mitochondrial outer membrane protein involved 
in the degradation of dopamine and other amine neurotransmitters was increased in abundance in 
-syn overexpressing cells.  This increased expression of MAO-A may in part lead to the 
decreased dopamine levels observed in PD patients as well as the increased toxic levels of 
DOPAL, the aldehyde product formed from MAO catabolism of dopamine, contributing to the 
death of substantia nigra neurons in PD patients (Goldstein, Sullivan et al. 2013).  A significant 
decrease in abundance was observed for mitochondrial superoxide dismutase SOD2 (Fig. 19).  
The decreased expression of SOD2 was surprising given that -syn overexpressing cells showed 
decreased ROS production in the absence of FeSO4.  However, the decreased ROS production 
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was likely due to the decreased entry of electrons into the ETC due to the decreased complex I 
activity.  The decreased SOD2 levels may play a role in the higher ROS levels observed when 
the -syn expressing cells are exposed to oxidative stressors such as FeSO4. 
 
Discussion  
We found that overexpression of WT -syn in M17 human neuroblastoma cells resulted 
in an increased susceptibility to mitochondrial dysfunction characterized by increased ROS 
production and decreased ATP levels following FeSO4 treatment.  This susceptibility may in part 
be caused by the increased levels of monoamine oxidase A (MAO-A), and the decreased levels 
of mitochondrial superoxide dismutase (SOD2).  We also report several natural metabolites such 
as serine, succinate, and melatonin that partially rescue the increased ROS production induced by 
paraquat addition to α-syn overexpressing cells without decreasing ATP levels.  We also showed 
that α-syn overexpression resulted in increased levels of oligomeric -syn. These oligomers may 
interact with mitochondria to inhibit complex I to make the cells more susceptible to cell death in 
the iron-rich, oxidative environment of the SN.  
The results from the oxygen consumption measurements described here correspond very 
well with the results obtained when WT α-syn and the A30P and A53T α-syn mutants were 
expressed in SHSY cells (Parihar, Parihar et al. 2009).  The results of the ROS production 
measurements reported here are also consistent with the results from two other groups.  In the 
previous reports, the authors treated either SH-SY5Y neuroblastoma cells (Perfeito, Lazaro et al. 
2014) or SK-N-SH neuroblastoma cells (He, Song et al. 2011) expressing WT -syn with iron.  
However, these other groups did not measure ATP levels.  In addition, neither of the groups used 
paraquat treatment as an oxidative stressor, although one of the groups made a similar 
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observation using rotenone, another generator of ROS production (Perfeito, Lazaro et al. 2014).  
One of the groups used ferric ammonium citrate (FAC) as the iron source when measuring ROS 
production (He, Song et al. 2011) as ferric ion more readily stimulates oligomerization of -syn 
than ferrous ion (Levin, Hogen et al. 2011).  However, when we used FAC as an iron source, we 
found an increase in oxygen consumption (data not shown) as the citrate was likely used a 
mitochondrial respiratory substrate confounding the results, so we switched to using FeSO4 as 
the iron source.  Other major novel aspects of our study are the mitochondrial protective effects 
observed with amino acid and succinate supplementation. 
 
Overexpression of -syn may predispose cells to FeSO4 toxicity by 4 mechanisms 
converging on aberrant iron metabolism and ROS production 
 
1. Endosomal/lysosomal membrane disruption resulting in iron leakage. Even small 
increases in α-syn levels may increase dopaminergic neuron susceptibility to mitochondrial stress 
given the highly oxidizing environment of the SN. We showed that overexpression of α-syn 
induced increased levels of an -syn multimer, which could possibly lead to the formation of 
amyloid pores and altered ion homeostasis (Pacheco, Morales et al. 2015). -syn may insert into 
endosomes/lysosomes destabilizing the membranes allowing iron to leak (Zhu, Li et al. 2003). 
Unsequestered iron can promote free radical damage through Fenton chemistry.  α-syn has also 
been shown to form pores in the plasma membrane allowing extracellular Ca
2+
 leak into the 
cytoplasm (Pacheco, Morales et al. 2015), which may also cause mitochondrial dysfunction. 
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2. Increased MOA-A levels increasing ROS production. MOA-A is a drug target for 
many psychiatric disorders as MAO-A degrades not only dopamine, but other amine 
neurotransmitters as well.  In the brain MAO-A is the main MAO isoform in neurons (Fitzgerald, 
Ugun-Klusek et al. 2014).   MAO-B, the product of a separate gene, is a specific target for 
Parkinson’s disease as MAO-B function is specific for dopamine degradation and not other 
biogenic amines. In the brain MAO-B is expressed largely in astrocytes (Fitzgerald, Ugun-
Klusek et al. 2014).   MAO-B activity predominates in the aged brain (Fowler, Wiberg et al. 
1980), but MAO-A is the major isoform expressed in the SN (Westlund, Denney et al. 1988).  
MAO levels are hypothesized to increase in PD brain, in part because MAO-B levels have been 
measured to increase in PD patient platelets (Zhou, Miura et al. 2001) and in part because Parkin, 
an E3 ubiquitin ligase mutated in familial PD negatively regulates MAO levels by targeting 
estrogen-related receptors (ERRs), which induce their expression, for degradation (Ren, Jiang et 
al. 2011). 
A metabolic byproduct of normal MAO activity is hydrogen peroxide, which can be 
readily converted into more damaging oxygen radicals by interaction with iron, present at high 
levels in the cytoplasm of the SN (Edmondson 2014). Because of this peroxide production, MAO 
activity has been shown to damage ETC function (Cohen, Farooqui et al. 1997).  α-syn could 
also possibly increase MAO-A by inhibiting the proper degradation of mitochondrial outer 
membrane proteins by the proteasome (Taylor and Rutter 2011) or by slowing down degradation 
of the entire organelle by mitophagy (Xilouri, Brekk et al. 2013), although one report has shown 
increased α-syn expression to damage mitochondria and increase mitophagy (Chen, Xie et al. 
2015). Interestingly, upregulation of MAO-B has been shown to disrupt the ability of Parkin to 
signal for mitophagy of damaged mitochondria (Siddiqui, Hanson et al. 2012).  
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Increased MAO-B levels have been shown to increase oxidative stress to damage 
mitochondrial DNA (Hauptmann, Grimsby et al. 1996) and inhibit the TCA cycle enzyme alpha-
ketoglutarate dehydrogenase leading to deficiencies in spare respiratory capacity (Kumar, 
Nicholls et al. 2003).   Most strikingly, transgenic overexpression of MAO-B in astrocytes has 
been shown to induce Parkinson’s-like pathology in the mid-brain of mice (Mallajosyula, Kaur et 
al. 2008).  Not as much attention in PD research has been given to MAO-A.  But it is known that 
MAO-A levels are upregulated by oxidative stress (De Zutter and Davis 2001; Fitzgerald, Ufer et 
al. 2007).  In addition it was recently shown that MAO-A was upregulated during rotenone-(an 
inhibitor of ETC complex I) mediated cell death of neuroblastoma cells and knockdown of 
MAO-A partially restored viability (Fitzgerald, Ugun-Klusek et al. 2014).  Furthermore, 
knockdown of MAO-A under these conditions substantially decreased ROS levels showing that 
MAO-A is an important contributor to neuronal cellular ROS generation.  Under basal conditions 
knockdown of MAO-A increased ETC complex I activity and cellular ATP levels showing how 
normal MAO-A function may be detrimental to cellular energetics (Fitzgerald, Ugun-Klusek et 
al. 2014). 
 
3. Decreased abundance of SOD2. α-syn has many properties in common with prion 
proteins (Olanow and Brundin 2013).  SOD2, which is normally localized to mitochondria, can 
be mislocalized to the cytoplasm, where it aggregates with caspases and gets ubiquitinated and 
degraded as previously reported in scrapie PrP
Sc
 models (Sinclair, Lewis et al. 2013). Like the 
PrP
Sc
 prion aggregates, α-syn aggregates could be promoting the same type of mislocalization of 
SOD2, resulting in decreased SOD2 levels and further ROS susceptibility.  This explanation is in 
line with the recent descriptions of the prion hypothesis of PD (Chu and Kordower 2015). 
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Molecular similarities between α-syn and prion protein could lead to some pathological overlaps, 
perhaps like the decreased levels of SOD2 reported here. 
Specific alleles of SOD2 confer increased risk for developing PD (Shimoda-
Matsubayashi, Hattori et al. 1997; Fong, Wu et al. 2007).  It has previously been shown that 
there was a large decrease in SOD2 activity in a rotenone-induced model of PD in rats (Thakur 
and Nehru 2015), and a small decrease in SOD2 levels in either a MPTP-induced model (Liu, 
Peritore et al. 2015) or a dichlorvos pesticide-induced PD model in mice (Binukumar, Bal et al. 
2010).  Levels of SOD2 were increased in the cortex of PD patients (Marttila, Lorentz et al. 
1988; Radunovic, Porto et al. 1997) and also in the blood (Santiago, Scherzer et al. 2014).  SOD2 
was also shown to be oxidatively modified in PD patient brain (Dalfo, Portero-Otin et al. 2005).  
However, since SOD2 levels have yet to be measured in human SN, it is too early to determine if 
our observation of decreased SOD2 levels following α-syn overexpression are clinically relevant.  
 
4. Decreased abundance of brain derived neurotrophic factor (BDNF). BDNF was 
decreased in abundance in the α-syn overexpressing cells.  BDNF has been shown to increase 
mitochondrial biogenesis and antioxidant defenses by upregulating peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) (Markham, Cameron et al. 2004; Yuan, 
Sun et al. 2010).  For example, PGC-1α interacts with FOX3a to induce SOD2 (Olmos, Valle et 
al. 2009).  So downregulation of BDNF could greatly exacerbate the MAO-A and α-syn-induced 
oxidative stress through decreasing SOD2 levels.   In addition α-syn was shown to bind to the 
promoter and inhibit expression of PGC-1α (Siddiqui, Chinta et al. 2012), which may also 
contribute to the decreased complex I activity and SOD2 levels occurring when α-syn is 
overexpressed.  In addition PGC-1α levels have been shown to be decreased in PD patient brain 
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(Eschbach, von Einem et al. 2015).  But, since MAO-A was upregulated by α-syn 
overexpression and since PGC-1α is a required coactivator for ERR-mediated upregulation of 
gene expression (Giguere 2008), it is likely that PGC-1α is still expressed and at least partially 
functional. 
Further investigations into the mechanisms of α-syn-induced PD pathology as discussed 
above are warranted. Ultimately, in the oxidative environment of the SN, the changes induced by 
increased α-syn levels may contribute to increased ROS production, which results in ETC 
damage and damage to other proteins of central metabolism, specifically those involved in 
glycolysis and the TCA cycle.  TCA cycle enzyme dysfunction due to oxidative damage would 
affect both energy production and biosynthetic processes relying on TCA cycle intermediates. 
Mechanisms that could be acting in concert to damage mitochondria in PD are summarized in 
Figure 4.8. 
 
Increased expression of ETC complex I subunits and complex IV assembly factor as 
a possible compensatory mechanism to reduce ROS production 
ROS production is governed by thermodynamic conditions within the mitochondria, 
namely those pertaining to the NADH/NAD
+
 ratio and oxygen tension (Murphy 2009).  High 
membrane potential and high NADH/NAD
+
 ratio predispose ETC complex I to ROS production. 
Additionally, ETC complex I inhibition mediated by α-syn or lipid peroxidation caused by 
excessive MAO-A activity and free iron levels could also lead to decreased flux of electrons 
down the ETC.  Ground state oxygen can only accept one electron at a time according to Hund’s 
rule.  Increasing the amount of time it takes the second electron necessary to reduce oxygen 
completely allows more time for an oxygen with an unpaired electron to exist, creating a free 
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oxygen radical. Increasing the expression of ETC complexes I and IV (Fig. 19) could potentially 
decrease ROS production by increasing the flux of electrons down the ETC decreasing the 
amount of time oxygen exists with an unpaired electron. 
 
Supplementation with metabolic intermediates as a possible treatment for PD  
The TCA cycle integrates catabolic and anabolic pathways. Metabolic intermediates 
generated are siphoned off for synthetic reactions and high energy molecules such as NADH and 
FADH2, which donate electrons for oxidative phosphorylation, are generated in the process. 
Damage to TCA cycle enzymes would decrease their activity and result in energy deficits and 
imbalances in intermediates essential for anabolic reactions. These energetic deficits may result 
in decreased altered levels of amino acids, fatty acids, and other metabolites and altered activity 
of the molecular target of rapamycin (mTOR) kinase, responsible for nutrient sensing and 
metabolic integration. mTOR is inhibited when nutrients are low resulting in increased 
autophagy leading to degradation of proteins to increase free amino acid and other nutrient 
levels, decreased cell cycle progression, and decreased mitochondrial function (Schieke, Phillips 
et al. 2006). Indeed, when we inhibited mTOR through rapamycin treatment (Table 3) we saw an 
increase in ATP levels, and decrease in ROS production (Table 3).  However, in another study 
rotenone inhibition of ETC complex I increased ROS production inhibiting mTOR function 
leading to neuronal apoptosis (Zhou, Liu et al. 2015).  α-syn overexpression was shown to 
increase mTOR activity (Gao, Duan et al. 2015), perhaps as a compensatory response to attempt 
to increase mitochondrial function in response to inhibition of ETC complex I. 
Supplementation with amino acids such as serine that decrease ROS production in 
concert with TCA cycle intermediates such as succinate is a possible strategy to address this 
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metabolic demand, because of their generally regarded as safe (GRAS) classification by the 
FDA.  Several other metabolic intermediates and amino acids were also found to partially restore 
ATP levels and decrease ROS production (Table 3).  Since the efficacy of amino acid or TCA 
cycle metabolite therapy for the treatment of neurodegenerative diseases may be limited by their 
rate of transport, treatment with TCA cycle and amino acid esters may increase their efficacy. 
Consistent with this, we found a TCA cycle ester diethyl oxaloacetate to greatly increase ATP 
levels.  Others have found similar results with ethyl pyruvate or alpha-ketoglutarate showing 
protection against oxidative damage and motor deficits in an MPTP-induced mouse model of PD 
(Satpute, Lomash et al. 2013). 
Somewhat consistent with our results, a study using the Caco-2 intestinal epithelial cell 
line found 8 out of the 20 amino acids tested protected against hydrogen peroxide-induced 
oxidative stress (Katayama and Mine 2007).  However, that study found alanine, cysteine, 
histidine, isoleucine, leucine, lysine, tryptophan, and valine to protect from oxidative stress. In 
the M17 cells overexpressing α-syn, we tested all the amino acids except glutamate, glycine, 
threonine, and tyrosine.  In the untreated cells, we found serine, proline, and phenylalanine to 
decrease ROS production.  In the paraquat-treated cells we found alanine, aspartate, proline, and 
serine to decrease ROS production, while valine and isoleucine increased ROS production.  In 
the FeSO4-treated cells we found aspartate, valine, proline, and serine to decrease ROS 
production, while methionine and phenylalanine increased ROS production.  In the M17 
neuronal cell line used here, the amino acids most consistently able to decrease ROS production 
were serine, proline, and aspartate, which were not protective in the Caco-2 cells.  Using the 
nematode C. elegans we have recently shown that 18 of the 20 amino acids (exceptions were 
aspartate and phenylalanine) extended lifespan with proline and serine having the largest effects 
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(Edwards, Canfield et al. 2015).  Lifespan extension relied upon activation of DAF-16/FOXO, 
SKN-1/Nrf2, and AMP kinase signaling pathways.  In the study using the Caco-2 cells, the 
authors found that 5 of the amino acids increased glutathione levels, 6 of the amino acids 
increased glutathione-S-transferase activity, and the 3 branched chain amino acids increased 
catalase activity  (Katayama and Mine 2007).  This suggests that certain amino acids may 
activate the Nrf2-antioxidant response element signaling pathway to protect against oxidative 
stress. Future plans are to test this hypothesis. 
 
Conclusions 
Overexpression of α-syn resulted in mitochondrial susceptibility to FeSO4 insult. FeSO4 
was used in this study to approximate the iron rich physiological milieu of dopaminergic neurons 
and because of the ability of iron to oligomerize α-syn into a higher order structures that can 
permeabilize phospholipid bilayers (Kostka, Hogen et al. 2008). The observed FeSO4-induced 
increase in mitochondrial sensitivity in α-syn-overexpressing cells is likely due to oxidative 
damage to ETC complex I and TCA cycle enzymes. Our proteomics analysis suggests one 
possible mechanism of action is through an α-syn-induced increase in MAO-A levels, which in 
turn increases hydrogen peroxide production and increases levels of the toxic aldehyde DOPAL.  
Hydrogen peroxide is readily converted to more harmful free radicals via Fenton chemistry, 
possibly due to α-syn disruption of iron trafficking. Increased ROS and α-syn levels may 
decrease SOD2 levels, which may lead to oxidative damage of ETC complexes and TCA cycle 
enzymes. Succinate and amino acids were found to be partially protective against this oxidative 
stress, while valine or diethyl oxaloacetate greatly increased ATP levels. These findings merit 
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further investigation into the mechanisms through which amino acid and other metabolic 
therapies decrease ROS production, increase ATP levels, and possibly protect against PD. 
  
Highlights: 
α-synuclein overexpression increases mitochondrial susceptibility to iron or paraquat 
α-synuclein overexpression leads to an increase in MAO-A and a decrease in SOD2 
Succinate or aspartate decrease ROS in paraquat-treated α-synuclein-expressing cells 
Serine, proline, or alanine decrease ROS in paraquat-treated α-syn-expressing cells 
Valine or isoleucine increase ATP in paraquat treated α-synuclein-expressing cells 
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Table 3 Effects of metabolites on ROS production and ATP levels 
 
No insult Iron insult 4.0 mM Paraquat insult 600 µM 
 
ATP ROS ATP ROS ATP ROS 
Compound % 
increase 
p-
value 
% 
increase 
p-
value 
% 
increase 
p-
value 
% 
increase 
p-
value 
% 
increase 
p-
value 
% 
increase p-value 
Glutaric Acid 1 
mM 14 0.0578 -3 0.782 410 0.0001 4 0.5429 -37 0.0002 -19 0.1219 
Valine 5mM 1 0.8851 -12 0.172 143 0.0001 -48 0.0026 76 0.0008 56 0.0047 
Serine 5 mM 3 0.2297 -18 0.043 99 0.0001 -46 0.0034 3 0.5797 -44 0.0025 
Fumarate 1mM -52 0.0001 -11 0.280 98 0.0030 -25 0.0001 -3 0.0001 -10 0.0001 
Aspartate 5 mM 10 0.0053 -10 0.291 82 0.0001 -56 0.0011 -35 0.0004 -60 0.0018 
Rapamycin 10 nM -50 0.0001 -18 0.108 76 0.0004 -19 0.0024 -21 0.0004 -15 0.0111 
Methionine 1 mM 10 0.0040 2 0.623 61 0.0001 34 0.0318 N/P N/P N/P N/P 
L-Alanine 1 mM -1 0.6075 -7 0.126 55 0.0001 -15 0.2034 -38 0.0008 -70 0.0004 
Melatonin 10 μM  7 0.2303 7 0.004 40 0.0646 -32 0.0001 -6 0.0787 -19 0.0216 
Proline 5mM -11 0.0012 -26 0.008 39 0.0001 -46 0.0033 -22 0.0058 -50 0.0017 
Phenylalanine 
1mM 
-19 0.0003 -14 0.025 26 0.0065 112 0.0001 N/P N/P N/P N/P 
Asparagine 1 mM -2 0.5654 -4 0.566 26 0.0073 28 0.0873 N/P N/P N/P N/P 
Succinate 1 mM 13 0.0001 29 0.014 20 0.0231 0 0.9927 30 0.3209 -136 0.0011 
Diethyl 
oxaloacetate 1 mM 
-7 0.6338 41 0.042 20 0.0600 16 0.1545 89 0.0001 69 0.0001 
Isoleucine 5 mM 0 0.9808 8 0.096 20 0.0070 -2 0.9160 35 0.0001 34 0.0001 
                    N/P=not performed 
 
The effect of select metabolites on ROS production and ATP levels following a 72 hour 
treatment. FeSO4 and paraquat were titrated until ~ 50% reduction in ATP and ~50% increase in 
ROS was achieved in WT21 cells but not in M17 control cells. Metabolic intermediates were 
also titrated, starting with high, but physiologically attainable millimolar concentrations. 
Compounds shown in this table were the 15 hits that either increased ATP levels or decreased 
ROS production in a larger screen of 32 compounds.  Compounds found to significantly increase 
ROS production in the presence of FeSO4 were excluded from the paraquat screen.  ATP was 
measured as relative luminescence using CellTiter-Glo (Promega) and ROS as relative DCF 
fluorescence in 96 well plates.  The percent increase was determined comparing cells receiving 
FeSO4 only and cells receiving FeSO4 and the treatment. This allowed for internal normalization 
and allowed us to combine experiments performed on different days. A statistically significant 
increase in ATP or decrease in ROS production from the untreated FeSO4 insulted control was 
determined using one-way ANOVA.  
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Figure 13 Oxygen consumption 
Overexpression of WT or mutant forms of α-syn decreases oxygen consumption.  Oxygen 
consumption was determined using a Clark type oxygen electrode.  Cells were trypsinized from a 
confluent 10 cm plate (n=4 per genotype). Trypsin was neutralized by addition of 5 ml of 
DMEM containing FBS. Cells were counted in a 6 ml suspension with a hemocytometer before 
being pelleted, and resuspended in 1 ml of media.  350 μl of the 1 ml cell suspension was 
transferred to a respiratory chamber. O2 consumption was measured for 4 minutes and the 
respiratory rate was normalized per cell. Statistical significance was determined using one-way 
ANOVA, * p < 0.005 compared to control.  
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Figure 14 Densitometric analysis of α syn levels 
Densitometric analysis of α-syn levels in cells stably overexpressing WT α-syn show increased 
amounts of an α-syn multimer.  Western blot band quantification was performed using NIH 
ImageJ software. Values were combined from 3 biological replicates after they were normalized 
to the GAPDH loading control. The values were compared using one-way ANOVA, * p < 0.05.  
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Figure 15 Oxygen consumption in the presence of FeSO4 
FeSO4 treatment decreases oxygen consumption.  Oxygen consumption was determined in WT 
α-syn-overexpressing or control cells using a Clark oxygen electrode following incubation for 48 
hours with or without 4 mM FeSO4. Cells were trypsinized from confluent 10 cm plates (n=4 for 
each treatment).  The oxygen consumption rate for WT α-syn cells in the presence of iron was 
below what could be detected from one plate of cells. Biological replicates of 4 were pooled into 
2 biological replicates, which had identical values.  Trypsin was neutralized by the addition of 5 
ml of DMEM containing FBS. Cells were counted in a 6 ml suspension with a hemocytometer 
before being pelleted and re-suspended in 1 ml of media.  350 μl of a 1 ml cell suspension was 
transferred to a respiratory chamber. O2 consumption was measured for 4 minutes and the 
respiratory rate was normalized per cell.  The values were compared using two-way ANOVA, * 
p < 0.05. 
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Figure 16 ROS levels 
WT α-syn-overexpressing cells only showed higher ROS production than control cells in the 
presence of FeSO4.  In the absence of FeSO4 WT α-syn-overexpressing cells showed less ROS 
production than control cells (two-way ANOVA p < 0.005).  ROS production was measured 
following a 48 hour incubation with or without 4 mM FeSO4.   
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Figure 17 ATP levels in the presence of iron 
WT α-syn-overexpressing cells only showed lower ATP levels than control cells in the presence 
of FeSO4.  In the absence of FeSO4 WT α-syn-overexpressing cells showed higher ATP levels 
than control cells (two-way ANOVA p < 0.005).  ROS production was measured following a 48 
hour incubation with or without 4 mM FeSO4. 
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Figure 18 ATP levels in the presence of paraquat 
WT α-syn-overexpressing cells only showed lower ATP levels than control cells in the presence 
of paraquat.  In the absence of paraquat WT α-syn-overexpressing cells showed higher ATP 
levels than control cells (two-way ANOVA p < 0.005). Paraquat also increased ATP levels 
significantly albeit slightly in control cells; statistical indicators were omitted for clarity. ATP 
 
 
 
116 
 
 
Figure 19 Mitochondrial protein level changes 
Figure 4.7 Select proteome changes accompanying overexpression of α-syn. Red indicates 
increased abundance, while green indicates decreased abundance. Monoamine oxidase-A (MAO-
A), NADH dehydrogenase (ubiquinone) 1 alpha sub-complex, 13 (NDUFA13), NADH 
dehydrogenase (ubiquinone) 1 beta sub-complex 4 (NDUFB4), and surfeit 1 (SURF1) show log2 
fold increases of 1.6, 1.4, and 1.7, while superoxide dismutase 2 (SOD2) showed a log2 fold 
decrease of 1.4. 
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Figure 20 Mechanisms leading to ROS mediated damage 
Mechanisms leading to ROS mediated damage of ETC complexes and TCA cycle enzymes. (A) 
Overexpression of α-syn results in a decreased abundance of SOD2 preventing adequate 
superoxide conversion to the less toxic hydrogen peroxide. (B) Overexpression of α-syn likely 
leads to increased MAO-A activity and increased hydrogen peroxide production. (C) Decreased 
BDNF signaling may decrease mitochondrial biogenesis and SOD2 levels leading to increased 
ROS production. (D)  When α-syn levels increase α-syn aggregates into amyloid pores which 
penetrate lysosomes and endosomes transporting iron releasing it into the cytoplasm where it can 
stimulate α-syn aggregation. Free iron can convert hydrogen peroxide to more harmful oxygen 
free radicals. (E) Tricarboxylic acid cycle enzymes and electron transport chain complexes are 
damaged by increased ROS levels decreasing energy production, and unbalancing metabolites 
essential for key anabolic processes. 
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Table 4 List of all the compounds screened 
Drugs Metabolic intermediates Ester metabolic intermediates Amino acids  
AICAR Succinate Diethyl fumurate essential non-essential 
Melatonin Beta-hydroxybutyrate Diethyl malate L-isoleucine L-asparagine 
Rapamycin Citrate Diethyl oxaloacetate L-leucine L-cysteine  
 Fumurate Dimethyl malate L-histidine L-glutamine 
 Glutaric acid Dimethyl succinate L-lysine L-alanine 
 L-Malate  L-methionine L-arginine 
 Malonic acid  L-phenylalanine L-proline 
 Pyruvate  L-tryptophan L-serine 
   L-valine L-aspartate 
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Figure 21Full Western blot and GAPDH loading control 
Western blots were not cropped for clarity. The blot on the left shows the most intense banding 
at approximately 58 kDa indicating that most of the alpha synuclein is present in the oligomers 
smaller than 98 kDa but larger than 36 kDa.  
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CHAPTER FIVE: MITOCHONDRIAL DYSFUNCTION IN THE NEUROVASCULAR 
UNIT OF THE SPINAL CORD IN SPORADIC ALS PATIENTS 
 
Abstract 
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease 
characterized by progressive motor neuron degeneration in the brain and spinal cord, leading to 
muscle atrophy, paralysis and death, typically around four-five years after the initial symptoms. 
Mitochondrial dysfunction is a major contributor to cell damage promoting the progression of 
ALS. Mitochondrial function abnormalities are characterized in the spinal cords of ALS animal 
models and ALS patients. However, the role of mitochondria is still unclear in the context of the 
neurovascular unit in the spinal cord of sporadic ALS patients. In the present study, activities of 
mitochondrial electron transport chain (ETC) complexes were analyzed in post-mortem gray and 
white matter cervical and lumbar spinal cords from sporadic ALS patients. Also, 
immunohistochemical analysis of mitochondrial density in lateral funiculus, spinal cord motor 
neurons, and capillaries in gray and white matter was performed. Our results demonstrated 
differences between activities of mitochondrial ETC complexes. Complex IV activity, but not 
Complex I, was significantly decreased only in the gray matter in both cervical and lumbar spinal 
cords, Quantitative analyses of mitochondrial density showed mitochondrial aggregation mainly 
in cervical motor neurons and white matter capillaries in cervical and lumbar spinal cords.     
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Findings herein suggest for the first time that aberrant mitochondrial dynamics affect the 
neurovascular unit of the spinal cord in ALS patients likely due to mitochondrial complex IV 
deficits 
 
Introduction 
Sporadic amyotrophic lateral sclerosis (sALS) is an adult onset neurodegenerative 
disorder with no known cure or effective treatment. It is characterized by progressive motor 
neuron degeneration in the brain and spinal cord, leading to muscle atrophy and eventual death 
(Kinsley and Siddique 1993). Mitochondrial dysfunction is a well-established contributor to the 
progression of many neurodegenerative disorder including Alzheimer’s disease, Parkinson’s 
disease, and ALS (Cozzolino and Carri 2012; Cozzolino, Rossi et al. 2015; Delic, Brownlow et 
al. 2015).  Mitochondrial is characterized by a decrease in adenosine triphosphate (ATP) 
production, an increase in reactive oxygen species (ROS) production.  Mitochondrial dysfunction 
is also characterized by a decrease in oxygen consumption and a decrease in mitochondrial 
membrane potential (de Moura, dos Santos et al. 2010). These mitochondrial defects are directly 
linked to improper function of the electron transport chain (ETC).   
A diagram of the mitochondrial ETC is shown in Figure 1.  Nicotinamide adenine dinucleotide 
(NADH) dehydrogenase or ETC Complex I contributes to around 40% of the proton gradient 
across the mitochondrial inner membrane and its dysfunction has been implicated in several 
neurodegenerative disorders including ALS, Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease (Marella, Seo et al. 2009; Moreira, Carvalho et al. 2010; Ghiasi, 
Hosseinkhani et al. 2012; Papa and De Rasmo 2013). It has been recently determined that 
mitochondrial complex I function is modulated by the cAMP/PKA signaling pathway (Piccoli, 
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Scacco et al. 2006; Papa, Scacco et al. 2010). Succinate dehydrogenase (Complex II), is the only 
ETC complex that also participates in the tricarboxylic acid (TCA) cycle and is entirely encoded 
by genes in the nucleus, having no mitochondrial DNA-encoded subunits.  Complex II 
enzymatic activity functions to convert succinate to fumarate, and it has been implicated in early-
onset Parkinson’s disease and ALS (Haas, Nasirian et al. 1995; Wiedemann, Manfredi et al. 
2002). The cytochrome bc1  complex (ETC Complex III) contributes to the proton gradient by the 
translocation of protons and the reduction of the lipid soluble electron carrier cytochrome c. 
Dysfunction in ETC Complex III is associated with mitochondrial myopathy and lactic acidosis 
(Darley-Usmar, Kennaway et al. 1983).  Complex II and III activity has also been shown to 
decrease in the spinal cords of ALS patients (Wiedemann, Manfredi et al. 2002). Cytochrome c 
oxidase (ETC Complex IV) is the last complex in the electron transport chain and it oxidizes 
cytochromes by sequential transfer of electrons to the terminal electron acceptor oxygen. 
Complex IV deficiency has also been shown to contribute to the progress of many 
neurodegenerative diseases, including sporadic Alzheimer disease, and sporadic ALS (Fujita, 
Yamauchi et al. 1996; Mosconi, de Leon et al. 2011; Hroudova, Singh et al. 2014). 
Unfortunately, these studies did not delineate between complex IV activity of the cervical and 
lumbar white and gray matter mitochondrial activity. Early death in ALS is associated with 
degeneration of the phrenic nerve, innervating the diaphragm. It is possible that mitochondrial 
dysfunction is more sever in the cervical compared to lumbar spinal cord. F0-F1-ATP synthase 
(Complex V), utilizes the electrochemical gradient generated by the ETC complexes I-IV to 
phosphorylate ADP to ATP. Dysfunction of complex V has been implicated in Alzheimer’s 
disease, and Parkinson’s disease (Martinez-Cano, Ortiz-Genaro et al. 2005; Ferrer, Perez et al. 
2007). But the activity of complex V in spinal cords of ALS patients remains unexplored.  
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Mutations in the gene coding for superoxide dismutase 1 (SOD1) were shown to contribute to 
the development of familial ALS (fALS), which is presented with the same symptoms as sALS. 
Currently, mutations in 19 genes are known to cause fALS , with the most recently identified 
being TANK-binding kinase 1(TBK1) (2015; Cirulli, Lasseigne et al. 2015). Proteins coded for 
by these 19 genes range in function from RNA stability in the case of TAR DNA binding 
protein, to conversion of free radicals to less reactive oxygen species as in the case of SOD1. Yet 
these mutations are not present in sALS, although they yield the same mitochondrial phenotypes. 
Recently, a mitochondrial contribution to ALS pathology has been contested (Parone, Da Cruz et 
al. 2013). Using an SOD 1 mutant mouse, Parone et al showed that improving mitochondrial 
functions, does not improve ALS associated muscle atrophy and death. Establishing a clearer 
picture of the mitochondrial involvement in the pathology of sALS in patients is necessary in 
order to advance our current knowledge.  
The neurovascular unit (NVU) provides a stage for a complex interplay between neuronal energy 
demand and nutrient supply. It encompasses interaction of neurons, astrocytes, endothelial cells, 
myocytes, pericytes and extracellular matrix components (Neuwelt, Bauer et al. 2011; 
Stanimirovic and Friedman 2012; Abbott 2013; Muoio, Persson et al. 2014). Disruption of 
proper NVU function contributes to the progress of neurodegenerative disorders and to the 
pathology following traumatic brain injury (Zlokovic 2005; Desai, Monahan et al. 2007; Khan, 
Im et al. 2009). Mitochondrial involvement in the breakdown of NVU in neurodegenerative 
disorders remains poorly understood.   
Recently, Garbuzova-Davis et al. described sALS as a disease characterized by 
dysfunction in endothelial cells and capillaries that comprise the neurovascular unit (Garbuzova-
Davis, Haller et al. 2007; Garbuzova-Davis and Sanberg 2014). We therefore wanted to 
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determine if mitochondrial dysfunction contributed to the collapse of the NVU in addition to 
contributing directly to neuronal degeneration. We determined the ETC complex IV activity in 
gray and white matter of cervical and lumbar spinal cord.  We also assayed ETC complex I 
activity and mitochondrial aggregation in the capillaries of gray and white matter, lateral 
funiculus, and motor neurons.  
 
Methods 
Mitochondrial Isolation 
The gray and white matters were dissected in frozen post-mortem cervical and lumbar 
spinal cords from ALS patients and controls. Homogenate was enriched for mitochondria by first 
placing  tissue samples in 2.5 mL of ice cold mitochondrial isolation buffer (75 mM sucrose, 
0.1% BSA, 1 mM 152 EGTA, 215 mM mannitol, 20 mM K 153 + HEPES, pH 7.2). The tissue 
samples were homogenized in the isolation buffer with seven strokes in a dounce homogenizer 
with a tight fitting teflon pestle on ice. The homogenates were then centrifuged at 13,000 x g for 
5 minutes at 4℃. The supernatant was removed and the pellet was re-suspended in 150 µL of ice 
cold mitochondrial isolation buffer with 1 mM n-dodecyl-β-D-maltoside. 
 
ETC complex I analysis 
ETC complex I activity was measured by first adding 10 µL of mitochondrial suspension 
to 495 µL of reaction buffer (25 mmol/L Potassium Phosphate, 3.5 g/L BSA, 60 µM DCPIP 
(2,6-dichlorophenol indophenol), 70 µmM decylubiquinone, and 1.0  µM antimycin-A).  A 96 
well plate was used and 98 µL of the reaction buffer with mitochondria was added to 3 wells and 
incubated at 37℃ for 3 minutes. The absorbance was then measured at 600 nm and readings 
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were taken for 2 minutes at 30 second intervals. A multi-channel pipette was used to inject 2 µL 
of 10 mM NADH for a final concentration of 0.2 mM. The absorbance was then was measured at 
600 nm and readings were taken for 20 minutes at 2 minute and 30 second intervals. Afterwards 
1 µL of 10 mM rotenone (in DMSO) and the absorbance was measured at 600 nm for the same 
length of time and interval of time as the NADH reading. 
 
ETC complex IV analysis 
A Clark electrode was used to measure ETC complex IV activity. The electrode chamber 
was filled with 35 µL of mitochondrial suspension. The volume was brought up to 350 µL with 
COX buffer  having a final concentration of 1 µM FCCP, 50 µM cytochrome c, 2 mM ascorbate, 
1 µM antimycin A and 5 mM TMPD (N,N,N',N'-tetramethyl-p-phenylenediamine). The oxygen 
concentration was recorded for at least 6 minutes and then 10 mM of KCN was added and the 
oxygen concentration was recorded for 2 more minutes. 
 
ETC complex V analysis 
As previously described by Delic et al (Delic, Brownlow et al. 2015) A molybdenum-based 
assay measuring free phosphate was used to determine the F0F1-ATPase hydrolytic activity of 
frozen-thawed human spinal cord post mortem tissue enriched for mitochondria. The reaction 
buffer consisted of 80 mM KCl, 3 mM MgCl2, 5 mM sodium azide, 0.2 mM EGTA, 0.2 mM 
CaCl2, and 25 mM MOPS. The pH was adjusted to 7.0 using Tris base.  2 µM oligomycin was 
added to control samples to obtain the F0F1-ATPase-independent rate of phosphate release, 
which was subtracted off.  The coloring solution consisted of 0.7 mM ammonium 
heptamolybdate, 3 mM ascorbic acid, 100 µM potassium antimony tartrate, and 140 mM H2SO4 
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made from stock concentrations of 0.3 M ascorbic acid, 4 mM potassium antimony tartrate and 
24 mM ammonium heptamolybdate. 1 mM ATP and 10 µg/ml of mitochondrial protein were 
added to the reaction buffer at 37°C.  After 20 minute incubation, 270 L of coloring solution 
was added to 30 L of reaction buffer (containing ATP and mitochondrial protein) and the 
absorbance was read at 850 nm on a Biotek Synergy 2 microplate reader 4 minutes later. 
 
Immunohistochemistry 
A series of spinal cord tissue sections from ALS patients and controls, previously cut on a 
cryostat, were labeled with a specific marker for mitochondria. Briefly, after blocking tissue for 
60 minutes, the mouse monoclonal anti-VDAC1 antibody (1:50, Millipore) was applied on 
tissues overnight at 4°C.  The next day the slides were washed with PBS and then incubated with 
goat anti-mouse secondary antibody conjugated to FITC (1:700, Alexa, molecular Probes) for 2 
hours. A coverslip was added to the sections with Vectashield containing DAPI and examined 
using epifluorescence with an Olympus BX60 microscope. Integral density of mitochondria was 
analyzed using NIH ImageJ software.  
 
Protein assay 
Protein levels were measured using a BCA protein assay (Thermo Scientific).  
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Statistical analysis:  
Error bars represent the standard error of the mean.  One-way ANOVA tests were 
performed with control and ALS patient tissue as variables, * indicates a p value of < 0.05. 
Analysis was performed using SigmaPlot version 11.  
 
Results 
Human spinal cord autopsied samples from ALS and aged-matched controls were 
obtained.  Gray and white matter were dissected out and enriched for mitochondria. Since there 
have been mixed reports on mitochondrial ETC complex dysfunction in ALS patients, we 
measured complex I and complex IV activity in the gray and white matter homogenates. We 
found no statistical difference in the activity of complex I between the ALS patients and the aged 
matched controls or between gray matter and white matter (Fig. 22 A).    However, we found that 
complex IV activity was higher in gray matter than in white matter in control samples (Fig. 22 
B).  In addition we found that complex IV activity was reduced in gray matter, but not in white 
matter of ALS patient cervical and lumbar spinal cord samples.  
To examine any possible changes in mitochondrial morphology or number in ALS 
immunostaining of mitochondria in spinal cord sections was performed (Fig. 23 A- 23 P). 
Nuclear counterstaining was performed with DAPI.  Micrographs were taken of capillaries in 
white and gray matter, regions of lateral funiculus, and individual motor neurons. Surprisingly, 
the density of staining appeared stronger in ALS cervical and lumbar sections compared to 
controls. It is important to note that although consistent and statistically significant, the 
differences were minor. More sensitive methods of quantifying the micrographs are currently 
being explored. Excluding hemosiderin staining artifacts, larger mitochondrial aggregates were 
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observed in lumbar and cervical ALS motor neurons (Fig. 23 I, 23 M) than age matched controls 
(Fig. 23 A, 23 E). More dense mitochondrial aggregates were also present in ALS white matter 
(Fig. 23 J, 23 N) compared to control white matter (Fig. 23 B, 23 F). Mitochondrial aggregation 
and density in white matter capillaries of ALS patient spinal cord also appear higher (Fig. 23 K, 
23 O) than in control white matter capillaries (Fig. 23 C, 23 G). Mitochondrial aggregation and 
density also appeared higher in the gray matter capillaries of cervical and lumbar ALS patient 
spinal cord (Fig. 23 L, 23 P) compared to controls (Fig. 23 D, 23 H).  
Mitochondrial density from the images in Figure 23 was quantified (Fig. 24 A - 24 D). 
The threshold was adjusted to exclude hemosiderin. As expected from the manual inspection of 
the images, the mitochondrial density was higher in motor neurons than in capillaries or the 
lateral funiculus (Fig. 24 A). Interestingly, ALS cervical motor neurons showed higher 
mitochondrial density than those of controls (Fig. 24 A). Similarly, the increased mitochondrial 
density observed in ALS patients compared to controls was also observed when examining the 
lateral funiculus sections (Fig. 24 B) or white matter capillaries (Figure 24 D), but there was no 
statistical difference in gray matter capillaries (Figure 24 C).  
 
Discussion 
In this study we showed that there is decreased ETC complex IV activity in the gray 
matter of both lumbar and cervical spinal cord samples from sALS patients. We also showed that 
there appears to be greater amount of mitochondrial aggregation in the capillaries of gray and 
white matter, the lateral funiculus, and motor neurons in the samples from the ALS patients. 
Although the activities of ETC complexes I, IV, and V were assayed in our samples, we only 
report complex I and IV activities as complex V activity in the spinal cord lysates lost the ability 
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to be inhibited by oligomycin and therefore we could not distinguish between complex V 
ATPase activity and non-complex V ATPase activity present in the samples. Several autolysis 
studies have shown that ETC complex V was the most susceptible complex of oxidative 
phosphorylation to breakdown and its function was completely lost 20 hours following 
mitochondrial isolation (Rouslin 1983; Gribanov, Pankrushina et al. 1994; Vincent, Gratton et al. 
1995). 
 
ETC complex IV is decreased in both cervical and lumbar spinal cord. 
Progression of sALS varies greatly, with the majority of patients dying within five years 
of diagnosis. Respiratory problems are associated with negative prognosis and patient outcome 
(Shoesmith, Findlater et al. 2007).  Deterioration of the neurons located in the cervical spine 
leads to loss of innervation of chest wall, diaphragm, and muscles involved with swallowing.  
We therefore originally hypothesized that cervical mitochondria would have more profound 
dysfunction than those in the motor neurons of the lumbar spine. Deficits in complex IV activity 
were, however, of the same magnitude in both regions, suggesting that cervical mitochondria are 
not more damaged.  It is possible that motor neurons of the cervical spine are more susceptible to 
neuronal cell death and loss at the same level of mitochondrial damage.  No complex IV deficits 
were observed in white matter. The reasons for this are unclear at present, but it is possible that 
mitochondria in the cell bodies are in close proximity to the ER, where they are exposed to 
higher levels of released Ca
2+
 that stimulates mitochondrial citric acid cycle metabolism and 
ROS production leading to more oxidative damage of complex IV. 
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Increased mitochondrial aggregation in the neurovascular unit of ALS patient 
spinal cord 
Several groups have shown decreased levels of mitochondrial DNA and complex I+III, 
II+III, and IV activities in ALS patient spinal cord or muscle (Vielhaber, Kunz et al. 2000; 
Wiedemann, Manfredi et al. 2002). These results are consistent with our results assuming there 
was a complex III deficit in our ALS patient samples that we did not measure.  However, a 
decreased amount of the mitochondrial marker citrate synthase led one of the groups to conclude 
there were decreased amounts of mitochondria in the ALS patient spinal cord (Vielhaber, Kunz 
et al. 2000; Wiedemann, Manfredi et al. 2002) .  We show what appears to be increased 
mitochondrial density following IHC mitochondrial staining and subsequent micrograph density 
analysis in spinal cord from our ALS patient samples. Increased mitochondrial density was 
observed in lateral funiculus, and capillaries. This apparent increase in mitochondrial density 
could be due to mitochondrial aggregation or impaired fission (Shi, Gal et al. 2010).  
Dysfunctional mitochondria fuse with healthy mitochondria in an attempt to correct deficits 
(Schon and Gilkerson 2010). When this process collapses, mitochondria are unable to undergo 
fission, resulting in poorly functioning mega-mitochondria. This appears to be a problem not 
only in neurons, but the entire NVU (see Fig. 24).  
Future studies will focus on assaying ETC complex III and mitochondrial DNA levels in 
our human spinal cord samples and analyzing mitochondrial ETC complex activities in each of 
the components of the NVU in a mouse model of ALS.  Once the degree of mitochondrial 
dysfunction is established, potential therapies can be administered to the mice to determine if 
they improve ETC complex function.  
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Figure 22 Diagram of the ETC 
NADH from the citric acid cycle is oxidized by the removal of two electrons, which are donated 
to complex I and then transferred to the lipid-soluble carrier, ubiquinone, converting it to 
ubiquinol. Complex II, or succinate dehydrogenase, also contributes to the ubiquinol pool by 
reduction of succinate. Succinate dehydrogenase reduction of succinate to fumarate is an 
essential step in the citric acid cycle as well. In complex III, also known as the cytochrome bc1 
complex, hydrogens are translocated to the intermembrane space, by oxidation of ubiquinol to 
ubiquinone. The electrons are transferred to the water-soluble electron carrier protein 
cytochrome c in the inner membrane space, and then finally shuttled to cytochrome c oxidase 
(complex IV). Complex IV sequentially transfers electrons on to a molecule of oxygen. In 
response, oxygen is converted to two molecules of water, further consuming hydrogens in the 
mitochondrial matrix.  During this process, NAD
+
 is regenerated for use in the citric acid cycle, 
and the electrochemical gradient is generated by protons pumped out of the matrix. This gradient 
is then used by complex V, ATP synthase, to generate ATP. 
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Figure 23 Mitochondrial complex I and complex IV activity 
Decreased complex IV activity, but not complex I activity in ALS spinal cord. 
(A) ETC complex I activity in mitochondria from post-mortem spinal cords of ALS patients and 
controls.  Mitochondria were isolated and suspended in reaction buffer with DCPIP. The 
absorbance was read at 800 nm. The reduction of (DCPIP) changed its color from blue to clear. 
The reaction was inhibited by 1µM rotenone.  (B) Decreased activity of mitochondrial ETC 
complex IV was observed in ALS gray matter compared to controls.  
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Figure 24 Immunohistochemistry staining of mitochondria 
Immunohistochemistry staining of mitochondria (green) in post-mortem spinal cords of ALS 
patients and controls. The scale bar in panels A-P is 25 µM.  Mitochondrial aggregation is 
indicated with an arrow. DAPI stained nuclei are shown in blue. 
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Figure 25 Integrated density analysis of mitochondria area in spinal cord micrographs 
Figure 5.4 Integrated density analysis of mitochondrial area in spinal cord micrographs.  ImageJ 
software was used to quantitate mitochondrial areas from the panels in figure 3. 10 ALS and 4 
control sections were analyzed.  
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CHAPTER SIX: THE EFFECTS OF AICAR AND RAPAMYCIN ON 
MITOCHONDRIAL FUNCTION IN TRANSFORMED MTDNA MUTATOR MEFS 
 
Abstract 
Mitochondrial DNA point mutations and deletions accumulate with age and may play a 
role in aging as suggested by the premature aging phenotype in mitochondrial DNA polymerase 
gamma (POLG) exonuclease-deficient mice.  Increased AMP-activated protein kinase (AMPK) 
signaling and decreased mammalian target of rapamycin (mTOR) signaling delay aging and 
influence mitochondrial function.  Transformed murine embryonic fibroblasts (MEFs) from 
POLG proofreading-deficient mice were more sensitive to most mitochondrial inhibitors than 
WT MEFs.   When cultured in high glucose media (HGM), POLG exonuclease-deficient MEFs 
had a similar respiratory rate, but higher reactive oxygen species (ROS) production and higher 
ATP levels than WT MEFs due to an upregulation of glycolysis. Large deficits in oxygen 
consumption were revealed when POLG exonuclease-deficient MEFs were cultured in low 
glucose, pyruvate-containing media (LGPM).  The effects of AICAR (5-Aminoimidazole-4-
carboxamide ribonucleotide), an AMPK activator, and rapamycin, an inhibitor of mTOR, on 
mitochondrial function and ATP levels were tested.  Treatment with rapamycin led to a transient 
increase in oxygen consumption only in WT MEFs.  Rapamycin treatment generally increased 
ATP levels without affecting ROS production.  Short term treatment with AICAR increased ATP 
levels in POLG exonuclease-deficient MEFs only when cultured in LGPM.  AICAR treatment 
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did not affect oxygen consumption, decreased ATP levels, and increased ROS production when 
MEFs were cultured in HGM.  In contrast, long term AICAR treatment in HGM with pyruvate 
and uridine decreased oxygen consumption and ROS production without decreasing ATP levels.  
These results demonstrate the complex interactions between mitochondrial function, nutrient 
levels, cellular energy status, and mTOR and AMPK signaling. 
 
Introduction 
Several lines of evidence suggest the involvement of mitochondrial dysfunction in the 
development of mammalian aging (Navarro and Boveris 2010; Park and Larsson 2011; Dai, 
Rabinovitch et al. 2012; Prolla and Denu 2014).  With aging, most eukaryotic organisms studied 
to date have been shown to accumulate mitochondrial DNA (mtDNA) point mutations and/or 
deletions (Melov, Lithgow et al. 1995; Yui, Ohno et al. 2003; Kazachkova, Ramos et al. 2013).  
Whether these mtDNA mutations in aged individuals are primarily caused by reactive oxygen 
species (ROS)-mediated mtDNA damage in mid to late life or are due to mtDNA polymerase 
gamma (POLG) errors early in development that clonally expand with age has been debated 
(Larsson 2010), but accumulating evidence from mammalian studies have shown minimal levels 
of mitochondrial DNA heteroplasmy in aged cells suggesting the latter. The degree to which the 
accumulation of mtDNA mutations contributes to normal human aging is still unknown 
(Trifunovic, Wredenberg et al. 2004; Kujoth, Hiona et al. 2005; Khrapko and Vijg 2007).  
Mitochondria DNA mutations may not accumulate to an extent to play a detrimental role in most 
tissues, but they can buildup to deleterious levels in specific tissues or tissue regions such as in 
muscle fibers (McKenzie, Bua et al. 2002), the substantia nigra region of the brain (Kraytsberg, 
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Kudryavtseva et al. 2006), and stem cells, such as those present in the colonic crypts (McDonald, 
Preston et al. 2006).   
If clonal expansion of mtDNA mutations that occur due to polymerase errors in young 
organisms is responsible for the majority of mutations in aged mitochondrial genomes, than 
modulating anti-oxidant defense mechanisms may have little effect on aging outcomes, as was 
recently proposed in a study examining muscle from SOD1 knockout mice (Wanagat, Ahmadieh 
et al. 2015).  Instead therapies that stimulate mitochondrial turnover through increased 
mitophagy and mitochondrial biogenesis may prove effective at delaying mtDNA mutation 
accumulation.  This strategy is promising as mitophagy has been shown to selectively degrade 
damaged or dysfunctional mitochondria with a low membrane potential.  The low membrane 
potential stabilizes the PINK1 protein on the outer mitochondrial membrane to recruit the Parkin 
E3 ubiquitin ligase necessary for recruitment of autophagosomes and mitochondrial degradation 
(Koyano and Matsuda 2015).  However, studies using human cell lines have suggested that 
deleted mitochondrial DNA molecules may have a replicative advantage that counters the 
increased rate of degradation of dysfunctional mitochondria (Diaz, Bayona-Bafaluy et al. 2002).  
But data from human muscle fibers (Campbell, Krishnan et al. 2014) did not support the findings 
that mtDNA molecules with deletions have a replicative advantage.  Two methods for inducing 
autophagy and mitophagy are activation of the AMP-dependent protein kinase (AMPK) pathway 
and inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway and so 
modulating the activity of theses pathways may be able to protect mitochondrial function and 
delay aging.   
AMPK is one of the main metabolic sensors responding to increases in ADP and AMP 
levels in the cell as a result of ATP consumption (Steinberg and Kemp 2009; Hardie 2011).  
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AMPK is a conserved heterotrimer (αβγ) and overexpression of an alpha subunit has been shown 
to extend lifespan in C. elegans (Apfeld, O'Connor et al. 2004).  More recent studies have shown 
that activation of AMPK by lipoic acid (LA), which is also a strong antioxidant, improves 
skeletal muscle energy metabolism possibly through increased expression of peroxisome 
proliferator-activated receptor-gamma coactivator-1alpha (PGC-1) to increase mitochondrial 
biogenesis and glucose transporter-4 (GLUT4) to increase glycolysis, while decreasing the 
phosphorylation of mTOR to stimulate autophagy (Wang, Li et al. 2010).  Activation of AMPK 
by AICAR was blunted in aged rats resulting in reduced mitochondrial biogenesis (Reznick, 
Zong et al. 2007).  This result suggests that aging-related declines in AMPK activity could be a 
contributing factor in the impaired mitochondrial function in aged organisms. 
mTOR is a kinase that forms two distinctive complexes, mTORC1 and mTORC2.  In the 
mTORC1complex, mTOR associates with raptor and other proteins.  mTORC1 is stimulated by 
increased oxygen levels, amino acid levels, energy levels, and nutrient availability to promote 
increased metabolism and cell cycle progression (Halloran, Hussong et al. 2012; Laplante and 
Sabatini 2012). mTORC1 is inhibited by nutrient stress such as calorie restriction (CR), and is 
potently inhibited by the compound rapamycin (Laplante and Sabatini 2012), although long term 
rapamycin treatment also inhibits mTORC2 function (Schreiber, Ortiz et al. 2015).  Decreasing 
mTOR activity with rapamycin has been shown to increase lifespan in mice possibly through 
enhanced proteostasis due to a decreased rate of protein synthesis and an increase in autophagy 
(Harrison, Strong et al. 2009).   
CR leads to the activation of AMPK and sirtuins, which are NAD
+
 dependent protein 
deacetylases.  Together, sirtuins and AMPK inhibit the mTORC1 pathway leading to a decreased 
rate of protein synthesis.  mTORC1 has also been reported to have a significant positive effect on 
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mitochondrial activity, increasing resting oxygen consumption and oxidative capacity.  
Rapamycin treatment to inhibit mTOR has been shown to lower mitochondrial membrane 
potential, oxygen consumption, and ATP synthesis in cultured cells (Schieke, Phillips et al. 
2006).  Short term (12-hour) inhibition of mTORC1 did not affect mitochondrial function 
(Morita, Gravel et al. 2013), but longer term inhibition lowered the levels of the transcriptional 
regulator yin-yang 1 (YY1), resulting in downregulated expression of PGC-1, ERR- and 
other regulators of mitochondrial function (Cunningham, Rodgers et al. 2007).  Consistent with 
this, mTOR has been shown to translocate from the cytoplasm to the outer mitochondrial 
membrane in response to radiation stress to inhibit hexokinase II to inhibit glycolysis and 
increase the reliance of the cell on oxidative metabolism (Lu, Qin et al. 2015). 
mTORC2 is composed of mTOR and other proteins such as rictor.   Knockdown of rictor 
increased mTORC1 levels and the rate of oxygen consumption, while knockdown of raptor 
decreased the rate of oxygen consumption (Schieke, Phillips et al. 2006).  mTORC2 associates 
with mitochondria associated ER membranes (MAM).  mTORC2 inhibition led to increased Ca
2+
 
transfer between the organelles, stimulating mitochondrial metabolism (Betz, Stracka et al. 
2013).  Contrary to expectations, chronic rapamycin treatment led to increased mitochondrial 
biogenesis in adipose tissue of obese db/db mice (Deepa, Walsh et al. 2013).  Therefore, the 
effect of rapamycin on mitochondrial function may be tissue-specific or depend upon the 
duration of the treatment (Fang, Westbrook et al. 2013).    
TOR signaling has also been shown to alter mitochondrial function through effects on 
protein synthesis (Morita, Gravel et al. 2013).  In dietarily restricted Drosophila melanogaster, 
there was increased expression of eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein (d4E-BP), a target of TOR kinase that globally decreases the rate of translation, but 
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specifically increases the translation of genes involved in mitochondrial ETC function  (Zid, 
Rogers et al. 2009).  In mammalian cells, mTOR has been shown to upregulate translation of 
mitochondrial transcription factor A (TFAM) and several subunits of mitochondrial ETC 
complexes I and V (ATP synthase) (Morita, Gravel et al. 2013). Therefore, decreased respiration 
was observed following mTOR inhibition.  Conversely, hyperactivation of mTORC1 by a PTEN 
mutation greatly stimulated respiration (Goo, Lim et al. 2012). 
The degree to which mTOR or AMPK signaling is modified by different sugars or 
respiratory substrates remains relatively unexplored.  In the studies described here, we 
specifically examine how altering glucose and pyruvate levels in the culture media modify the 
effects of AICAR and rapamycin treatment on mitochondrial function in WT and mtDNA 
mutator murine embryonic fibroblast (MEF) cell lines. The mtDNA mutator cell line was 
established as a culture model to study the effects of random mtDNA mutations, similar to those 
that occur with aging, on cellular energetics under different nutrient conditions, which we varied 
by altering the media glucose and pyruvate levels. The experiments were also designed to 
compare the effects of anti-aging rapamycin and AICAR treatments on cellular respiration, ROS 
production, and ATP levels in WT and mtDNA mutator cells. 
 
Methods 
Generation of stable cell lines 
Murine embryonic fibroblasts (MEFs) were obtained from WT and homozygous 
POLG
D257A/D257A
 mitochondrial DNA mutator (Kujoth, Hiona et al. 2005) embryos following 
removal of the head according to standard protocols and frozen down (Lei 2013).  To generate 
stable cell lines, we thawed the MEFs, plated them, and then stably transfected them with a 
141 
 
plasmid containing the viral E1A gene and a puromycin selectable marker using a retroviral 
transfection system (Swift, Lorens et al. 2001).  E1A-induced transformation was used instead of 
spontaneous transformation in attempt to preserve the function of genes in signaling pathways 
that commonly mutate during spontaneous transformation. 
 
Cell culture 
WT and POLG
D257A/D257A
 MEFs were grown in either 96 well plates or in 10 cm culture 
dishes using HyCloneⓇ
 Dulbecco’s modiﬁed Eagle's medium (DMEM) with 10% FBS, 30 µg/ml 
penicillin, 50 µg/ml streptomycin, and 4 mM L-glutamine. Cells were grown using either high 
(4.5 g/L) or low (1 g/L) glucose DMEM with or without 1 mM pyruvate for 24 hours or 48 
hours.  For longitudinal studies, high glucose media with 1 mM pyruvate and 50 µg/ml uridine 
(HGPUM) was used.  Cells with mtDNA mutations require uridine and pyruvate to survive due 
to insufficient NADH oxidation and pyrimidine synthesis.  Longitudinal (10, 20, and 29 days of 
treatment) studies were only performed in HGPUM since MEFs cultured in low glucose media 
for the measurement of oxygen consumption frequently did not survive the trypsinization step 
prior to placing the cells in the Clark electrode chamber.  The media was changed every 2 days 
for cells grown for the 10, 20, and 29 day longitudinal studies.  For the respiratory, ROS 
production, and ATP measurements cells were treated with 1 mM 5-Aminoimidazole-4-
carboxamide ribonucleotide (AICAR) or with 10 nM rapamycin. 
 
ATP assays 
CellTiter-Glo (Promega, Madison, WI) ATP detection reagent was used to determine the 
levels of ATP following a 10 minute 22°C incubation of cells with CellTiter-Glo reagent. 
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CellTiter-Glo reagent was combined with the cell suspension in a 1:1 ratio in a 96-well 
microplate and then shaken for 2 minutes. Luminescence was read using a Biotek Synergy 2 
microplate reader after the contents of the 96 well plate were transferred to a white opaque 
bottom plate for increased signal.  
 
Oxygen consumption analysis 
Cells were trypsinized from the 10 cm dishes, the trypsin was deactivated with culture 
media, and the cells were spun down and resuspended in 1 mL of the appropriate fresh culture 
media.  350 µl of the suspension was then placed into a Strathkelvin Mitocell MT200A 
respiratory chamber with a Clark type electrode at 37⁰C with a stir bar. The cellular respiratory 
rate was recorded for 4 minutes. The middle 1 minute was chosen for slope analysis. Oxygen 
consumption was normalized to the total cell number in the chamber. Cell counts were obtained 
using a hemocytometer.  Cells were only grown in low glucose conditions for up to 30 hours due 
to the low O2 consumption signal obtained at further timepoints. 
 
Reactive oxygen species level measurements 
2’,7’-dichlorodihydrofluorescein diacetate was used to detect reactive oxygen species 
(ROS) production. Following hydrolysis of the acetate esters by intracellular esterases, 
dichlorodihydrofluorescein is produced.  Dichlorodihydrofluorescein, when oxidized by ROS 
becomes the highly fluorescent compound dichlorofluorescein (DCF). A 2’,7’-
dichlorodihydrofluorescein diacetate stock solution of 500 µM was made up in 2% DMSO in 
PBS and the tube was wrapped in foil to prevent exposure to light. Media was aspirated from the 
cells grown in 96-well plates and the cells were washed once with 100 µl PBS.  An assay 
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concentration of 50 µM was obtained by mixing 10 µl of the stock solution with 90 µl of PBS 
and added to the monolayer of cells. As a positive control, 0.5 µl of denatured 100% EtOH was 
added, as it can greatly stimulate mitochondrial ROS production at electron transport chain 
complexes I and III (Cunningham and Bailey, 2001).  The plate was incubated in the dark at 
37°C for 30 minutes. The fluorescence was then measured using a Biotek Synergy 2 microplate 
reader with an excitation filter of 485/20 nm and emission filter of 528/15 nm. Values were 
normalized to the total amount of protein in each well. 
 
Protein assays 
Cells were lysed and extracts were solubilized using modified RIPA buffer without SDS.  
A determination of the protein concentration was performed using the BCA protein assay 
(Thermo Scientific Pierce). Results were normalized using the protein concentrations present for 
the assays. 
 
Colony formation drug toxicity assays 
The E1A-transformed MEFs were cultured in high glucose media (HGM) consisting of 
high glucose DMEM with the addition of 10% fetal bovine serum, penicillin (100 U/ml), 
streptomycin (100 mg/ml), and L-glutamine (2 mM).     Three distinct POLG
D257A/D257A
 MEF 
clones and three distinct WT MEF clones were used for each experiment.  2,000 cells were 
placed in each well of a 6-well plate in HGM.  For each 6-well plate, 5 different concentrations 
of a drug were added one day after the cells were plated leaving one untreated well per plate.  
Drug concentrations were doubled or tripled from one well to the next depending upon the 
specific compound tested.  Cells were grown for 8-10 days with one change of media.  Then the 
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culture media was removed and the cells were washed twice with PBS.  A 5% crystal violet 
stock solution was made in 95% ethanol. 500 mL of a 1x 0.5% crystal violet staining solution 
was made by combining 50 mL of the 5% crystal violet stock solution with 350 mL of methanol, 
50 mL of 35% formaldehyde, and 50 mL of deionized water.  The cells were fixed and stained 
for 10 minutes.  Then the solution was removed and the wells were washed several times with 
deionized water until the colonies became easily visible, the wells were allowed to dry, and the 
colonies were manually counted with a colony counting pen.  * indicates a p-value < 0.05.  The 
IC50 is the stressor concentration that allows half the maximal number of colonies to grow. The 
IC50 values were calculated from the dose response data using GraphPad Prism software. 
 
Assays for determining compounds that alter the rate of pyruvate addiction 
The E1A transformed MEFs were cultured in triplicate in 6-well plates using high 
glucose, pyruvate and uridine-containing media (HGPUM) consisting of high glucose DMEM 
media with 10 % fetal bovine serum, penicillin (100 U/ml), streptomycin (100 mg/ml), L-
glutamine (2 mM), pyruvate (1 mM), uridine (50 g/mL), and a compound to be tested.  Several 
autophagy inhibitors including bafilomycin A1, chloroquine, and ammonium chloride were toxic 
to the cells at the normal doses used to inhibit autophagy, so concentrations were titrated down to 
allow for long term viability.  Every 3-4 days, cells would become confluent and so were washed 
in PBS and trypsinized, 90% of the cells were discarded and the remaining 10% of the cells 
returned to the same well for continued culture.  Every 9-12 days the 90% of the cells that were 
normally discarded were counted using a Coulter Z1 Particle Counter and 2,000 cells from each 
well were seeded into a well in each of two new 6-well plates.  One 6-well plate was cultured 
using the (HGPUM) pyruvate and uridine containing culture media without drug treatment and 
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the second 6-well plate was cultured in the same media lacking pyruvate and uridine (HGM).  
Cells were grown for 8-10 days with one change of media.  Culture media was removed and the 
cells were washed twice with PBS, and fixed and stained with 0.5% crystal violet staining 
solution as described above, de-stained with deionized water, and colonies were counted 
manually.  The percent of the number of colonies that formed in the absence of pyruvate and 
uridine (HGM) compared to the number of colonies that formed in the presence of pyruvate and 
uridine (HGPUM) was plotted each 9-12 days for 3 weeks to 3 months depending upon the rate 
of the loss of colony formation of the cells seeded in media lacking pyruvate and uridine (HGM).  
 
Statistical analysis 
Error bars represent the standard error of the mean.  Two-way ANOVA tests were 
performed with genotype and treatment variables, followed by Fisher’s LSD post hoc means 
comparison.  * indicates a p value of < 0.05, ** indicates a p-value < 0.005, and *** indicates a 
p-value < 0.001.  SigmaPlot 11.0 was used for statistical analysis and graph generation. 
 
Results 
POLG
D257A/D257A
 cells are more sensitive to some but not all mitochondrial inhibitors 
We first generated stable E1A-transfected WT and POLG
D257A/D257A
 MEFs and 
characterized their ability to form colonies when grown in the presence of various concentrations 
of mitochondrial inhibitors, oxidants, or nucleoside analogs that could potentially affect 
mitochondrial function.  The results showed that the cell growth and colony formation of 
POLG
D257A/D257A
 MEFs was more susceptible than WT MEFs to the mitochondrial ETC complex 
I inhibitor rotenone, the ETC complex IV inhibitor azide, the uncoupler FCCP, the mitochondrial 
146 
 
protein synthesis inhibitor chloramphenicol, and the DNA intercalating agent ethidium, which 
because of its positive charge accumulates in mitochondria (two tailed t-test p <0.05).  No 
statistical difference in sensitivity was found for treatment with the ETC complex III inhibitor 
antimycin A, the mitochondrial F0F1-ATP synthase inhibitor oligomycin, or the oxidants tert-
butylhydroperoxide or hydrogen peroxide (Fig. 25 A-I). There was also no statistical difference 
for the prevention of colony formation between the two cell lines when the ETC complex III 
inhibitor myxothiazol was added (data not shown).  It is not entirely clear why the 
POLG
D257A/D257A
 MEFs were more sensitive than WT MEFs to complex I and complex IV 
inhibitors, but not to complex III or complex V (ATP synthase) inhibitors, but it is likely due to 
the fewer number of genes present in mtDNA in complexes III and V.  Mammalian mtDNA only 
encodes 1 gene for complex III and 2 genes for complex V, while mtDNA encodes 3 genes for 
complex IV and 7 genes for complex I.  The greater the number of genes present in mtDNA, the 
more likely that the genes will be disrupted by mutation to sensitize the cells to the toxic effects 
of the ETC inhibitors.  This also likely explains why the mtDNA mutator MEFs were more 
sensitive to the mitochondrial protein synthesis inhibitor as mitochondrial ribosomal function 
requires 2 large ribosomal RNAs as well as 22 small tRNAs encoded in mtDNA. 
Since some nucleoside analog antivirals such as azidothymidine (AZT), dideoxycytidine 
(ddC), and fialuridine (FIAU) are suspected to cause mitochondrial dysfunction by incorporation 
into mtDNA (Johnson, Ray et al. 2001), we tested the toxicity of several nucleoside drugs on 
WT and POLG
D257A/D257A
 MEFs.  Results showed no significant differences in sensitivity for the 
prevention of colony formation following the administration of any of the nucleoside analogs 
including AZT, ddC, FIAU, cytarabine (Ara-C), or bromodeoxyuridine (BrdU) (Supplementary 
Fig. 31 A-E) suggesting that the murine POLG exonuclease domain does not play a major role in 
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protecting cells from the toxicity of any of these nucleoside analogs.  This is consistent with the 
very slow removal of chain-terminating AZT monophosphate and ddC monophosphate from the 
end of a DNA strand by the human mitochondrial polymerase gamma exonuclease site (Johnson, 
Ray et al. 2001).   Although FIAU monophosphate was shown to be a good substrate for POLG 
exonuclease activity (Johnson, Ray et al. 2001), murine POLG exonuclease-deficient MEFs did 
not show increased sensitivity to FIAU toxicity.  It is known that FIAU causes mitochondrial 
toxicity in humans, but not in mice (Xu, Nishimura et al. 2014) and this is likely due to a 
nucleoside transporter targeted to human mitochondria that lacks the targeting signal in mice 
(Lee, Lai et al. 2006). 
  
Long term culture of MEFs in pyruvate-containing media can induce pyruvate 
addiction 
It is known that many mammalian cell lines without functional mtDNA can grow in a 
high glucose medium (HGM) with the supplementation of pyruvate and uridine to the culture 
(King and Attardi 1989).  Pyruvate reduction to lactate oxidizes NADH to NAD to maintain the 
NAD needed for glycolytic flux in the absence of ETC activity.  ETC function is also needed for 
pyrimidine synthesis, which can be bypassed by uridine supplementation.  We hypothesized that 
the transformed POLG
D257A/D257A
 MEFs could only accumulate a small amount of mtDNA 
mutations before cell death when cultured in normal HGM because of the cell’s reliance on 
mitochondrial function under this condition, but a larger mitochondrial phenotype may be 
revealed if the MEFs were cultured in HGM with pyruvate and uridine (HGPUM) that is 
permissive for the loss of mtDNA.  Therefore, we cultured the MEFs for two to three months in 
HGPUM and roughly every ten days seeded some cells into wells on plates containing HGM to 
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determine if colonies would form. The same number of cells was also seeded into wells on plates 
containing HGPUM (the same media as the long term culture media) as a positive control for 
plating efficiency.   One E1A transformed POLG
D257A/D257A
 MEF clone slowly lost the ability to 
form colonies in HGM over two months of culture while two others did not, giving variable 
results.  In contrast we didn’t find any of three spontaneously transformed POLGD257A/D257A cell 
lines to lose the ability to form colonies in HGM after being cultured for two months in HGPUM 
Data from one clone is shown in Supp. Fig. 32 A.  Surprisingly, one of three E1A-transfromed 
WT MEFs also showed a decreased ability to form colonies when taken from HGPUM and 
seeded in HGM (Supp. Fig. 32 B).  We also found this slow loss of colony formation to occur 
when uridine was removed from the media, but not when pyruvate was removed (data not 
shown), and so we call the phenomenon “pyruvate addiction”.   
To learn more about the pyruvate addiction phenotype, we performed the same types of 
long term culture experiments, but this time supplemented the POLG
D257A/D257A
 MEF line that 
previously showed the pyruvate addiction phenotype with compounds known to protect 
mitochondria or stimulate mitochondrial biogenesis and then assayed the ability of the cells to 
form colonies in HGM without the added compound.  As shown in Supp. Fig. 33 A, AICAR 
treatment delayed the pyruvate addiction, while rosiglitazone, metformin, nicotinamide, 
resveratrol, or a high (50 mM) pyruvate concentration did not.  Treatment with a high pyruvate 
concentration has been shown to induce mitochondrial biogenesis (Wilson, Yang et al. 2007).   
Since autophagy of damaged mitochondria maintains a healthy mitochondrial population and is 
required for lifespan extension, we tested the effect of autophagy modulators on pyruvate 
addiction.  In contrast to AICAR, we found that rapamycin (Supp. Fig. 33 B and 33 C) or low 
dose ammonium chloride addition (Supp. Fig. 34 A and 34 B) to the HGPUM media greatly 
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stimulated the rate of onset of the pyruvate addiction.  Rapamycin treatment stimulates 
autophagy, while ammonium chloride treatment is known to interfere with lysosome 
acidification to inhibit autophagy.  We also found rapamycin and ammonium chloride to greatly 
stimulate pyruvate addiction in WT MEFs (Supp Fig. 34 C).   
Since we observed effects with the 2 autophagy modulators, we performed similar long 
term experiments using both mtDNA mutator and WT MEFs supplementing the media with the 
autophagy inhibitors 3-methyladenine, bafilomycin A1, or chloroquine (Supp Fig. 34 A-C). 3-
methyladenine and bafilomycin A1 affected pyruvate addiction, but the results varied depending 
upon the specific cell line or clone used, while chloroquine, like AICAR, consistently delayed 
pyruvate addicition.  Of the 2 compounds consistently shown to stimulate pyruvate addiction 
(rapamycin and ammonium chloride) one stimulates and one inhibits autophagy.  Of the 2 
compounds (chloroquine and AICAR) shown to consistently inhibit pyruvate addiction, 
chloroquine is an established inhibitor of autophagy, while AICAR either stimulates or inhibits 
autophagy depending upon the specific cell line tested (Meley, Bauvy et al. 2006; Sanchez, Csibi 
et al. 2012).  Therefore, we conclude that the relationship between pyruvate addiction and 
autophagy is likely indirect.  Because of the effects of rapamycin and AICAR on pyruvate 
addiction and because of the known longevity-inducing effects of these compounds in model 
organisms, we decided to thoroughly characterize their effects on mitochondrial function and 
cellular ATP levels in POLG
D257A/D257A
 and WT MEF cell lines. 
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Pyruvate addition reveals large deficits in oxygen consumption in POLG
D257A/D257A
 
MEFs 
To determine if altering the carbohydrate source in the media affected mitochondrial 
function we cultured the MEFs in either low glucose media in the presence of 1 mM pyruvate 
(LGPM) or in HGM. We also chose to culture cells for up to 29 days in HGPUM, the same 
conditions used to stimulate pyruvate addiction.  When cultured in HGM, surprisingly, we found 
no difference in the respiratory rate between WT and POLG
D257A/D257A
 MEFs after 24 hours and 
only an insignificant trend toward decreased respiration for POLG
D257A/D257A
 MEFs after 48 
hours.  However, large deficits in oxygen consumption were revealed for POLG
D257A/D257A
 MEFs 
when they were cultured in pyruvate-containing media.  For example, POLG
D257A/D257A
 MEFs 
showed large deficits in oxygen consumption after 24 hours (Fig. 26 C) or 30 hours (Fig. 26 D) 
of culture in LGPM or after 10 (Fig. 26 E), 20 (Fig. 26F), or 29 (Supp. Fig. 35) days of culture in 
HGPUM.  Both the POLG
D257A/D257A
 and WT MEFs greatly lost the ability to respire upon 
trypsinization when cultured in LGPM for 36 hours or longer and so time points for oxygen 
consumption were not obtained beyond 30 hours when the MEFs were cultured in LGPM.  There 
was a slight increase in respiration between the 10 and 20 day time points for WT MEFs cultured 
in HGPUM, perhaps as a metabolic adaptation to the culture media. The POLG
D257A/D257A
 MEFs 
did not further lose respiratory capacity over the 29 days when cultured in HGPUM suggesting 
that increased levels of mtDNA mutations were not accumulating to any great extent in this 
limited time frame. 
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Long term AICAR treatment decreases O2 consumption in WT MEFs 
Although AICAR treatment has been described to increase mitochondrial biogenesis in 
rodents (Komen and Thorburn 2014), we like others studying mitochondrial function in 
hepatocytes (Guigas, Taleux et al. 2007) or myocytes (Spangenburg, Jackson et al. 2013) did not 
find a statistically significant increase in oxygen consumption upon AICAR treatment.  This was 
true using either WT or POLG
D257A/D257A
 MEFs irrespective of glucose or pyruvate levels or the 
duration of treatment (Fig. 26 A-D).  However, we did find that AICAR treatment of WT MEFs 
for 10 or 20 days in HGPUM led to a strong decrease in the respiratory rate (Fig. 26 E) that 
dissipated by 29 days of culture (Supp. Fig. 35).  The AICAR-mediated decrease in respiratory 
rate observed following long term treatment could be mediated by the slow buildup of an 
AICAR metabolite that either inhibits mitochondrial ETC complex I (Guigas, Taleux et al. 2007) 
or that down-regulates mitochondrial ETC components as has been shown for AICAR treatment 
of certain cancer lines (Jose, Hebert-Chatelain et al. 2011). 
 
Rapamycin transiently increases O2 consumption in WT but not POLG
D257A/D257A
 
MEFs 
Rapamycin treatment increased the rate of oxygen consumption in WT MEFs after 24 
hours (Figure 6.2A and 6.2C), but not after 48 hours (Fig. 26 B and 26 D) of treatment in HGM 
or LGPM or after 10 (Fig. 26 E), 20, (Fig. 26 F) or 29 (Supp. Fig. 35) days of treatment in 
HGPUM.  Rapamycin did not significantly increase oxygen consumption under any of these 
conditions in POLG
D257A/D257A
 MEFs. The mtDNA mutations in the POLG
D257A/D257A
 MEFs 
likely cause impaired mitochondrial biogenesis preventing the transient increase in respiration 
observed in WT MEFs. 
152 
 
 
In POLG
D257A/D257A
 MEFs ROS production increases in HGM, but decreases 
following long term culture in HGPUM 
We next determined the rate of ROS production of POLG
D257A/D257A
 and WT MEFs.  In 
LGM and LGPM depending upon the duration of treatment and the presence of pyruvate, there 
were trends for or very small increases in ROS production in POLG
D257A/D257A
 MEFs compared 
to WT MEFs (Figure 28 A-D).  However, upon culture in HGM, large increases in ROS 
production were observed in the POLG
D257A/D257A
 MEFs that declined substantially when 
cultured in HGPM, where pyruvate is present.  Pyruvate is known to have direct oxidant 
scavenging properties (Kladna, Marchlewicz et al. 2015) and can also prevent decreased anti-
oxidant gene expression induced by the presence of high sugar levels (Varma and 
Chandrasekaran 2015).  In contrast to these results from short term culture studies, culture for 10 
days in HGPUM led to decreased ROS production in POLG
D257A/D257A
 MEFs compared to WT 
MEFs (Fig. 27E and Fig. 27F) likely due to the lower ETC activity in POLG
D257A/D257A
 MEFs 
compared to WT MEFs at this time point as indicated by the respiratory studies.   Decreased 
ETC activity can decrease ROS production when fewer electrons enter and are passed down the 
ETC leading to fewer electrons bound by O2 to form superoxide.   
 
AICAR treatment for 48 hours increases, but for 10 days decreases ROS production  
After 24 hours of AICAR treatment there was little to no effect on ROS production 
depending upon the exact media composition (Fig. 27 A and 27C and Fig. 28 A and 28 C).   
AICAR treatment caused a slight decrease in ROS production in WT MEFs in low glucose 
media (LGM) (Fig. 27 A), while a slight increase in ROS production occurred in 
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POLG
D257A/D257A
 MEFs in HGM (Fig. 28 A).  After 48 hours of treatment, AICAR almost 
invariably increased ROS production in both POLG
D257A/D257A
 and WT MEFs (Fig. 27 B and 27 
D and Fig. 28 B and 28 D) irrespective of glucose and pyruvate levels.  The AICAR-induced 
increase in ROS production likely either reflects the initial buildup of an AICAR metabolite that 
inhibits mitochondrial ETC complex I (Guigas, Taleux et al. 2007) or a change in the expression 
of ETC genes (Jose, Hebert-Chatelain et al. 2011).  However, after 10 or 20 days of AICAR 
treatment in HGPUM (Fig. 28 E and Fig. 28 F), ROS levels were decreased, likely reflecting the 
low ETC activity induced by AICAR limiting the passage of electrons and generation of 
superoxide under these conditions. 
Rapamycin treatment does not affect the rate of ROS production in WT or 
POLG
D257A/D257A
 MEFs 
Under almost every culture condition tested, we found that rapamycin treatment had no 
statistically significant effect on ROS production (Fig. 27 A-D and Fig. 28 A-F).  The only 
exception to this was a very small decrease in ROS production in POLG
D257A/D257A
 MEFs after 
24 hours of treatment in HGM (Fig. 28A). 
 
POLG
D257A/D257A
 MEFs frequently show decreased ATP levels in low glucose 
conditions, but increased ATP levels in high glucose conditions 
We next monitored ATP levels in the POLG
D257A/D257A
 and WT MEFs. As expected in LGM and 
LGPM (Fig. 29A-D), POLG
D257A/D257A
 MEFs most frequently showed decreased ATP levels, 
except at the 24 hour time point in LGPM, where ATP levels were increased (Fig. 29 C).  But 
surprisingly, ATP levels were increased when POLG
D257A/D257A
 MEFs were cultured in HGM, 
HGPM, or HGPUM (Fig. 30 A-E) with the exception of the 24 hour timepoint in HGM (Fig. 30 
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A) and the 20 day timepoint in HGPUM (Fig. 30 F) where ATP levels were nearly the same as 
those in WT MEFs.  Therefore, there is a compensatory upregulation of glycolysis in the 
POLG
D257A/D257A
 MEFs that leads to increased ATP levels in the presence of high glucose.  To 
verify this, we measured the rate of acidification of fresh media on confluent cultures grown in 
HGM and found that POLG
D257A/D257A
 MEFs acidified the medium more rapidly, having a 
medium pH of 6.92 +/- 0.10 after 48 hours and a pH of 6.05 +/-0.02 after 72 hours, while WT 
MEFs had a medium pH of 7.24 +/- 0.04 after 48 hours and a pH of 6.84 +/- 0.05 after 72 hours.  
Similar findings of enhanced glycolysis were reported for POLG
D257A/D257A
 primary MEFs 
(Kukat, Edgar et al. 2011), dermal fibroblasts (Saleem, Safdar et al. 2015), and induced 
pluripotent stem cells following differentiation (Wahlestedt, Ameur et al. 2014).  But induced 
pluripotent stem cells from POLG
D257A/D257A
 mice in their non-differentiated state were shown to 
maintain a normal glycolytic rate (Wahlestedt, Ameur et al. 2014).    
 
AICAR treatment decreases ATP levels under high glucose conditions, except for in 
WT MEFs cultured for long term in HGPUM 
We next treated the WT and POLG
D257A/D257A
 MEFs with AICAR and measured cellular 
ATP levels.  Under most conditions, especially when using WT MEFs in LGM and LGPM, 
AICAR treatment decreased ATP levels, but there were exceptions due to the use of the 2 
different cell genotypes and 2 different durations of treatment (Fig. 29 A-D).  For example, a 24 
hour AICAR treatment of WT MEFs in LGPM slightly increased ATP levels (Fig. 29 C), while a 
48 hour treatment of POLG
D257A/D257A
 MEFs slightly increased ATP levels in LGM (Fig. 29 B) 
and greatly increased ATP levels in LGPM (Fig. 29 D).  The results of AICAR treatment in 
HGM and HGPM were very consistent. Under all conditions AICAR treatment decreased ATP 
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levels (Fig. 30 A-D).  This was also true for the 10 and 20 day treatments of POLG
D257A/D257A
 
MEFs in HGPUM (Fig. 30 E and Fig. 30F).  But in contrast to this, WT MEFs cultured for 10 
days in HGPUM showed increased ATP levels (Fig. 30 E), but this increase dissipated by 20 
days of treatment (Fig. 30 F).  
 
Rapamycin greatly increases ATP levels following 48 hours of treatment in low 
glucose media 
We next determined the effects of rapamycin on cellular ATP levels in the MEFs.  When 
cultured in LGM and LGPM, rapamycin treatment for 24 hours (Fig. 29 A and C) generally had 
no statistically significant effect on ATP levels, except for an increase in POLG
D257A/D257A
 MEFs 
cultured in LGM.  In contrast, when MEFs were cultured for 48 hours in LGM or LGPM 
rapamycin treatment led to a consistent increase in ATP levels (Fig. 29 B and 29D).  In HGM 
and HGPM (Fig. 30 A-D), the cells showed a quicker, but greatly blunted response to the 
rapamycin treatment, especially the POLG
D257A/D257A
 MEFs, which only showed increased ATP 
levels at the 24 hour timepoint in HGM.  The WT MEFs showed small to moderate increases in 
ATP levels with rapamycin treatment under all high glucose culture conditions including 10 days 
in HGPUM, where mtDNA mutator MEFs only showed a small increase in ATP levels (Fig. 30 
E).   In both cell types the increased ATP levels dissipated by 20 days of treatment (Fig. 30 F).  It 
was surprising that rapamycin treatment did not lead to consistently larger increases in ATP 
levels as mTOR inhibition both stimulates autophagy to increase respiratory substrate levels and 
slows the rate of translation, a very energy intensive process (Morita, Gravel et al. 2015).  
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Discussion 
We found that E1A-transformed MEFs from POLG
D257A/D257A
 mice were more sensitive 
than WT MEFs to growth inhibition and toxicity caused by a mitochondrial uncoupler or an 
mtDNA intercalating agent, or to inhibition of mitochondrial ETC complexes I or IV, or to 
inhibition of mitochondrial protein synthesis.  The POLG
D257A/D257A
 MEFs possessed oxygen 
consumption deficits and increased ROS production that were accentuated in LGPM compared 
to HGM.  We also showed that rapamycin treatment transiently increased the rate of oxygen 
consumption.  Interestingly, isolated mitochondria from heart or liver of aged mtDNA mutator 
mice (Kujoth, Hiona et al. 2005) or primary MEFs from these mice (Kukat, Edgar et al. 2011) 
showed oxygen consumption deficits without increased ROS production, whereas the 
transformed MEFs showed increased ROS production.  This highlights the utility of this cell 
model where an important phenotype was revealed that was not present when initially analyzing 
primary tissues.  Recently however, increased ROS production has been found in Leydig cells 
from mtDNA mutator mice (Shabalina, Landreh et al. 2015) and increased oxidative damage has 
been found in muscle from these animals (Kolesar, Safdar et al. 2014).  In addition the 
antioxidant N-acetyl-L-cysteine was able to rescue deficits in neuronal and hematopoetic stem 
cell differentiation (Ahlqvist, Hamalainen et al. 2012) and mitochondrial-targeted catalase was 
able to restore age-dependent cardiomyopathy (Dai, Chen et al. 2010).  So therefore increased 
ROS production and oxidative damage likely contribute to the premature aging phenotype in 
certain tissues of these mice.    
It is somewhat surprising that AICAR and rapamycin gave different respiratory responses 
as AMPK activation mediates many of its effects through inhibition of the mTOR pathway 
(Bolster, Crozier et al. 2002).  AMPK mediates this inhibition in part through phosphorylation of 
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the mTORC1-specific protein raptor (Gwinn, Shackelford et al. 2008).  AMPK activation 
(Faubert, Boily et al. 2013) or mTOR inhibition (Kittipongdaja, Wu et al. 2015) have both been 
shown to inhibit glycolytic flux under normal physiological conditions, which may limit toxic 
methylglyoxyl formation (Allaman, Belanger et al. 2015), as well as limit pyruvate production 
important for fueling the citric acid cycle and oxidative phosphorylation.  But AICAR treatment 
has many non-specific effects on cells including inhibition of mitochondrial ETC complex I that 
may have prevented AICAR treatment from transiently increasing respiration.  The transient 
increase in respiration following rapamycin treatment was surprising given other authors 
studying myotubes (Cunningham, Rodgers et al. 2007; Ye, Varamini et al. 2012), leukemic 
Jurkat T cells (Schieke, Phillips et al. 2006; Ramanathan and Schreiber 2009), or T-cell 
lymphoma (Kittipongdaja, Wu et al. 2015) did not find mTOR inhibition to stimulate respiration 
and in most cases found decreased respiration.  However, when studying adipose tissue it was 
found that mTOR inhibition is associated with increased mitochondrial biogenesis (Deepa, 
Walsh et al. 2013) or enhanced respiration (Polak, Cybulski et al. 2008). Importantly, the Bartke 
group found that the effects of rapamycin on oxygen consumption in mice depend upon the 
duration of rapamycin treatment.  Mice treated for 2 weeks showed decreased oxygen 
consumption, while those treated for 20 weeks showed increased oxygen consumption (Fang, 
Westbrook et al. 2013).  The mechanisms behind these findings are currently unclear.  But if 
rapamycin treatment gradually mimics the longevity-promoting effects of calorie restriction, then 
mitochondrial transcripts may slowly become preferentially translated by the ribosome through 
increased expression or activity of 4E-BPs (Zid, Rogers et al. 2009) to increase mitochondrial 
biogenesis over time.  The kinetics of these events are likely much different in cell culture and a 
rapamycin-induced preferential translation of mitochondrial-targeted transcripts could be 
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responsible for the transient increase in oxygen consumption of WT MEFs.  Oxygen 
consumption likely returned to control rates due to the slower kinetics of rapamycin-induced 
decreases in transcription of YY1 and PGC-1, leading to decreased mitochondrial biogenesis as 
has been previously described following mTORC1 inhibition in myotubes (Cunningham, 
Rodgers et al. 2007).   
 
Transformed POLG
D257A/D257A 
MEFs are a convenient model to study therapies for 
aging-induced mitochondrial dysfunction 
POLG
D257A/D257A
 MEFs did not show significant mitochondrial respiratory dysfunction in 
standard HGM conditions.  The presence of pyruvate in either high or low glucose conditions 
revealed the respiratory dysfunction.  We did not perform respiratory experiments in LGM 
without pyruvate. But we believe it likely that this condition would also reveal the respiratory 
dysfunction.  Low glucose conditions are known to shift cultured cells from a primarily 
glycolytic metabolic state to a more oxidative state, stimulating mitochondrial biogenesis to 
maintain adequate levels of cellular ATP (Elkalaf, Andel et al. 2013). Moderate mitochondrial 
dysfunction was found in postmitotic tissues from the POLG
D257A/D257A
 mice, but cell and tissue 
dysfunction in mitotic cells and tissues such as blood cells and intestine appeared more severe 
leading to mortality of the mice (Kujoth, Hiona et al. 2005).  To model the large degree of 
mitochondrial dysfunction in vivo, we find it critical to culture the POLG
D257A/D257A
 MEFs in 
LGPM or at least in HGPUM, but not in HGM.  When the MEFs are grown in LGPM, they are 
well suited for use in high throughput screens attempting to identify compounds that improve 
mitochondrial function.  Others have identified the requirement to culture mitochondrial ETC 
complex I-deficient patient fibroblasts in low glucose or galactose-containing media when 
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screening for drugs that may increase mitochondrial biogenesis (Golubitzky, Dan et al. 2011). 
Out of ten candidate compounds in their small screen, they identified AICAR as the most 
promising compound to increase mitochondrial function in these cells, even though AICAR did 
not increase the respiratory rate. 
 
 Mitochondrial inhibitor sensitivity of WT and POLG
D257A/D257A
 MEFs
 
 
POLG
D257A/D257A 
MEFs were more susceptible to the mitochondrial toxins FCCP, 
ethidium, chloramphenicol, rotenone, and azide, but not to the mitochondrial inhibitors 
antimycin A or oligomycin or to the oxidizing agents hydrogen peroxide or tert-butyl 
hydroperoxide (Fig. 25).  Greater susceptibility of POLG
D257A/D257A
 MEFs to rotenone and azide 
suggests ETC complex I and complex IV deficits in the MEFs.  This leads to either decreased 
respiration when the mtDNA mutator MEFs are cultured in LGPM or  to lower complex I and 
complex V reserve capacity, such as what likely occurs when the mtDNA mutator MEFs are 
grown in HGM. 
 
Effects of AICAR on oxygen consumption rates 
An increase in oxygen consumption was not observed in response to AICAR treatment of 
the MEFs. Our results are consistent with many other groups that failed to find an increase in 
oxygen consumption following AICAR treatment (Guigas, Taleux et al. 2007; Golubitzky, Dan 
et al. 2011; Spangenburg, Jackson et al. 2013), even though AICAR treatment was shown to 
induce PGC-1 expression and mitochondrial biogenesis in rodent muscle (Suwa, Nakano et al. 
2015).  After 10 days of AICAR treatment in HGPUM, there was decreased respiration of the 
WT MEFs and after 20 days there was decreased respiration in the POLG
D257A/D257A
 MEFS, but 
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neither of these declines was observed after 29 days of treatment. Therefore it appears that 
AICAR treatment causes transient inhibition of mitochondrial respiration.  AICAR has many 
non-specific effects on cells due to the many enzymes that respond to altered AMP levels, but 
AICAR as well as the highly specific AMPK inhibitor A-769662 have both been shown to 
inhibit oxygen consumption in cell culture, with A-769662 specifically inhibiting respiration in 
SV40-transformed MEFS (Vincent, Coelho et al. 2014).  The transient inhibition of respiration 
could be due to changes in AICAR levels in the media due to cellular metabolism of AICAR. 
 
Effects of AICAR on ATP levels 
Pharmacological stimulation of AMPK activity has been shown to either increase or 
decrease the rate of glycolysis depending upon the specific culture conditions (Dagher, 
Ruderman et al. 1999; Marsin, Bouzin et al. 2002).  Under conditions of oxidative stress AMPK 
activation has been shown to increase glycolysis through phosphorylation and activation of the 
glycolytic enzyme phosphofructokinase 2 (PFK2) (Wu and Wei 2012).  During mitochondrial 
inhibition AMPK activation has been shown to upregulate the glucose transporters GLUT1 or 
GLUT4 (Chen, Ye et al. 2010; Pinheiro, Silveira et al. 2010). AMPK has also been shown to 
phosphorylate and activate the glycolytic enzyme hexokinase (Abnous and Storey 2008).  We 
hypothesize that activation of glycolysis by AMPK only occurs during very low energy levels 
(and perhaps also during high ROS conditions) as we found AICAR, with the one exception 
noted above, to only increase ATP levels when MEFs were cultured in LGM or LGPM, and most 
consistently following a 48 hour AICAR treatment of POLG
D257A/D257A
 MEFs, a condition where 
glucose would nearly be depleted from the media.   
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More commonly, however, such as during well-fed, high nutrient conditions it has been 
shown that specific activation of AMPK decreases glycolysis and lactate production (Martinez-
Martin, Blas-Garcia et al. 2012; Faubert, Boily et al. 2013).  But strikingly, AICAR treatment 
has been shown to decrease glycolysis in AMPK-deficient MEFS, suggesting that it functions 
through an independent, unidentified mechanism (Vincent, Coelho et al. 2014).  The ability of 
AICAR treatment and specific AMPK activation to inhibit or downregulate electron transport 
chain activity and to inhibit glycolysis likely explains the decreased ATP levels measured when 
using a high glucose culture medium following 24 or 48 hour treatments.  Under high glucose 
conditions, AICAR only increased ATP levels in WT MEFs after a 10 day incubation in 
HGPUM.  The decreases in ATP levels at the 48 hour time points, before the strong 
downregulation of oxygen consumption observed at 10 days, may be caused in part by AICAR-
mediated upregulation of pyruvate dehydrogenase kinase 4 (PDK-4) gene expression (Houten, 
Chegary et al. 2009), which leads to inhibition of pyruvate conversion to acetyl-CoA.  The 
overall effect of this is a metabolic switch away from glucose utilization to oxidation of fatty 
acids and amino acids for energy production that likely led to the decreased ATP levels 
measured as these other respiratory substrates are present at lower concentrations in culture 
media.  But it is difficult to explain why long term 10 and 20 day AICAR treatment in HGPUM 
did not lead to decreased ATP levels in WT MEFs since respiratory rates declined.  It is possible 
that long term AICAR treatment to WT MEFs led to a buildup of cells in the culture population 
that evolved to divide slightly more rapidly than the rest due to resisting the AICAR-mediated 
decrease in glycolysis. This could explain why the WT MEFs did not show decreased ATP 
levels, even though respiratory rates greatly declined. 
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Pyruvate addiction in E1A-transformed MEFs 
While culturing the E1A-transformed MEFs long term in HGPUM and then re-seeding 
them at equal concentrations in HGM and HGPUM, we found that roughly one-third of the WT 
and POLG cell lines isolated gradually became addicted to pyruvate and eventually could no 
longer form colonies without it added to the media.  In addition it was found that compounds that 
modulate the rate of autophagy altered the rate at which the cells became addicted to pyruvate, 
with rapamycin and ammonium chloride greatly facilitating the rate and AICAR and chloroquine 
decreasing the rate.  The molecular mechanisms behind this phenomenon remain 
uncharacterized, but one possibility includes that when the E1A-transformed MEFs are grown 
long term in the presence of pyruvate they downregulate mechanisms for oxidizing NADH to 
NAD, so they cannot divide due to reductive stress.  Adding pyruvate back to the media then 
allows for a re-oxidation of NADH through the action of lactate dehydrogenase enzymes.  
Alternatively, when grown for long periods of time in the presence of pyruvate, the cells could 
downregulate their antioxidant defense mechanisms since pyruvate is a strong antioxidant.  Then 
once the cells are grown without pyruvate, they could die from oxidative damage, being unable 
to upregulate their antioxidant defense mechanisms in time. Future studies could test these 
hypotheses.  
  
Conclusions 
Mitochondrial dysfunction may be a major contributing factor for aging and age-related 
diseases underscoring the need for cell models of mitochondrial dysfunction to conveniently 
study this phenomenon.  E1A-transformed POLG
D257A/D257A 
MEFs are a model of mitochondrial 
dysfunction that shows enhanced sensitivity to mitochondrial ETC complex I and IV inhibitors, a 
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mitochondrial uncoupler, a mitochondrial protein synthesis inhibitor, and a DNA intercalating 
agent that accumulates in mitochondria.  But POLG
D257A/D257A 
MEFs did not show enhanced 
sensitivity to mitochondrial complex III or complex V (ATP synthase) inhibitors, peroxides, or 
nucleoside analogs.  POLG
D257A/D257A
 MEFs showed decreased respiratory rates and ATP levels 
and enhanced ROS production when grown under low glucose conditions.  Rapamycin treatment 
of WT MEFS resulted in a transient increase in respiration that did not occur following treatment 
of POLG
D257A/D257A 
MEFs.  AICAR treatment affected POLG
D257A/D257A 
and WT MEFs similarly. 
For example, under high glucose conditions AICAR treatment decreased ATP levels and 
increased ROS levels, which upon a longer duration of treatment transitioned into decreased 
respiratory rates.  Under low glucose conditions short term AICAR treatment increased ATP 
levels when they were low and decreased ATP levels when they were higher suggesting that 
AMPK activation normalizes cellular ATP levels around a set threshold level.  As the respiratory 
rate was not altered significantly under these conditions, the rate of glycolysis was likely 
adjusted by AICAR to mediate this effect.   
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Figure 26 IC50 values of WT and POLG exonuclease-deficienct MEFs 
POLG
D257A/D257A 
MEFS are more sensitive than WT MEFs to growth inhibition by FCCP, azide, 
chloramphenicol, and ethidium bromide. Error bars represent the standard error of the mean * 
p<0.05, ** p<0.001. 
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Figure 27 Oxygen consumption in high or low glucose 
O2 consumption rates of WT and POLG
D257A/D257A
 MEFs.  Rapamycin transiently increases 
oxygen consumption in WT MEFs at the 24 hour timepoint either in the absence or presence of 
pyruvate.   Error bars represent the standard error of the mean * p<0.05, ** p<0.001. 
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Figure 28 ROS levels in low glucose 
ROS production of WT and POLG
D257A/D257A
 MEFs was altered by AICAR under low glucose 
conditions.  Rapamycin treatment in LGM or LGPM had no effect on ROS production. Error 
bars represent the standard error of the mean * p<0.05, ** p<0.001. Lines indicate two groups 
being compared.   (A) ROS levels after 24 hours in LGM.  (B) ROS levels after 48 hours in 
LGM. (C) ROS levels after 24 hours in LGPM. (D) ROS levels after 48 hours in LGPM. 
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Figure 29 ROS levels in high glucose 
ROS production of WT and POLG
D257A/D257A
 MEFs was altered by AICAR or rapamycin 
treatment under high glucose conditions. Error bars represent the standard error of the mean * 
p<0.05, ** p<0.001. Lines indicate two groups being compared.   (A) ROS levels after 24 hours 
in HGM.  (B) ROS levels after 48 hours in HGM. (C) ROS levels after 24 hours in HGPM. (D) 
ROS levels after 48 hours in HGPM. (E) ROS levels after 10 days in HGPUM.  (F) ROS levels 
after 20 days in HGPUM. 
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Figure 30 ATP levels in low glucose 
ATP levels of WT and POLG
D257A/D257A
 MEFs were altered by AICAR or rapamycin treatment 
under low glucose conditions.  Error bars represent the standard error of the mean * p<0.05, ** 
p<0.001. Lines indicate two groups being compared.  (A) ATP levels after 24 hours in LGM.  
(B) ATP levels after 48 hours in LGM. (C) ATP levels after 24 hours in LGPM. (D) ATP levels 
after 48 hours in LGPM. 
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Figure 31 ATP levels in high glucose 
ATP levels of WT and POLG
D257A/D257A
 MEFs were altered by AICAR or rapamycin treatment 
under high glucose conditions. Error bars represent the standard error of the mean * p<0.05, ** 
p<0.001.   (A) ATP levels after 24 hours in HGM.  (B) ATP levels after 48 hours in HGM.  (C) 
ATP levels after 24 hours in HGPM. (D) ATP levels after 48 hours in HGPM. (E) ATP levels 
after 10 days in HGPUM.  (F) ATP levels after 20 days in HGPUM. 
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Figure 32 supplemental IC50 values when given nucleoside analogs 
POLG
D257A/D257A
 MEFs do not show increased sensitivity to the toxicity of nucleoside analogs.  
A colony counting assay was performed to determine IC50 values for the nucleoside analogs. The 
nucleoside anlogs tested were (A) AZT, (B) ddC, (C) FIAU, (D) Ara-C, and (E) BrdU.  Error 
bars represent the standard error of the mean * p<0.05. 
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Figure 33 % colony formation 
Select E1A-transformed MEF clones become addicted to pyruvate when cultured long term in 
HGPUM.  (A) POLG
D257A/D257A
 MEFs (B) WT MEFs.  Roughly every 10 days equal numbers of 
cells were seeded in both HGM and HGPUM media and the percentage of cells that form 
colonies in HGM compared to those that form colonies in HGPUM was plotted. 
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Figure 34 supplemental  % colony formation in HGM/HGPUM 
AICAR treatment delays pyruvate addiction, while rapamycin treatment stimulates it.  Colony 
counting assays were performed following long term growth of the POLG
D257A/D257A
 MEFs in 
HGPUM in the presence of (A) AICAR, rosiglitazone, metformin, nicotinamide, resveratrol, or 
pyruvate at the concentration indicated or in the presence of (B) 100 nM rapamycin 
(POLG
D257A/D257A
 clone 1) or (C) 100 nM rapamycin (POLG
D257A/D257A
 clone 2). 
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Figure 35 supplemental % colony formation in HGM/HGPUM 
Ammonium chloride treatment stimulates pyruvate addiction while chloroquine treatment delays 
it.  Colony counting assays were performed following long term growth in HGPUM of either (A) 
POLG
D257A/D257A
 MEFs (clone 1) or (B) POLG
D257A/D257A
 MEFs (clone 2) in the presence of 3-
methyladenine, ammonium chloride, chloroquine, or bafilomycin A1 or (C) WT MEFs in the 
presence of 3-methyladenine, rapamycin, or ammonium chloride. 
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Figure 36  O2 consumption following culture in HGPUM for 29 days 
AICAR or rapamycin treatment for 29 days in HGPUM did not significantly alter the rate of 
oxygen consumption.  Untreated POLG
D257A/D257A
 MEFs showed a lower rate of oxygen 
consumption than untreated WT MEFs.  Error bars represent the standard error of the mean ** p 
< 0.005. 
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CHAPTER SEVEN: FUTURE DIRECTIONS  
 
Calorie restriction  
Although we measured brain mitochondrial function following calorie restriction (CR) of 
P301L tau transgenic mice, several lines of inquiry merit additional research. For instance, 
deficits of ADP driven oxygen consumption still remain incompletely explained. We have 
eliminated complex V as a culprit, at least in cells, for causing reduced ADP-driven oxygen 
consumption, but we did not rule out dysfunction of adenine nucleotide translocase (ANT-1), 
which transports ADP into the mitochondrial matrix or voltage dependent anion channel 
(VDAC), which transports ADP across the outer mitochondrial membrane. Deficits in ANT-1 or 
VDAC1 could explain the decreased ADP driven oxygen consumption observed in our studies.  
In our studies, we determined global neural mitochondrial dysfunction in P301L tau 
model of AD. We did not discriminate between neuronal and glial mitochondria. It would be of 
interest to determine if CR has a differential effect on the mitochondria of neurons compared to 
glia in AD. It would also be of interest to see how mitochondrial function of brain stem cells in 
the hippocampus and the sub-ventricular zone is affected by CR. Synaptic mitochondria could be 
isolated to specifically examine mitochondria from neurons.  In addition microglia, astrocytes, or 
neural stem cells could be isolated and mitochondrial function could be studied in these primary 
cells. 
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Melatonin receptors  
In these studies it was determined that melatonin receptors are necessary for full 
restoration of normal cytochrome c oxidase (COX) activity with melatonin treatment in aged WT 
or APP/PS1 mice (figures 3.1, 3.2), however the downstream signaling mechanisms from the 
receptors were not determined in these studies.  In aged WT mice, melatonin completely restored 
the age-dependent decrease of COX activity in the presence of melatonin receptors and only 
partially restored the activity in the absence of melatonin receptors (figure 3.1). The SIRT1 
deacetylase activates the mitochondrial master regulator, PGC1-α, which increases the 
transcription of both antioxidant response element containing genes and genes coding for 
mitochondrial proteins.  SIRT1 has been shown to decrease with age (Quintas, de Solis et al. 
2012). Future studies will determine if increased melatonin levels results in increased 
transcription of SIRT1.  Melatonin has also been shown to inhibit the ubiquitin-dependent 
proteasome pathway (Kwon, Kim et al. 2011).  Future studies will also determine if the partial 
rescue of COX activity in the absence of melatonin receptors in aged WT mice is achieved by 
melatonin's ability to inhibit the proteasome.  
Higher levels of ROS associated with AD could increase the direct phosphorylation of 
PGC1-α by activating AMPK (Jager, Handschin et al. 2007). Melatonin levels are significantly 
decreased in the CSF of AD patients (Liu, Zhou et al. 1999; Zhou, Liu et al. 2003). Critically low 
levels of melatonin signaling could prevent proper SIRT1 deacetylation of PGC1-α by 
decreasing SIRT1 expression. Future studies will determine if both deacetylation and 
phosphorylation are necessary for PGC1-α activation of Nrf2 and if NRF1 and NRF-2 activation 
by PGC1-α can occur with only phosphorylation by AMPK. Future experiments will also 
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determine whether MT1 and MT2 are necessary for decreasing the transcription of 
proinflammatory mediators.  
 
Amino acids and metabolic intermediates as therapeutics for neurodegenerative disease 
In our PD study, we determined that cells overexpressing alpha-synuclein were 
susceptible to mitochondrial dysfunction caused by FeSO4 treatment. These mitochondrial 
deficits may be in part due to decreased levels of mitochondrial superoxide dismutase 2 (SOD2), 
and increased levels of monoamine oxidase type A MAO-A, as shown in chapter 4. We were 
able to rescue some of these mitochondrial deficits by supplementation with amino acids and 
other metabolic intermediates. It would be important to determine if additive or synergistic 
effects can be achieved by co-supplementation with multiple amino acids, since they are 
frequently co-transported across cell membranes. Ester forms of amino acids were not tested, but 
like the ester forms of TCA cycle intermediates administered, they would not require active 
transport. This could potentially increase their effectiveness by increasing the rate of delivery 
and decreasing the requirement for active transport.  
Using proteomics we determined significant fold change differences in protein 
expression. The top canonical signaling pathways that were significantly changed were: protein 
ubiquitination pathway, thrombin signaling, tight junction signaling, regulation of eIF3 and 
p70S6K signaling, and of most interest to us mitochondrial dysfunction signaling (appendix A 
figure 1). Mitochondrial proteins in cells overexpressing alpha-synuclein (table 4.1). These 
findings must be confirmed using Western blotting. Furthermore, it would be of interest to 
determine if the rescue was achieved by improving function of existing mitochondria and/or by 
increasing mitochondrial biogenesis. To test this we will measure total mitochondria using the 
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mitochondria-specific dye MitoTracker (MT) Green® (Life Technologies). MT Green has been 
described to bind to all mitochondria regardless of their health. To test if the increased total 
mitochondria are also healthier, we will use a cationic dye JC-1 that is imported into 
mitochondria in response to the mitochondrial membrane potential.  
Leuicine-rich repeat kinase 2 (LRRK2) has been implicated in the pathology of sporadic 
PD and may prove to be a viable therapeutic target (Sen and West 2009). LRRK2 has also been 
shown to interact with Parkin, an E3 ubiquitin ligase, important in directing mitophagy (Smith, 
Pei et al. 2005). It would be of great interest to determine if aberrant interaction of LRRK2 with 
Parkin prevents proper association of Parkin and Pink1, a mitochondrial kinase associated with 
PD. This would result in the buildup of mitochondria with low membrane potential that would 
normally be directed toward mitophagy through proper Parkin and Pink1 interaction. This would 
potentially be a novel mechanism of mitochondria-related PD pathology. 
  
Role of mitochondrial dysfunction in the collapse of the NVU in ALS 
Future studies will focus on assaying ETC complex III and mitochondrial DNA levels in 
our human spinal cord samples. To further study the mechanisms of mitochondrial dysfunction 
and their contribution to the collapse of the neurovascular unit, we will analyze mitochondrial 
ETC complex activities in each of the components of the NVU (e.g. astrocytes, neurons, 
oligodendrocytes, and endothelial cells) in a mouse model of ALS.  Once the degree of 
mitochondrial dysfunction is established, potential therapies can be administered to the mice to 
determine if ETC complex function improves. Strategies we found protective in our other studies 
could be explored as potential therapeutic approaches for ALS as well.  
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Effects of AICAR and rapamycin on mitochondrial function  
In our studies we have found that AICAR treatment decreased mitochondrial function in 
both WT and POLG
D257A/D257A
 MEFs. It would be important to confirm that AMPK is indeed 
activated by performing western blots for phosphorylated AMPK. Conversely, non-
phosphorylated mTOR would be indicative of mTOR activation. Future studies should also 
determine other effects of AICAR and rapamycin on metabolism, particularly on glycolysis, to 
help elucidate the transient effects of rapamycin and the persistent decrease in ATP levels by 
AICAR. Similar studies should also be performed on other lineages of cells obtained from 
polymerase gamma exonuclease-deficient mice. As previously discussed, mitochondrial 
dysfunction can vary between different tissues in POLG exonuclease-deficient mice.     
Potential clinical and translational applications of the current research 
This body of work has demonstrated the existence of mitochondrial dysfunction in major 
neurodegenerative diseases, namely the contribution of mitochondrial dysfunction to the 
progress of: amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and Parkinson’s 
disease (PD). We have also shown herein, that some aspects of mitochondrial dysfunction can be 
rescued by neuroprotective nutritional interventions. Many of these compounds, like TCA cycle 
intermediates and essential amino acids are generally regarded as safe (GRAS) by the food and 
drug administration (FDA). This makes metabolic intermediates and amino acids attractive 
treatments to explore, since they could be fast-tracked into human trials. At present, we have no 
effective way of gauging the progress of mitochondrial dysfunction clinically. This would make 
the study of potential mitochondrial beneficial, like TCA intermediates and amino acids 
impossible. Below we outline how current ideas on the metabolic health index (MHI) could be 
improved upon by advent of databases, use of standardized mitochondrial analytic techniques, 
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and proteomic approaches that would overcome current hurdles to furthering our knowledge of 
cellular metabolism and neurodegenerative diseases. We will also propose how these new 
approaches could be used to test the efficacy of GRAS compounds, which could be protective on 
human mitochondria via minimally invasive approaches.  
 
Development of biomarkers for neurodegenerative diseases 
In addition to the previously discussed neurodegenerative diseases Friedreich’s Ataxia 
(FA) and Huntington’s disease (HD) are also some of the most common neurological diseases. 
Although their etiology varies, a common underlying contributor to progression of all these 
diseases is mitochondrial dysfunction (Quintanilla and Johnson 2009; Shi, Wei et al. 2010; 
Exner, Lutz et al. 2012; Puccio, Anheim et al. 2014; Swerdlow, Burns et al. 2014). Their 
economic and societal impact is alarming. Alzheimer’s disease alone is estimated to cost $100 
billion a year (Meek, McKeithan et al. 1998).  The economic impact of PD is estimated to be 
$14.4 billion a year, and the prevalence is projected to more than double by 2040 (Kowal, Dall et 
al. 2013). In 2010 cost of all brain disorders in Europe was estimated to be €798 billion 
(Gustavsson, Svensson et al. 2011).  At present, no cures or effective treatments exists for the 
above neurodegenerative diseases. Improved diagnostic tools for diseases characterized by 
mitochondrial dysfunction would greatly improve early detection, intervention, and aid insight 
into the disease mechanisms. 
  
Hurdles to research and diagnosis 
Neither detailed disease progression nor effectiveness of drugs on mitochondrial function 
can be adequately measured using currently available clinical methods. These were identified as 
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major hurdles in the way of progress toward effective treatments by NIH intramural and 
extramural scientists and industry and foundation representatives (Moraes, Anderson et al. 2013). 
For example, the best current tool available for diagnosis of Alzheimer’s disease (AD) is brain 
imaging (magnetic resonance imaging or positron emission tomography). These procedures can 
only detect damage that has advanced to the tissue level. For diseases like HD and FA genetic 
diagnostic tests are available. However, the ability to effectively gauge the progress of these 
diseases and their impact on mitochondria does not exist. Many neurodegenerative diseases have 
established metabolic and mitochondrial dysfunctions that also affect the platelets in peripheral 
blood (Zharikov and Shiva 2013). In addition to modulating mitochondrial activity in the brain, 
AD, ALS, FA, HD, and PD can also affect mitochondrial activity in peripheral blood cells. 
Ability to measure these metabolic dysfunctions from patient derived platelets would be a 
powerful clinical diagnostic and research tool. Furthermore, curating these mitochondrial disease 
state phenotypes in databases would create a powerful research and eventually diagnostic tool. 
Analysis of the patient’s biological sample for proteomic, metabolomics, and transcriptomic 
changes, coupled with carefully curated mitochondrial disease state phenotypes could potentially 
usher in a new field of research in “transmetabolomics.” Mitochondrial phenotypic changes 
could be cross referenced with proteomic level changes at unprecedented levels. This inevitable 
new field of research would overcome the hurdles discussed above that are preventing 
discoveries of cures and effective treatments for mitochondria related diseases. 
 
Assessing mitochondrial health 
The rate of adenosine triphosphate (ATP) production is an important indicator of 
mitochondrial health. Mitochondria are after all the “powerhouse of the cell”. ATP production is 
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accomplished by the use of the electrochemical potential across the mitochondrial inner 
membrane or the mitochondrial membrane potential (MMP). MMP is maintained by a constant 
flux of electrons down the electron transport chain (ETC) and their deposition onto oxygen, 
reducing it to water. These high energy electrons and accompanying hydrogens are obtained 
from glycolysis and the tricarboxyclic acid cycle (TCA). The reduction of oxygen is coupled to 
phosphorylation of adenosine diphosphate (ADP) into ATP. This is ADP-driven oxygen 
consumption, resulting in oxidative phosphorylation (OXPHOS). If the flux of electrons down 
the ETC is interrupted or other mitochondrial perturbation are caused by a diseased state, levels 
of reactive oxygen species (ROS) may increase, further damaging the mitochondria. In order to 
determine many of these parameters mitochondria have to be isolated from tissue and rapidly 
analyzed. Once frozen, the mitochondrial membrane is damaged and only analysis of individual 
electron transport chain complexes can be performed. Mitochondria can be analyzed without 
removal from the cytoplasm, in monolayered cultured cells or from non-adherent cells in 
suspension. Analyzing whole cells for mitochondrial function will be considerably less labor 
intensive if phenotypic differences are detectable. Established methods of mitochondrial analysis 
were never applied together in a cohesive way, in order to create an index for mitochondrial 
health. Furthermore, no efforts were made to establish databases, both of mitochondrial disease 
state phenotypes using standardized methods, and proteomic changes under the same disease 
conditions.  
Hopefully, future grant funding will allow for rapid creation of a model database with 
standardized mitochondrial values for each of these specific diseases. This data would then allow 
for the creation of a health index for the first time in history that would aggregate multiple 
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indicators of mitochondrial function i.e. ATP production, OXOPHOS, MMP, ROS levels and 
proteomic level changes under the same conditions using peripheral blood.   
 
Why use platelets as surrogates 
Over the past couple of decades, platelets have been used as surrogates of mitochondrial 
dysfunction in other tissues in several patient populations (Parker, Boyson et al. 1989; Parker, 
Boyson et al. 1990; Parker 1991; Sangiorgi, Mochi et al. 1994; Blandini, Nappi et al. 1998; 
Sjovall, Morota et al. 2010; Zharikov and Shiva 2013). However, standardized methods were not 
used in the experiments over the years and due to the absence of centralized repositories for this 
type of data, creation of a meaningful clinical score is currently impossible (Moraes, Anderson et 
al. 2013). Furthermore, some mitochondrial diseases like Freidreich’s ataxia have conflicting 
findings on whether blood cells are suitable surrogates for an inference into mitochondrial 
dysfunction of post-mitotic cells with a higher degree of heteroplasmy (Selak, Lyver et al. 2011). 
Studies also show that transformed peripheral blood mononuclear cells exhibit mitochondrial 
dysfunction phenotypes (Napoli, Taroni et al. 2006). This suggests that although cells might be 
harboring mitochondrial defects the phenotype is below the threshold of detection in certain 
cases and depends on the detection methods used.  
Recently, in a hypothesis paper Balu Chacko et al, proposed a bioenergetics health index 
(BHI) and have verified the potential for the use of platelets as a “canary in a coal mine” for 
mitochondria in less accessible areas like the brain (Chacko, Kramer et al. 2014). Using Seahorse 
Bioscience’s extracellular flux analyzer they were able to demonstrate the feasibility of platelets 
as surrogates for mitochondrial function in other tissues.   
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Innovation 
Their approach however, lacks key components that significantly diminish its application 
to establishing an effective BHI. Using a flux analyzer, extracellular changes in dissolved 
oxygen concentration and acidity are used to determine mitochondrial function. 
Thesemeasurements are only part of the story. Their BHI does not measure mitochondrial 
membrane potential (MMP), reactive oxygen species (ROS) production, adenosine triphosphate 
(ATP) production, nor individual mitochondrial electron transport chain (ETC) complex activity. 
These are key indicators of mitochondrial function and any integrated score would be served 
well to include them. Furthermore, the BHI proposed by Chacko et al. relies only on patients 
own baseline, which only allows measurements of disease progress from that point in time. 
Comparing the individual’s BHI to a database of values from both healthy individuals and from 
various disease states would be more telling. Patients could be informed as to the progress of the 
disease and what can be expected with the disease progression. Their progress can also be 
monitored. Obtaining and curating proteomic level changes under these same conditions and 
cross-referencing them with phenotypic changes would allow for an unprecedented level of 
treatment, research, and innovation.  
The environment of the blood is highly dynamic. This can have considerable impact on 
the variability of any blood cell’s metabolic activity and protein abundance levels. Sampling 
blood from the same patient at different times of the day and pre and post meal could mask 
phenotypic differences present as previously discussed.  Growing cells in a standard culture 
medium for 2 days could streamline metabolic activity between individuals and allow for finer 
detection of phenotypic differences. As with our studies of mouse embryonic fibroblasts with a 
defective mitochondrial DNA polymerase, phenotypic differences can be unmasked by the 
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growth of cells for 24-48 hour under limited nutrient conditions. Using these approaches will 
significantly increase the sensitivity of the detection of potential differences between control 
donors within an age group (i.e. 20-30 year olds) and patients that are pre-clinical for a disease.  
This may also allow for the detection of fine proteome level changes that can be used as a 
diagnostic tool or as biomarkers for the progress of the disease or efficacy of the treatment 
regimen in pre-clinical patients. Moving away from a single indicator of disease to a concert of 
phenotypic and proteomic level changes (that themselves could only work for certain segments 
of the population) will allow for more rapid drug design and treatment innovations and 
personalized medicine.  The feasibility of this approach could be demonstrated by obtaining 
blood from 10 healthy donors (20-30 years old) and 10 age matched donors with HD and/or FA 
at the earliest or pre-clinical stages of the disease. Using the data from all of the mitochondrial 
health parameters previously discussed, databases could be created to curate the data. An 
algorithm could be written that integrates phenotypic values into a single score and cross 
references the score with proteomic level changes.  
 
Commercial opportunities and societal benefits  
Once streamlined, the database and the process can be licensed out to hospitals, research 
institutes, and government agencies for diagnostic and research purposes. The reagents necessary 
to perform the assays at any hospital lab would be pre-prepared for quality control purposes and 
provided as part of the package along with access to the score and the database. This would also 
significantly cut down on the diagnostics time and the cost of the procedure.  The ability to 
diagnose mitochondrial dysfunction and gauge the effectiveness of potential therapeutics will 
eliminate the biggest hurdle identified by the NIH to development of treatment of mitochondria- 
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related diseases. Access to the growing database would allow scientists to compare 
mitochondrial function across a multitude of diseases, age groups, treatments, and accompanying 
proteomic level changes in unprecedented numbers. This would lead to a new era of rapid 
discovery.   
Maintaining these mitochondrial values for each patient and monitoring progress over 
time will result in more personalized medicine. The same approach can also be used to gauge 
improvements in mitochondria of diabetics, as they undergo a diet or exercise regimen. 
Furthermore, professional athletes, those under specific diets, or multidrug regiments, which can 
impact central metabolism can also benefit from having access to the database. As the metabolic 
health index becomes a standard staple of blood tests available to physicians, it can serve as a 
forecast of patients declining health, or show improvement in response to a treatment before 
physical symptoms improve.  
Compounds we previously found to be protective in our in vitro PD model are generally 
regarded as safe (GRAS) by the FDA. This would allow us to move quickly toward approval for 
human trials, where we could measure the efficacy of these drugs on the patient population used 
to established BHI and the database. Proteomic and metabolomic analysis combined with 
phenotypic improvements would allow us to rapidly map out mechanisms by which these 
compounds improve metabolic function, leading to more effective rational drug design. This new 
approach to metabolic research would revolutionize the current drug discovery process and likely 
decrease bench to bedside time by orders of magnitude and in the process decrease the massive 
drug discovery costs. Benefits of developing this technology can have far reaching effects well 
beyond medicine. For instance, similar metabolic health indices and markers could be developed 
for agricultural and wildlife conservation purposes. Fitness’ of animal populations we rely on for 
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food could be determined. If prey species metabolic health index drops, so would their fitness 
measured by their ability to reproduce. We would have a rapid, robust, and inexpensive forecast 
for their health in response to environmental changes. We could measure the impact of 
pollutants, natural disasters, and global warming on metabolic health. The development of 
metabolic health indices that draw upon mitochondrial phenotypic values obtained using 
standardized methods and nutrient limiting conditions, and cross referencing them with 
proteomic and metabolomics changes under the same conditions would usher in a new field of 
transmetabolomics. 
 
CONCLUSION 
The research presented here describes the presence of mitochondrial dysfunction in 
several neurodegenerative disease models and a model of aging.  It also describes several 
strategies for improving mitochondrial function that may be used in attempt to improve 
mitochondrial function.   Through targeting mitochondrial function in combination with the more 
traditional targets in neurodegenerative diseases, new therapies may one day be developed that 
profoundly delay the onset and progression of these devastating diseases.  
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APPENDIX A: MASS SPECTROMETRY DATA 
 
 
Figure 37 Top canonical pathways 
Using ingenuity pathway analysis software (IPA), top canonical pathways were identified. 
Mitochondrial canonical pathways contributing to AD, and PD progression were among the top 
pathways identified in this data set.  
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Table 5 Statistically significant fold change differences in at least 2 biological replicates 
Ratio of light (α-syn WT) to heavy isotope labeled (M17 control). The fold change for each ID 
was determined to be statistically significant using Perseus software, using Significance A 
setting (outlier test) to determine significance with a p value < 0.05. Only IDs that were 
significant in 2/3 or 3/3 biological replicates are reported.  
 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Cellular retinoic acid-
binding protein 2 
7.8 + 7.2 + 6.8 + 3 7.2 
Keratin, type II 
cytoskeletal 1 
2.2 + 7.5 + 9.3 + 3 7.5 
Keratin, type I 
cytoskeletal 10 
4.1 + 8.8 + 10.6 + 3 8.8 
Dihydropyrimidinase-
related protein 3 
4.0 + 3.8 + 2.7 + 3 3.8 
Zinc-binding alcohol 
dehydrogenase domain-
containing protein 2 
4.7 + 2.9 + 3.5 + 3 3.5 
Alpha-aminoadipic 
semialdehyde synthase, 
mitochondrial;Lysine 
ketoglutarate 
reductase;Saccharopine 
dehydrogenase 
2.4 + 2.3 + 3.0 + 3 2.4 
Amine oxidase [flavin-
containing] A 
1.5 + 3.1 + 1.6 + 3 1.6 
RNA-binding protein 
Musashi homolog 1 
2.0 + 2.3 + 1.9 + 3 2.0 
Galanin 
peptides;Galanin;Galanin 
message-associated 
peptide 
2.3 + 2.2 + 1.9 + 3 2.2 
Insulinoma-associated 
protein 2 
1.8 + 2.4 + 2.2 + 3 2.2 
Neurofilament light 
polypeptide 
1.7 + 1.3 + 2.2 + 3 1.7 
Protein NDRG4 1.9 + 2.4 + 1.8 + 3 1.9 
Ancient ubiquitous 
protein 1 
1.7 + 1.8 + 2.4 + 3 1.8 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Tissue-type plasminogen 
activator;Tissue-type 
plasminogen activator 
chain A;Tissue-type 
plasminogen activator 
chain B 
2.7 + 1.7 + 1.6 + 3 1.7 
Transgelin-3 1.8 + 1.5 + 1.6 + 3 1.6 
Neurofilament medium 
polypeptide 
1.6 + 1.6 + 1.7 + 3 1.6 
Isoaspartyl peptidase/L-
asparaginase;Isoaspartyl 
peptidase/L-
asparaginase alpha 
chain;Isoaspartyl 
peptidase/L-
asparaginase beta chain 
1.7 + 1.5 + 1.5 + 3 1.5 
Secretogranin-1;GAWK 
peptide;CCB peptide 
1.5 + 1.6 + 1.9 + 3 1.6 
Plastin-2 1.9 + 1.8 + 1.4 + 3 1.8 
Bromodomain-
containing protein 3 
1.5 + 1.3 + 1.6 + 3 1.5 
HIG1 domain family 
member 2A, 
mitochondrial 
1.6 + 1.4 + 2.7 + 3 1.6 
Synaptosomal-associated 
protein 25 
1.7 + 1.4 + 1.5 + 3 1.5 
Ganglioside-induced 
differentiation-
associated protein 1 
1.5 + 1.5 + 1.5 + 3 1.5 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Phosphatidylglycerophos
phatase and protein-
tyrosine phosphatase 1 
1.4 + 1.3 + 1.5 + 3 1.4 
Antigen KI-67 1.4 + 1.5 + 1.5 + 3 1.5 
Nuclear factor NF-kappa-
B p100 subunit;Nuclear 
factor NF-kappa-B p52 
subunit 
1.4 + 1.5 + 1.4 + 3 1.4 
Vesicle-associated 
membrane protein 7 
1.7 + 1.5 + 1.8 + 3 1.7 
Cyclin-dependent kinase 
6 
1.4 + 1.6 + 1.5 + 3 1.5 
NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 4 
1.7 + 1.5 + 1.8 + 3 1.7 
Retinol-binding protein 1 1.5 + 1.4 + 1.4 + 3 1.4 
Ornithine 
aminotransferase, 
mitochondrial;Ornithine 
aminotransferase, 
hepatic form;Ornithine 
aminotransferase, renal 
form 
1.7 + 1.4 + 1.4 + 3 1.4 
Retrotransposon-derived 
protein PEG10 
1.9 + 1.4 + 1.5 + 3 1.5 
Laminin subunit gamma-
1 
1.4 + 1.4 + 1.5 + 3 1.4 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(O) subunit 
gamma-2;Guanine 
nucleotide-binding 
protein subunit gamma 
1.5 + 1.4 + 1.4 + 3 1.4 
Creatine kinase U-type, 
mitochondrial 
1.4 + 1.3 + 1.4 + 3 1.4 
Nucleolysin TIAR 0.7 + 1.4 + 1.7 + 3 1.4 
Syntaxin-binding protein 
1 
1.3 + 1.3 + 1.4 + 3 1.3 
Threonine--tRNA ligase, 
mitochondrial 
1.4 + 1.6 + 0.7 + 3 1.4 
CB1 cannabinoid 
receptor-interacting 
protein 1 
0.7 + 0.7 + 0.7 + 3 0.7 
39S ribosomal protein 
L17, mitochondrial 
0.3 + 0.3 + 1.5 + 3 0.3 
BRCA1-associated 
protein 
1.7 + 1.8 + 1.5 + 3 1.7 
Cyclin-D1-binding protein 
1 
0.6 + 0.7 + 0.6 + 3 0.6 
Talin-1 0.7 + 0.7 + 0.7 + 3 0.7 
Argininosuccinate 
synthase 
0.7 + 0.7 + 0.7 + 3 0.7 
Charged multivesicular 
body protein 5 
0.7 + 0.8 + 0.6 + 3 0.7 
Tyrosine-protein kinase 
Lyn;Tyrosine-protein 
kinase HCK 
0.7 + 0.7 + 0.7 + 3 0.7 
Talin-2 0.7 + 0.7 + 0.7 + 3 0.7 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Isochorismatase domain-
containing protein 1 
0.7 + 0.7 + 0.7 + 3 0.7 
Paxillin 0.7 + 0.8 + 0.7 + 3 0.7 
Insulin-like growth factor 
II;Insulin-like growth 
factor II;Insulin-like 
growth factor II Ala-25 
Del;Preptin 
0.6 + 0.6 + 0.5 + 3 0.6 
Aldo-keto reductase 
family 1 member C3 
0.7 + 0.7 + 0.7 + 3 0.7 
NAD-dependent protein 
deacetylase sirtuin-
1;SirtT1 75 kDa fragment 
0.7 + 0.7 + 0.6 + 3 0.7 
A-kinase anchor protein 
12 
0.7 + 0.6 + 0.6 + 3 0.6 
Lanosterol synthase 0.5 + 0.6 + 0.7 + 3 0.6 
Phospholipase A-2-
activating protein 
0.7 + 0.7 + 0.6 + 3 0.7 
 0.7 + 0.6 + 0.6 + 3 0.6 
Cysteine and glycine-rich 
protein 2 
0.6 + 0.7 + 0.6 + 3 0.6 
Adenylate kinase 
isoenzyme 6 
0.7 + 0.6 + 0.5 + 3 0.6 
Isopentenyl-diphosphate 
Delta-isomerase 1 
0.6 + 0.6 + 0.6 + 3 0.6 
Integrin alpha-V;Integrin 
alpha-V heavy 
chain;Integrin alpha-V 
light chain 
0.6 + 0.6 + 0.6 + 3 0.6 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Ubiquitin-associated 
protein 2 
0.6 + 0.6 + 0.6 + 3 0.6 
Chromogranin-
A;Vasostatin-
1;Vasostatin-2;EA-92;ES-
43;Pancreastatin;SS-
18;WA-8;WE-14;LF-
19;AL-11;GV-19;GR-
44;ER-37 
0.6 + 0.7 + 0.6 + 3 0.6 
Proto-oncogene tyrosine-
protein kinase receptor 
Ret;Soluble RET kinase 
fragment;Extracellular 
cell-membrane anchored 
RET cadherin 120 kDa 
fragment 
0.6 + 0.6 + 0.6 + 3 0.6 
Aldo-keto reductase 
family 1 member 
C1;Aldo-keto reductase 
family 1 member 
C2;Aldo-keto reductase 
family 1 member C4 
0.6 + 0.6 + 0.6 + 3 0.6 
S-methyl-5-
thioadenosine 
phosphorylase;Purine 
nucleoside 
phosphorylase 
0.6 + 0.6 + 0.6 + 3 0.6 
Phosphofurin acidic 
cluster sorting protein 1 
0.6 + 0.5 + 0.6 + 3 0.6 
Neuroblast 
differentiation-
associated protein 
AHNAK 
0.6 + 0.6 + 0.5 + 3 0.6 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Neural cell adhesion 
molecule 1 
0.6 + 0.5 + 0.5 + 3 0.5 
Perilipin-2 0.5 + 0.4 + 0.6 + 3 0.5 
Synemin 0.5 + 0.5 + 0.5 + 3 0.5 
BTB/POZ domain-
containing protein 
KCTD12 
0.5 + 0.5 + 0.5 + 3 0.5 
Quinone oxidoreductase 
PIG3 
0.4 + 0.5 + 0.5 + 3 0.5 
Heterogeneous nuclear 
ribonucleoprotein K 
0.7 + 0.3 + 0.4 + 3 0.4 
Hydroxymethylglutaryl-
CoA synthase, 
cytoplasmic 
0.5 + 0.4 + 0.6 + 3 0.5 
Tropomyosin alpha-1 
chain 
0.4 + 0.6 + 0.4 + 3 0.4 
Cellular retinoic acid-
binding protein 1 
0.4 + 0.4 + 0.4 + 3 0.4 
Protein-glutamine 
gamma-
glutamyltransferase 2 
0.4 + 0.3 + 0.3 + 3 0.3 
Keratin, type I 
cytoskeletal 9 
NaN  5.9 + 3.2 + 2 4.5 
Lysocardiolipin 
acyltransferase 1 
3.1 + 7.2 + NaN  2 5.1 
Neuronal migration 
protein doublecortin 
2.7 + 3.1 + NaN  2 2.9 
Pleckstrin homology 
domain-containing family 
A member 6 
2.8 + 2.3 + NaN  2 2.6 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Protein asunder homolog 1.6 + 3.5 + NaN  2 2.5 
Dachshund homolog 1 NaN  1.4 + 2.5 + 2 2.0 
Protein DEK 6.1 + 1.2  2.8 + 2 2.8 
Tripartite motif-
containing protein 67 
1.7 + 2.1 + NaN  2 1.9 
UPF0444 
transmembrane protein 
C12orf23 
NaN  2.2 + 1.6 + 2 1.9 
Periphilin-1 1.3  1.9 + 1.7 + 2 1.7 
ProSAAS;KEP;Big 
SAAS;Little SAAS;Big PEN-
LEN;PEN;Little LEN;Big 
LEN 
NaN  1.7 + 1.7 + 2 1.7 
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(O) subunit 
gamma-8 
1.6 + 1.6 + NaN  2 1.6 
Protein-tyrosine 
sulfotransferase 1 
1.5 + NaN  1.4 + 2 1.4 
Ribose-phosphate 
pyrophosphokinase 
2;Ribose-phosphate 
pyrophosphokinase 
1.5 + 1.6 + NaN  2 1.5 
Kinesin-like protein KIF1A 1.5 + 1.6 + 1.2  2 1.5 
Gamma-
glutamylcyclotransferase 
NaN  1.5 + 1.7 + 2 1.6 
Aspartate--tRNA ligase, 
mitochondrial 
1.5 + 0.9  1.5 + 2 1.5 
Transmembrane protein 
205 
1.6 + 1.5 + 1.3  2 1.5 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Dehydrogenase/reductas
e SDR family member 7 
1.5 + 1.4 + 1.3  2 1.4 
Alpha-galactosidase A 1.6 + NaN  1.4 + 2 1.5 
Spartin 1.3  1.7 + 1.4 + 2 1.4 
DNA topoisomerase 
2;DNA topoisomerase 2-
beta 
1.6 + 1.1  1.4 + 2 1.4 
Plastin-1 1.6 + 1.7 + 1.2  2 1.6 
Zinc finger MYM-type 
protein 3 
1.4 + 2.2 + NaN  2 1.8 
Midkine NaN  1.4 + 1.5 + 2 1.4 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 8 
1.4 + 1.3 + 1.2  2 1.3 
Uncharacterized protein 
C11orf96 
1.4 + 1.4 + 1.3  2 1.4 
Calcium/calmodulin-
dependent protein 
kinase type IV 
1.4 + 1.3  1.4 + 2 1.4 
Myc box-dependent-
interacting protein 1 
1.4 + 1.5 + 1.2  2 1.4 
Leucine-rich repeat and 
calponin homology 
domain-containing 
protein 1 
NaN  1.5 + 1.5 + 2 1.5 
Ribosome production 
factor 1 
1.7 + 1.1  1.5 + 2 1.5 
RNA binding protein fox-
1 homolog 2;RNA binding  
1.2  1.4 + 1.4 + 2 1.4 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Melanoma-associated 
antigen G1 
NaN  1.4 + 1.3 + 2 1.4 
Probable 2-oxoglutarate 
dehydrogenase E1 
component DHKTD1, 
mitochondrial 
1.3  1.4 + 1.4 + 2 1.4 
Ester hydrolase C11orf54 1.3 + 1.4 + 1.3  2 1.3 
Heterogeneous nuclear 
ribonucleoprotein A3 
1.8 + 1.4 + 1.3  2 1.4 
Spectrin beta chain, non-
erythrocytic 2 
1.3  1.3 + 1.4 + 2 1.3 
Aldehyde 
dehydrogenase;Fatty 
aldehyde dehydrogenase 
1.3  1.3 + 1.5 + 2 1.3 
Tudor and KH domain-
containing protein 
1.4 + NaN  1.4 + 2 1.4 
Metastasis-associated 
protein MTA1 
1.4 + 1.4 + 1.3  2 1.4 
Dedicator of cytokinesis 
protein 11 
1.4 + 1.5 + 1.2  2 1.4 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 13 
1.4 + 1.3 + NaN  2 1.4 
Zinc fingers and 
homeoboxes protein 1 
1.4 + 1.3 + NaN  2 1.4 
Small nuclear 
ribonucleoprotein 
G;Small nuclear 
ribonucleoprotein G-like 
protein 
NaN  1.4 + 1.4 + 2 1.4 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Glutaredoxin-related 
protein 5, mitochondrial 
1.1  3.1 + 1.7 + 2 1.7 
Probable global 
transcription activator 
SNF2L1 
1.3 + 1.3  1.4 + 2 1.3 
Equilibrative nucleoside 
transporter 1 
1.9 + 1.3 + 0.8  2 1.3 
Nesprin-2 1.2  1.5 + 1.6 + 2 1.5 
Acyl-coenzyme A 
thioesterase 9, 
mitochondrial 
1.4 + 1.3  1.4 + 2 1.4 
Tripartite motif-
containing protein 65 
NaN  1.3 + 1.4 + 2 1.4 
UBX domain-containing 
protein 4 
1.4 + 1.3 + NaN  2 1.4 
REST corepressor 2 1.4 + 1.3 + NaN  2 1.4 
Apoptosis regulator BAX 1.4 + 1.3 + 1.3  2 1.3 
Kinectin 1.3 + 1.3  1.4 + 2 1.3 
Bromodomain adjacent 
to zinc finger domain 
protein 2A 
1.7 + 1.3 + NaN  2 1.5 
Cdc42 effector protein 4 1.3  1.3 + 1.4 + 2 1.3 
Phosphoinositide 3-
kinase regulatory subunit 
4 
1.3  1.3 + 1.4 + 2 1.3 
Golgi apparatus protein 1 1.4 + 1.1  1.3 + 2 1.3 
Bromodomain-
containing protein 2 
1.5 + 1.3 + 1.2  2 1.3 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Annexin;Annexin A4 1.3 + 0.1 + 1.3  2 1.3 
Probable asparagine--
tRNA ligase, 
mitochondrial 
1.4 + 1.6 + 1.2  2 1.4 
3-hydroxyisobutyrate 
dehydrogenase, 
mitochondrial 
1.4 + 1.2  1.3 + 2 1.3 
Prostaglandin reductase 
2 
1.3 + 1.3 + 1.0  2 1.3 
Bifunctional lysine-
specific demethylase and 
histidyl-hydroxylase 
NO66 
1.4 + 0.6 + NaN  2 1.0 
Helicase-like 
transcription factor 
1.4 + 1.3 + 1.1  2 1.3 
Surfeit locus protein 1 NaN  1.9 + 1.4 + 2 1.6 
Mediator of RNA 
polymerase II 
transcription subunit 12 
0.7 + 1.5 + 1.2  2 1.2 
Abnormal spindle-like 
microcephaly-associated 
protein 
1.0  1.4 + 1.4 + 2 1.4 
Uncharacterized protein 
C19orf43 
2.0 + 0.9  1.3 + 2 1.3 
Apolipoprotein O 1.8 + 1.4 + 1.2  2 1.4 
Cell division cycle-
associated protein 2 
1.6 + 1.3 + NaN  2 1.5 
Protein archease 1.1  1.7 + 1.7 + 2 1.7 
Translocator protein 1.1  1.8 + 2.3 + 2 1.8 
28S ribosomal protein 
S18b, mitochondrial 
1.3 + 1.6 + 1.0  2 1.3 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Serine/threonine-protein 
kinase SMG1 
1.1  0.7 + 1.5 + 2 1.1 
D-beta-hydroxybutyrate 
dehydrogenase, 
mitochondrial 
1.5 + 1.3 + NaN  2 1.4 
E3 ubiquitin-protein 
ligase HECTD1 
1.0  1.3 + 0.7 + 2 1.0 
TGF-beta-activated 
kinase 1 and MAP3K7-
binding protein 1 
0.6 + 1.0  0.7 + 2 0.7 
WD repeat-containing 
protein 5 
1.3 + 1.5 + 1.1  2 1.3 
Focadhesin 0.7 + 0.5 + NaN  2 0.6 
Gamma-glutamyl 
hydrolase 
0.7 + 0.6 + 1.0  2 0.7 
Integrin alpha-2 NaN  0.7 + 0.6 + 2 0.6 
Ubiquitin carboxyl-
terminal 
hydrolase;Ubiquitin 
carboxyl-terminal 
hydrolase 19 
1.8 + 1.3 + 1.2  2 1.3 
Inositol-3-phosphate 
synthase 1 
0.6 + 0.5 + NaN  2 0.6 
DNA polymerase epsilon 
subunit 4 
0.6 + 0.6 + 1.0  2 0.6 
Rab3 GTPase-activating 
protein catalytic subunit 
0.6 + 0.7 + 0.9  2 0.7 
Endophilin-B1 0.9  0.7 + 0.6 + 2 0.7 
LanC-like protein 1 1.4 + 0.6 + NaN  2 1.0 
DNA-directed RNA 
polymerase II subunit 
RPB7 
0.5 + 1.4 + NaN  2 1.0 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
SWI/SNF-related matrix-
associated actin-
dependent regulator of 
chromatin subfamily A 
containing DEAD/H box 1 
0.8  0.6 + 0.7 + 2 0.7 
Syndecan;Syndecan-2 0.8  0.7 + 0.7 + 2 0.7 
Protein FAM219A NaN  0.7 + 0.7 + 2 0.7 
RNA exonuclease 4 0.8  0.6 + 0.7 + 2 0.7 
Band 4.1-like protein 1 0.7 + 0.7 + 0.8  2 0.7 
Phytanoyl-CoA 
hydroxylase-interacting 
protein-like 
0.8  0.7 + 0.7 + 2 0.7 
Early endosome antigen 
1 
0.7 + NaN  0.6 + 2 0.7 
Cleft lip and palate 
transmembrane protein 
1-like protein 
0.7 + NaN  0.7 + 2 0.7 
Protein S100-A13 0.8  0.7 + 0.7 + 2 0.7 
Hexokinase-1 0.7 + 0.7 + 0.7  2 0.7 
CD166 antigen 0.7 + 0.7 + 0.7  2 0.7 
DnaJ homolog subfamily 
A member 1 
0.7 + 0.7 + 0.8  2 0.7 
Superoxide dismutase 
[Mn], 
mitochondrial;Superoxid
e dismutase 
0.6 + 0.7 + 0.8  2 0.7 
Myotubularin-related 
protein 5 
0.5 + 1.1  0.5 + 2 0.5 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Actin-binding LIM protein 
1 
0.7 + 0.7 + 0.8  2 0.7 
Glutaredoxin-1 0.5 + 0.8 + NaN  2 0.6 
Coiled-coil domain-
containing protein 6 
0.8  0.7 + 0.7 + 2 0.7 
Synaptotagmin-1 0.8  0.6 + 0.7 + 2 0.7 
GTP:AMP 
phosphotransferase AK3, 
mitochondrial 
0.7 + 0.9  0.5 + 2 0.7 
Glutathione 
peroxidase;Glutathione 
peroxidase 1 
0.6 + 0.6 + 0.8  2 0.6 
Translation factor GUF1, 
mitochondrial 
0.6 + 0.7 + NaN  2 0.6 
Hippocalcin-like protein 
1 
0.7 + 0.7 + 0.9  2 0.7 
Aprataxin 0.7 + NaN  0.6 + 2 0.7 
Selenoprotein O 0.7 + 0.7 + NaN  2 0.7 
Kelch-like protein 
13;Kelch-like protein 9 
0.1 + NaN  0.1 + 2 0.1 
Glutathione S-
transferase theta-
2B;Glutathione S-
transferase theta-2 
0.7 + 0.9  0.7 + 2 0.7 
HAUS augmin-like 
complex subunit 7 
0.7  0.6 + 0.6 + 2 0.6 
Phosphatidylinositol 5-
phosphate 4-kinase type-
2 alpha 
0.6 + NaN  0.7 + 2 0.6 
Pyruvate kinase 
PKM;Pyruvate kinase 
NaN  0.7 + 0.7 + 2 0.7 
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Table 5 continued 
Protein names Rep 1 
(1/x) 
Rep 1 
Sig A 
Rep 2 
(1/x) 
Rep 2 
Sig A 
Rep 3 
(1/x) 
Rep 3 
Sig A 
Count Media
n Ratio 
Angiotensin-converting 
enzyme;Angiotensin-
converting enzyme, 
soluble form 
0.6 + 0.5 + 0.8  2 0.6 
Four and a half LIM 
domains protein 2 
NaN  0.6 + 0.6 + 2 0.6 
Palmdelphin 0.7  0.6 + 0.5 + 2 0.6 
Zyxin 0.5 + 0.7 + NaN  2 0.6 
HAUS augmin-like 
complex subunit 6 
0.7 + 0.8 + NaN  2 0.7 
N-alpha-
acetyltransferase 38, 
NatC auxiliary subunit 
0.5 + 0.6 + NaN  2 0.6 
NEDD4 family-interacting 
protein 1 
NaN  0.5 + 0.5 + 2 0.5 
Junctional adhesion 
molecule C 
0.6 + 0.5 + NaN  2 0.5 
Triple functional domain 
protein 
0.5 + 0.6 + NaN  2 0.6 
Armadillo repeat-
containing protein 10 
0.8  0.3 + 0.6 + 2 0.6 
Vacuolar-sorting protein 
SNF8 
NaN  0.5 + 0.5 + 2 0.5 
Chondroitin sulfate 
proteoglycan 4 
0.5 + 0.5 + NaN  2 0.5 
CD44 antigen 0.2 + NaN  0.2 + 2 0.2 
Annexin;Annexin A1 0.1 + NaN  0.1 + 2 0.1 
DNA-3-methyladenine 
glycosylase 
0.7 + NaN  0.3 + 2 0.5 
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